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THE REGULATORY ROLE OF INTERLUKIN-1 RECEPTOR ASSOCIATED
KINASE M IN TOLL-LIKE RECEPTOR SIGNALING
HAO ZHOU

ABSTRACT

Toll-like receptors (TLRs) are one of the major groups of pattern recognition
receptors. TLRs are able to recognize the pathogen-associated molecular patterns and
transduce their signals through the adaptor molecule MyD88 and members of the IL-1Rassociated kinase family (IRAK1, 2, M and 4).
IRAKM was previously known to function as a negative regulator that prevents the
dissociation of IRAKs from MyD88, thereby inhibiting downstream signaling. However,
we now found that IRAKM was also able to interact with MyD88-IRAK4 to form IRAKM
Myddosome to mediate TLR7-induced MEKK3-dependent second wave NFκB activation.
As a result, the IRAKM-dependent pathway only induced expression of genes that are not
regulated at the posttranscriptional levels (including inhibitory molecules SOCS1, SHIP1,
A20 and IκBα), exerting an overall inhibitory effect on inflammatory response. On the
other hand, through interaction with IRAK2, IRAKM inhibited TLR7-mediated production
of cytokines and chemokines at translational levels.
While the TLR-mediated inflammatory response is critical for innate immunity and
host defense against infections, uncontrolled inflammation is detrimental to the host,
leading to chronic inflammatory diseases. Alcohol-induced liver injury is induced by
necrosis of hepatocytes and increased translocation of endotoxin from the intestinal tract
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into hepatic portal system, which trigger chronic inflammation that is damaging to the liver
together. We found that mice deficient of IRAKM, are protected from alcohol-induced
liver injury. IRAKM mediates the up-regulation of Mincle, a receptor for danger signals
release by damaged cells, in response to low level of LPS. Biochemical analysis revealed
that low-dose LPS preferentially induces the formation of IRAKM Myddosome, leading
to MEKK3-dependent NFκB activation. Mincle-deficient mice are also protected from
alcohol-induced liver injury. We found IRAKM deficiency and Mincle deficiency
drastically reduced alcohol feeding induced inflammasome activation in the mouse liver.
Ex vivo studies showed that both IRAKM and Mincle are required for inflammasome
activation by endogenous Mincle ligand, SAP130, which is a danger signal release by
damaged hepatocytes. Taken together, we identifies an IRAKM-Mincle axis critical for the
pathogenesis of alcohol induced liver disease through the activation of inflammasome.
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CHAPTER I
INTRODUCTION

A. The Mammalian Immune System
The main purpose of the immune system is to detect and appropriately respond to
foreign objects and pathogens [1]. The mammalian immune system is comprised of two
parts: innate and adaptive immunity. The innate immune system, the first line of immune
defense system, applies multiple layers to defend against invading pathogens[2]. One layer
includes the physical barrier surface such as skin and epithelium[3]. Another layer is the
immune cells which can active phagocytosis and inflammatory response. Macrophages
and dendritic cells (DC), two important cell types of phagocytes, can recognize different
groups of invading pathogens through conserved molecular patterns [4-6]. These
recognition events lead to the subsequent production of inflammatory mediators by
macrophages and DCs, such as pro-inflammatory cytokines, chemokines and interferons
[7, 8]. These mediators can further promote inflammatory responses by modifying vascular
endothelial cells to increase permeability to recruit leukocytes to infect tissues [9, 10]. They
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can also enhance macrophage-mediated phagocytosis or even induce the apoptosis
(programmed cell death) of infected cells [11].
While the activation of innate immune response depends on the recognition of
pathogen associated patterns (PAMPs) as non-self ligands, the adaptive immune response
is characterized by antigen specificity [4, 12]. Lymphocytes, including B cells and T cells,
bear a large repertoire of antigen-specific receptors that are generated by gene
rearrangement [13, 14]. Interaction between antigen-presenting cells and lymphocytes
stimulates the expansion and activation of a sub-group of lymphocytes that bear receptors
specific to the invading pathogens. Upon activation, B cells differentiate in plasma cells
and secrete a large amount of antibodies, each of which recognize a specific antigen and
mediate the neutralization of invading pathogens. Cytotoxic T cells can induce apoptosis
of pathogen-infected cells and T helper cells are critical to regulate immune response.

B. Pattern Recognition Receptors
The innate immune system is the primary barrier to the invading pathogens and acts
immediately. To eliminate the pathogens, the host immune system must be able to detect
the difference between pathogens and host tissues, e.g. “non-self” and “self”. Recognition
of microbial pathogens is essential for initiating the innate immune response. Germlineencoded pattern-recognition receptors (PRRs) that recognize pathogen-associated
molecular patterns (PAMPs) play a central role in host cell recognition and immune
response to invading pathogens [15]. Upon PAMPs recognition, PRRs initiate a series of
signaling events which execute the first line of host defense[16]. The first PRR, the Toll
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receptor, was identified in a mutant Drosophila line highly susceptible to fungal infection
[17]. Subsequent screening studies identified the human and murine homologue of Toll
receptor and lipopolysaccharide (LPS), a component of Gram-negative bacteria cell wall
was confirmed as the ligand [18-20]. To date, four PRR families have been identified,
including Toll-like receptors (TLRs), C-type lectin receptors (CLRs), retinoic acidinducible gene (RIG)-I-like receptors (RLRs) and Nucleotide oligomerization domain
(NOD)-like receptors (NLRs).
Toll-like receptors
Among all the PPRs, the members of TLR family have been studied most
extensively[21]. So far, 13 mammalian members of the TLR family have been
identified[22]. TLRs belongs to type I integral transmembrane glycoproteins characterized
by an extracellular domain and a cytoplasmic signaling domain [8]. The cytoplasmic
domain of TLRs is similar to that of the IL-1 receptor (IL-1R) family and appropriately
named the Toll/IL-1 receptor (TIR) domain [23]. Therefore, the TLRs and IL-1Rs are
grouped into a TLR/IL-1R superfamily. While the extracellular domains are markedly
different: IL-1R family has an immunoglobulin (Ig) domain and TLRs contain a leucinerich repeats (LRR) [24]. The LRR domain of TLR4 was shown to form a horseshoe
structure with LPS binding to the concave surface [25]. The intracellular signaling of TLRs
are primarily mediated by recruiting different TIR domain containing adaptor molecules
such as MyD88, TRIF, TIRAP and TRAM [26-28]. All TLRs, except TLR3, recruit
MyD88 and initiate MyD88-dependent pathway to activate multiple transcription factors,
including NFκB, AP-1, C-Fos/Jun. TLR3 and TLR4 recruit TRIF and initiate TRIF-
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dependent signaling to activate NFκB and IRF3 to induce production of pro-inflammatory
and type I interferons[29].
TLR1, TLR2, TLR4, TLR5, TL6 and TLR11 are expressed on the cytoplasmic
membrane, while TLR3, TLR7, TLR8 and TLR9 are expressed in intracellular vesicles,
such as endosomes [25]. TLR4, together with myeloid differentiation factor 2 (MD2),
recognize LPS, a component of the Gram-negative bacterial cell walls [20]. Recent studies
have also identified oxidized low-density lipoprotein (Ox-LDL) and free fatty acid (FFA)
as endogenous ligands of TLR4 [30]. TLR2 forms heterodimers with TLR1 or TLR6. The
TLR1/2 and TLR2/6 heterodimers recognize lipoproteins derived from gram-positive
bacteria [31]. TLR5 recognizes flagellin which is a conserved protein component of
bacteria flagella [32]. TLRs which recognize nucleotides derived from invading pathogens
including TLR3, TLR7, TLR8 and TLR9, are localized in intracellular compartments, such
as endosomes and early lysosomes. Both of TLR7 and TLR 8 recognize uridine or
guanosine-rich single strand (ss) RNA [24, 27, 33]. TLR3 can recognize double strand (ds)
RNA, which is typically an intermediate product during replication of ssRNA viruses [34].
TLR9 is responsible for the recognition of genomic DNA derived from invading bacteria
and viruses distinguished by a high abundance of unmethylated CpG nucleotides compared
to mammalian genomic DNA [35]. (Fig. 1)

4

Figure 1. Toll-like receptors and their ligands.

C-type lectin receptors
C-type lectin receptor (CLR) is another important family member of PPRs. It is
designed to bind to carbohydrates and named as C-type due to the requirement for calcium
to bind carbohydrates initially [36, 37]. CLRs constitute a group of over 1000 members.
They are characterized by a carbohydrate recognition domain (CRD) and a calcium binding
motif[38]. Subsequent studies found that not all the CLRs are calcium dependent and these
receptors can recognized multivalent ligands.
The N-terminal region of the genes encodes the extracellular domain which
contains at least a CRD, while the C-terminal region encodes the intracellular domain[39].
Based on the features of intracellular domain, CLRs can be divided into two distinct groups:
Dectin1 group (including Dectin-1 a, CLEC1, CLEC2, CLEC9A, CLEC12B, LOX1 and
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MICL) and Dectin2 group (including Dectin2, Mincle, Clescsf8, BDCA-2, DCAR and
DCIR)[40].
CLRs from the Dectin1 group all have a long intracellular tail including an
immunoreceptor tyrosine-based activation motif (ITAM) for signaling transduction [41].
The cytoplasmic tail of Dectin1, CLEC9A, CLEC2 and LOX1 contains an immunoreceptor
tyrosine-based activation motif which is required for signaling activation after ligation. In
contrast, the cytoplasmic tail of CLEC12A, CLEC12B, MICL and DCIR contains an
immunoreceptor tyrosine-based inhibitory motif (ITIM). The ligation of these receptors
leads to a suppression of transcription factor activation.
CLRs from the Dectin2 group have the similar structure with the Dectin1 group
with a notable exception: a short cytoplasmic tail [41]. The short cytoplasmic tail lacks the
ability to transduce signal. Thus these receptors typically pair with an FcRγ chain which
harbors an ITAM motif to activate signaling transduction.
Recent studies show that Dectin1 and Dectin2 mediated signaling activation are
both critical for anti-fungal responses [42, 43]. Dectin1 is able to recognize β-glucan while
Dectin2 recognizes high mannose [44, 45]. Mincle, a Dectin-2 member, has multiple
ligands including cord factor of Mycobacterium tuberculosis and α-mannose on the surface
of pathogenic fungus, Malassezia[46-51]. Mincle also recognized the endogenous protein
SAP130, a component of small nuclear ribonucloprotein released from damaged/nectrotic
cells [52]. Activation of CLRs usually leads to the activation of a tyrosine kinase SyK
which transduce the signal through CARD9-Bcl10-MALT1 complex. It has been
suggested that formation of this complex leads to the canonical NFκB activation through
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TAK1-IKK pathway, followed by pro-inflammatory cytokine and chemokine secretion [53,
54]. Overall, CLRs are essential for host immune response and homeostasis. (Fig. 2)

Figure 2. C-type lectins receptors and their ligands.

NOD-like receptors
NOD-like receptors (NLRs), are essential in recognizing cytosolic bacterial
components. Generally, they have a leucine-rich repeat (LRR) motif that mediates ligand
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recognition, a nucleotide binding oligomerization domain (NOD), and a caspase
recruitment domain (CARD) to mediate the recruitment and activation of downstream
signaling components. So far, at least 23 human and 34 murine NLR genes have been
identiﬁed, amongst which NOD1 and NOD2 are the best-characterized members and
recognize distinct structural motifs in bacterial peptidoglycans [55]. NOD1 recognizes γD-glutamyl-meso-diaminopimelic acid (iE-DAP) in all Gram-negative bacterial as well as
several Gram-positive bacteria, while, NOD2 recognizes muramyl dipeptide (MDP) in all
Gram-negative and Gram-positive bacteria [56-58]. After ligand binding, the CARD
domain of NOD1 and NOD2 interacts with a serine/threonine kinase, RIP2 (RICK) that
initiates a signaling cascade resulting NFκB activation, as well as the activation of MAPKs
[52, 59].
RIG-I-like receptors
The RIG-I-like receptor family is another group of cytosolic PRRs which are
essential for the detection of viral RNA in the cytoplasm of most cell types. It includes
RIG-I, melanoma differentiation associated gene 5 (MDA5) and LGP2. RIG-I and MDA5
contain a central DExD/H-box helicase domain and a C-terminal domain (CTD), both of
which are responsible for binding viral RNA [60-62]. It is well established that the signaltransducing activities of RIG-I and MDA5 are tightly regulated by a combination of
phosphorylation and ubiquitination. Interferon-beta promoter stimulator 1 (IPS-1, also
called MAVS, VISA or CARDIF) is an essential adaptor molecule for both RIG-I- and
MDA-5- mediated signaling. It associates with RIG-I and MDA-5 through CARD domains
upon viral infection, and activates downstream signaling components. The third RIG-I-
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like receptor, LGP2, lacks the CARD domain and has been shown to exert a regulatory role
in RLR signaling [63]. However, its precise action has not been well defined yet.

C. TLR-mediated Signaling Activation
The intracellular signaling cascades activated by PRRs results in the production of
inflammatory mediators, including a variety of pro-inflammatory cytokines and
chemokines. The production of pro-inflammatory cytokines, such as tumor necrosis factor
alpha (TNFα), interleukin-1 (IL-1β), and IL-6, are essential to promote inflammatory
responses [64].
All TLRs have a conserved intracellular TIR domain. After binding with the ligands,
TLRs undergo conformational changes, and recruit adapter molecules through interaction
with TIR domains [65]. Five TIR-containing adaptor molecules have been identified,
including MyD88, MAL, TRIF, TIRAP and TRAM. TLRs utilize different adaptor
molecules to activate downstream signaling cascades, which can be roughly divided into
the MyD88-dependent pathway and the TRIF-dependent pathway [29, 66].
The MyD88-dependent pathway
MyD88 is employed by all TLRs except TLR3 as an adaptor molecule. In addition
to a TIR domain, MyD88 also has a death domain (DD) [25]. Stimulation of TLRs by their
respective ligands causes the recruitment of MyD88 through TIR domain interaction. After
binding to the receptor complex, MyD88 interacts with the IL-1 receptor-associated
kinases (IRAKs) via the respective death domains. The MyD88-IRAK4-IRAK2/1
signaling complex has been named as Myddosome [67]. Formaiton of Myddsome leads
9

the activation the kinase activity of IRAK4, which activates IRAK1 and IRAK2 through
subsequent phosphorylation[68]. The activated IRAKs recruit TNFR-associated factor 6
(TRAF6), which is an E3-ubiquitin protein ligase. TRAF6, ubiquitination conjugating
enzymes (E2) UBC13 and UEV1A add lysine 63-linked polyubiquitin chain to TRAF6 as
well as to other signaling components [69]. The ubiquitinated TRAF6 recruits a protein
complex that is composed of TGF-β-activated kinase 1 (TAK1) and the TAK1 binding
proteins TAB1, TAB2, and TAB3. The activated TAK1 complex activates IKB kinase
(IKK) complex (composed of IKKα, IKKβ and /IKKγ) and mitogen-activated protein
kinase kinase (MAPKK) through phosphorylation [70]. The activated IKK complex
phosphorylates NF-κB inhibitory protein (IκBα), leading to the lysine 48-linked
polyubiquitination and degradation of IκBα[71]. The degradation of IκBα releases NFκB,
which translocates into the nucleus and induces the transcription of a series of NFκB target
genes, including pro-inflammatory cytokines and cytokines. Activation of MAP kinase
leads to the activation of another transcription factor, activator protein 1 (AP-1), which also
regulates the transcription of pro-inflammatory cytokine genes.
Recent studies also suggest that there is a parallel pathway which is TAK1independent MEKK3 dependent downstream of MyD88 [65, 72, 73]. In contrast to TAK1dependet pathway results in IKKα/β phosphorylation and IKKγ activation, leading to
classical NFκB activation via IκBα phosphorylation and degradation, MEKK3-dependent
pathway entails to IKKγ phosphorylation and IKKα activation, which leads to NFκB
activation by IκBα phosphorylation and its subsequent dissociation from NFκB, but
without IκBα degradation. IRAK4 kinase activity is not required for MEKK3-dependent
pathway, suggesting by the study of IRAK4 kinase activity dead knock-in mice [65].
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However, the precise mechanism of how MEKK3-dependent pathway gets activated is still
not well understood. (Fig. 3)

Figure 3. TLR-induced MyD88-dependent signaling pathway.
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The TRIF-dependent pathway
The TLR3 signaling pathway is mediated exclusively by the TRIF adaptor [74].
TRIF-mediated activation of TRAF3 leads to the activation of the non-canonical IKKs,
including TBK1 and IKKi. The subsequent phosphorylation of IRF3 by TBK1/IKKi leads
to the translocation IRF3 and the induction of type I IFNs and IL-10. TRIF recruitment and
activation of TRAF6 and RIP1 lead to NF-κB activity through TAK1.
TLR4 uses both the MyD88-dependent and the TRIF-dependent pathways to
induce the production of pro-inflammatory cytokines [20, 26]. MyD88 and TRIF doubledeficient cells show complete loss of NFκB activation in response to LPS stimulation [75].
(Fig. 4)

Figure 4. TLR-induced TRIF-dependent signaling pathway.
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D. Post-transcriptional Regulation of Proinflammtory Cytokine Production
Although proinflammatory cytokines promote host defense against infection, their
prolonged production may lead to chronic inflammation that can cause substantial tissue
damage. Therefore, it is crucial to maintain tight control of proinflammatory cytokine
production, not only to induce them promptly respond to infection, but also to shut them
off quickly after the pathogens are eliminated.
Regulation of mRNA stability
Cellular mRNA levels are established by both mRNA synthesis and degradation.
Many cytokine mRNAs have adenine and uridine-rich elements (AREs) in their 3’
untranslated regions (UTRs), characterized by a pentamer “AUUUA” or a nonamer
“UUAUUUAUU”. It has been shown that AREs are crucial for rapid mRNA decay [7678]. Numerous pro-inflammatory cytokines undergo ARE mediated regulation including
IL-6, TNFα, IL-1β, GM-CSF, TGFβ and CXCL1. Over twenty different ARE-binding
proteins have been identified which associate with AREs mediate interactions between
these mRNAs and exosome complexes, the major machinery for intracellular mRNA
degradation. Tristetraprolin (TTP), the prototype of an ARE binding protein, plays a critical
role in inhibiting TNFα production by destabilizing TNFα mRNA [79, 80]. By contrast,
the ELAV (embryonic lethal and abnormal vision) family members Hu-antigen R (HUR)
and HUD stabilize their targets by competing with the destabilizing ARE-binding proteins
for ARE occupancy [81].
Recently, Regnase 1 (Zc3h12a) has been identified as another negative regulator of
pro-inflammatory cytokine production [82]. Regnase 1 is induced rapidly and
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phosphorylated by IKKβ in response to TLR ligand stimulation. It binds to the 3’UTR
regions of multiple proinflammatory cytokine mRNAs, including IL-6 and IL-20p40, and
leads to mRNA degradation. Further studies indicated that Regnase 1 degrades mRNA via
its endonucleolytic activity[83]. These results demonstrate that the stability of mRNA
encoding different pro-inflammatory cytokines is regulated by different mechanisms.
Regulation of protein translation
In addition to stabilize mRNA, initiation of protein translation is also crucial for
prompt and robust cytokine production in response to pathogen infection. Among all
translation initiation factors, eukaryotic translation initiation factor 2 (eIF2) and eIF4e are
most well studied in innate immunity. eIF2 forms a ternary complex with the initiator
methionyl-tRNA and GTP. The binding of eIF2 complex to 40S ribosomal subunit is
essential for start codon recognition, followed by recruitment of the 60S ribosomal subunit
[84]. eIF4E is a cap-binding protein which interacts with 5’mRNA cap structure and the
scaffold initiation factor eIF4G[51]. In most cells, eIF4E levels are limited, therefore, the
regulation of its activity has strong impact on the translation efficiency. Two MAPKinteracting protein kinase, MNK1 and MNK2, are activated in response to LPS and
subsequently activate eIF4E through phosphorylation which greatly promote the
translation of a variety of pro-inflammatory genes [85-87].

E. Inflammasome Activation
IL-1 signaling is a key component of the immune and inflammatory responses. IL1β is synthesized as an inactive 31-kD precursor molecule which requires cleavage by the
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cysteine protease caspase-1 to release biologically active mature 17-kD IL-1β [88, 89].
Inflammasomes are multiprotein complex which contain a member of the nucleotidebinding domain leucine-rich repeat (NLR) or AIM2-like receptor (ALR) family, an adaptor
molecule known as apoptosis associated speck-like protein containing a CARD (ASC) and
a caspase. Inflammasomes are activated in response to a diverse range of microbial, stress
and damage signals that trigger caspase-1 activation, resulting in maturation of the proinflammatory cytokines interleukin (IL)-1β, IL-18 and IL-33 [90-92]. A great deal of work
over the past ten years has been committed to elucidating the mechanism by which the
inflammasome is activated, and the particular ligands that are capable of initiating this
activation.
The NOD-like receptors are a diverse family of intracellular pattern recognition
receptors that contain a C-terminal leucine-rich repeat (LRR) that is thought to contribute
to ligand recognition, a central NACHT nucleotide-binding domain that is involved in
orchestrating oligomerization, and an N-terminal “effector” domain that, in the case of
inflammasome-associated NLRs, consists of a either a caspase-1 recruitment domain
(CARD) or a Pyrin domain. The adaptor molecule ASC consists of an N-terminal CARD
domain and a C-terminal Pyrin domain [93]. The classical role for ASC is to function as a
“bridge”, linking NLRs containing an N-terminal Pyrin domain with caspase-1 via PYDPYD and CARD-CARD interactions, respectively [94]. Caspase-1 is a member of the
caspase family of cysteine proteases that function to carry out a variety of cellular programs,
including programmed cell death and inflammation. The caspases, including caspase-1,
are produced as zymogens and must be activated in order to commence catalytic activity.
Caspase-1 exists as a tetramer comprised of two p10 and two p20 subunits, and undergoes
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autoactivation following its recruitment to the inflammasome complex. Upon activation,
caspase-1 functions by processing the pro-IL-1β, pro-IL-18, and pro-IL-33 to their active
forms in preparation for extracellular secretion.
The NOD-like receptors (NLRs) are a large and diverse family of intracellular
pattern recognition receptors (PPRs). All NLRs, with the exception of NLRP10, contain a
C-terminal leucine-rich repeat (LRR) which is thought to contribute to ligand recognition.
The NLRP1, NLRP3 and NLRC4 (Ipaf) inflammasomes are only inflammasome
complexes that have been shown to lead to the activation of the inflammatory caspases.
Of the inflammasomes, the NLRP3 inflammasome is by far the best characterized,
and is the model from which essentially all mechanistic data on inflammasome activation
is derived. So far, the NLRP3 inflammasome has been found to be activated in response
to a surprisingly wide variety of triggers, including pathogen-associated molecular patterns
(PAMPs) such as the flagellin component of Salmonella, danger-associated molecular
patterns (DAMPs) of which ATP and mitochondrial DNA are considered prototypes, and
even to whole pathogens such as Staphylococcus aureus, Candida albicans, and influenza
virus.
Despite much effort, the exact mechanism by which the NLRP3 inflammasome is
activated remains elusive. It is known that in the resting state, NLRP3 is located in the
cytoplasm and is accompanied by the chaperone molecules HSP90 and SGT1, which are
thought to stabilize the inactive state. By some mechanisms, the NLRP3 molecules “senses”
one of its many activators and oligomerizes, with the Pyrin domains having been shown
by x-ray crystallographic studies to “stack” and therefore allow for homotypic interaction
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with the Pyrin domain of the adaptor ASC [94]. Following ASC association, procaspase-1
is recruited and cleaved and forms an active caspase-1 tetramer.
At this time, there are essentially three models for the initiation of NLRP3
activation, and all three have approximately equal support in the literature. One model
posits that when inflammasome agonists are phagocytosed and enter the lysosome, some
property of the agonist leads to lysosomal rupture, and the presence of lysosomal enzymes
or other constituents in the cytoplasm are sensed by NLRP3 [67, 95, 96] Another model
hypothesizes that ATP, a powerful inflammasome activator in macrophages, signals via
the P2X7-receptor, leading to potassium efflux through activation of the cell membrane
channel protein Pannexin-1 [97-103]. A third model suggests that all of the inflammasome
activators lead to the generation of reactive-oxygen species (ROS), and that the presence
of cytoplasmic ROS, either by change in cellular redox state or another factor, leads to
NLRP3 activation. This model is supported by very recent work suggesting that the
mitochondria is a key mediator of ROS production, and that inflammasome components,
including ASC and NLRP3, colocalize to the mitochondria during activation [92, 104].

F. Alcohol-induced Liver Diseases
Alcoholism results in about 2.5 million deaths annually worldwide and has long
been associated with various liver diseases accounting for about 4% of all deaths [105-107].
Alcoholic liver disease (ALD) ranges from steatosis to hepatitis, fibrosis, cirrhosis and
hepatocellular carcinoma. Hepatic steatosis is the earliest response to alcohol consumption
and develops in 90% of heavy alcohol drinkers. Simple steatosis usually is asymptomatic
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and reversible. 20-25% of alcoholics will develop alcoholic hepatitis, about 15% develop
alcoholic cirrhosis and about 10% develop hepatocellular carcinoma [108]. Meanwhile,
pharmacological treatment options are limited and the outcomes from the therapies are
poor. Thus understanding the detailed mechanisms involved in the pathogenesis and
progress of ALD is critical, which serves the need of developing novel and more effective
pharmacological agents for treatment.
The pathogenesis of ALD is multifactorial and is still not fully understood.
Emerging evidences suggest that the damage is the end result of the interplay among
ethanol metabolism, inflammation and innate immunity. Acetaldehyde, a direct
metabolism of ethanol, is a highly reactive and toxic chemical to hepatocytes which
contributes to liver tissue damage because it forms a variety of protein and DNA adducts
that promote glutathione depletion, lipid peroxidation and mitochondrial dysfunction. It
also leads to the formation of reactive oxygen species (ROS), which are potent inducers of
lipid peroxidation and leads to the eventual cell death of hepatocytes. Increased endotoxin
levels in the serum have been documented in both ALD patients and alcohol-fed
experimental animals [109]. One intriguing paradigm suggests that alcohol drinking
promotes altered gastrointestinal microbiota and increased intestinal permeability.
Translocation of bacterial related products from gut into blood stream arrive at the liver
through the portal vein. Antibiotic treatment significantly reduced the pathologic change
of livers in rats exposed to ethanol, which suggested endotoxin is a crucial mediator of
ALD [110-114]. Previous studies have shown Kupffer cells, the resident macrophages of
liver, express TLRs and are responsible for the uptake of gut-derived toxins such as LPS.
Seki et.al showed that Kupffer cells could response to various concentrations LPS
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stimulation to produce pro-inflammatory cytokines (TNFα, IL-1β, IL-6, IL-12, and IL-18)
and chemokines. Notably, induction of chemokines (MIP-1α, MIP-1β, RANTES, and
MCP-5) gene expression in livers from mice induced by LPS was reduced by 80–97% after
selective depletion of Kupffer cells [115, 116]. Furthermore, long-term ethanol
administration results in sensitization of LPS-induced liver injury and secretion of TNFα
by Kupffer cells. Thus TLRs, especially TLR4 expressed on Kupffer cells, are activated by
these PAMPs, resulting in pro-inflammatory cytokine and chemokine production and
recruitment of other immune cells such as neutrophils. All of these inflammatory responses
are critical contributors to disease progression. Consistent with this, both TLR4-mutated
(C3H/HeJ) mice and TLR4-deficient mice displayed dramatically reduced levels of
proinflammatory cytokines in the liver and protected mice from liver injury in a long-term
intragastric ethanol feeding model. Several studies have shown the role of inflammasomeIL-1 signaling in acute and chronic liver injury including ALD [19, 26, 115]. Petrasek et.al.
showed that IL-1β signaling is required for the development of alcohol-induced liver
steatosis, inflammation, and injury, using mice deficient in regulators of IL-1β activation
(caspase-1and ASC) or signaling (IL-1 receptor) as well as treating mice with IL-1 receptor
antagonist [117]. It is suggested that IL-1R/TLRs signaling and/or inflammasome
pathways are potential therapeutic targets to treat ALD.
Hepatocyte cell death is a major hallmark of ethanol-induced liver injury, reflected
by increased levels of serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST). It is also used to risk stratify and monitor ALD patients. Multiple
forms of cell death, including necrosis, apoptosis and necroptosis, commonly exist in ALD,
all of which may promote liver disease progression through distinct mechanisms. DAMPs
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released from dying cells, such as high-mobility group box 1 (HMGB1), are believed to
trigger sterile inflammation and thus exacerbation of injury in acute liver diseases [118].
However, the significance of DAMPs-induced sterile inflammation involved in the
progression of alcohol-induced chronic liver injury is underestimated.
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A. Abstract
Toll-like receptors transduce their signals through the adaptor molecule MyD88
and members of the IL-1R-associated kinase family (IRAK1, 2, M and 4). IRAK1 and
IRAK2, known to form Myddosomes with MyD88-IRAK4, mediate TLR7-induced
TAK1-dependent NFκB activation. IRAKM was previously known to function as a
negative regulator that prevents the dissociation of IRAKs from MyD88, thereby inhibiting
downstream signaling. However, we now found that IRAKM was also able to interact with
MyD88-IRAK4 to form IRAKM Myddosome to mediate TLR7-induced MEKK3dependent second wave NFκB activation, which is uncoupled from posttranscriptional
regulation. As a result, the IRAKM-dependent pathway only induced expression of genes
that are not regulated at the posttranscriptional levels (including inhibitory molecules
SOCS1, SHIP1, A20 and IκBα), exerting an overall inhibitory effect on inflammatory
response. On the other hand, through interaction with IRAK2, IRAKM inhibited TLR7mediated production of cytokines and chemokines at translational levels. Taken together,
IRAKM mediates TLR7-induced MEKK3-dependent second wave NFκB activation to
produce inhibitory molecules as a negative feedback for the pathway, while exerting
inhibitory effect on translational control of cytokines and chemokines.

B. Introduction
Toll-like receptors (TLRs) detect microorganisms and protect multicellular
organisms from infection by inducing the production of proinflammatory cytokines and
chemokines [18, 24, 33, 119-121]. TLRs transduce their signals through the adaptor
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molecule MyD88 and members of the IL-1R-associated kinase (IRAK) family, which
consists of four members: IRAK1, IRAK2, IRAKM and IRAK4[122-126]. The crystal
structure of the MyD88–IRAK4–IRAK2 death domain (DD) complex, referred as
Myddosome complex, demonstrated their sequential assembly, in which MyD88 recruits
IRAK4 and the MyD88-IRAK4 complex recruits the IRAK4 substrates IRAK2 or the
related IRAK1[127]. Subsequently, the IRAK1/2 form complex with TRAF6 and
dissociate from the receptor complex to activate cascades of downstream kinases, leading
to the activation of transcription factor NFκB [69].On the other hand, IRAKM is believed
to function as a negative regulator that prevents the dissociation of IRAK1/2 from receptor
complex, thereby inhibiting downstream signaling [128].
We previously reported the co-existence of the two parallel TLR/IL-1R-mediated
NFκB activation: TAK1-dependent and MEKK3-dependent, respectively. The TAK1dependent pathway leads to IKKα/β phosphorylation and IKKγ activation, resulting in
classical NFκB activation through IκBα phosphorylation and degradation [129]. The
TAK1-independent MEKK3-dependent pathway involves IKKγ phosphorylation and
IKKα activation, which leads to NFκB activation through IκBα phosphorylation and
subsequent dissociation from NFκB but without IκBα degradation. While TLR/IL-1R
regulates gene transcription, they also induce gene expression by stabilizing otherwise
unstable mRNAs of pro-inflammatory genes. Many cytokine and chemokine mRNA
exhibit very short half-lives due to the presence of AU-rich sequence elements (ARE)
located within their 3’ untranslated regions [130]. Therefore, the regulation of mRNA
stability is an important control of inflammatory gene expression. We have previously
reported that the kinase activity of IRAK4 is required for TAK1-dependent NFκB

24

activation and mRNA stabilization of cytokines and chemokines, but not for MEKK3dependent NFκB activation [131, 132]. Based on these findings, we propose that IRAK4
mediates IL-1R-TLR-induced receptor-proximal signaling events through its kinase
activity to coordinately regulate TAK1-dependent NFκB activation and mRNA
stabilization pathways to ensure robust production of cytokines and chemokines during
inflammatory response. In addition to mRNA stabilization, TLR signaling is also necessary
for efficient and sustained translation of cytokine and chemokine mRNAs [133, 134]. The
ratios of LPS-induced cytokine and chemokine mRNAs in translation-active versus
translation-inactive pools were lower in IRAK2-deficient macrophages compared with
wild type macrophages, indicating the requirement of IRAK2 for sustained translation of
these mRNAs[135].
In this study, we investigated the functional relationships among IRAK family
members and their roles in TLR signaling by analyzing mice deficient in IRAK1, IRAK2
and/or IRAKM. We found that IRAK1 and IRAK2, substrates of IRAK4, are required for
TAK1-dependent NFκB activation and mRNA stabilization of cytokines and chemokines,
but not for MEKK3-dependent NFκB activation. In contrast to the direct inhibitory role of
IRAKM in TLR signaling, IRAKM was able to interact with MyD88-IRAK4 to form
IRAKM Myddosome to mediate TAK1-independent MEKK3-dependent NFκB activation
in the absence of IRAK1 and IRAK2. This IRAKM-dependent pathway is required for the
second wave of TLR7-induced NFκB activation in the presence of IRAK1/IRAK2, which
is uncoupled from posttranscriptional regulation. Thus, the IRAKM-dependent pathway
only induced expression of genes that are not regulated at the posttranscriptional levels
(including inhibitory molecules SOCS1, SHIP1, A20 and IκBα), exerting an overall
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inhibitory effect on inflammatory response. Taken together, this study for the first time
demonstrates unique positive engagement of IRAKM in transmitting signaling upon TLR
activation, providing important insight into the mechanistic roles of IRAKM in modulating
TLR signaling.

C. Results
IRAKM mediates TLR-induced MEKK3-dependent NFκB activation in the absence
of IRAK1 and IRAK2
Although IRAKM has been implicated as a negative regulator in TLR signaling,
the precise molecular mechanism for how IRAKM participates and modulates TLR
signaling remains unclear. We recently found that substantial TLR7-induced NFκB
activation was retained in IRAK1/2-double deficient (DKO) BMDMs, whereas completely
abolished in MyD88- or IRAK4-deficient BMDMs (Fig. 5A and data not shown). These
results suggest that MyD88-IRAK4 either themselves or in conjunction with IRAKM can
mediate NFκB activation in IRAK1/2-DKO-BMDMs. To determine the role of IRAKM in
this process, we compared TLR7-mediated NFκB activation in IRAK1/2-DKOwith that in
IRAK1/2/M-deficient (TKO) BMDMs.TLR7-mediated NFκB activation was completely
abolished in IRAK1/2/M-TKO-BMDMs, indicating the importance of IRAKM in
mediating TLR7-dependent NFκB activation in the absence of IRAK1 and IRAK2 (Fig.
5A).
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Figure 5. IRAKM mediates TLR7-induced NFκB activation in the absence of IRAK1
and IRAK2. A. Nuclear extracts prepared from wild-type (WT), IRAK1/2-double
deficient (IRAK1/2 DKO), IRAK1/2/M-triple deficient (IRAK1/2/M TKO), IRAK4deficient (IRAK4 KO) bone marrow-derived macrophages (BMDMs) untreated or treated
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with TLR7 ligand R848 (1μg/ml) for the indicated times were analyzed by electrophoresis
mobility shift assay using an NFκB-specific probe. B. Cell lysates from wild-type (WT),
IRAK1/2- double deficient (IRAK1/2 DKO), IRAK1/2/M-triple deficient (IRAK1/2/M
TKO) bone marrow-derived macrophages (BMDMs) untreated or treated with TLR7
ligand R848 (1μg/ml) for the indicated times were analyzed by Western blot analysis with
antibodies against IRAK1, IRAK2, p-IKKα/β, TAK1, MEKK3, p-IκBα, IκBα, p-JNK, pp38, p-ERK and actin. The experiments were repeated for five times with similar results.

We previously uncovered two parallel TLR-mediated MyD88/IRAK4-dependent
signaling pathways for NFκB activation, TAK1-dependent and independent, respectively
[129]. The TAK1-dependent pathway leads to IKKα/β phosphorylation and IKKα
activation, resulting in classical NFκB activation through IκBα phosphorylation and
degradation. The TAK1-independent pathway involves activation of MEKK3 and IKKα,
resulting in NFκB activation through IκBα phosphorylation and subsequent dissociation
from NFκB but without IκBα degradation. TLR7-induced TAK1 activation (shown as
slower mobility shift bands) was greatly reduced in IRAK1/2-DKO-BMDMs, while
IRAK1/2-double deficiency also substantially decreased TLR7-induced IKKα/β
phosphorylation, indicating the important role of IRAK1/IRAK2 in mediating TAK1dependent NFκB activation.TLR7-induced TAK1-mediated IKK activation leads to the
phosphorylation and degradation of IκBα. Indeed, TLR7-induced IκBα degradation was
attenuated in theIRAK1/2-DKO-BMDMs.
However, consistent with the NFκB gel-shift assay, TLR7-induced IκBα
phosphorylation was still retained in IRAK1/2-DKO-BMDMs, which was completely
abolished in IRAK1/2/M-TKO-BMDMs, indicating the importance of IRAKM in
mediating TLR7-induced TAK1-independent NFκB activation in IRAK1/2-DKOBMDMs (Fig. 5B). Importantly, through co-immunoprecipitation we found that IRAKM
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formed a complex with MEKK3, but not with TAK1 (Fig. 5A-B). Furthermore, TLR7induced MEKK3 modification was still retained in IRAK1/2-DKO-BMDMs, whereas
abolished in IRAK1/2/M-TKO-BMDMs (Fig. 5A). Taken together, these results suggest
that IRAKM probably mediates TLR7-induced NFκB activation through the TAK1independent MEKK3-dependent pathway in the absence of IRAK1 and IRAK2. In addition
to NFκB activation, TLR7-mediated JNK and ERK phosphorylation were completely
abolished in IRAK1/2/M-TKO-BMDMs, although some levels of phosphorylation of p38
was still retained. Importantly, this positive signaling role of IRAKM was not restricted to
TLR7. Similarly, TLR2- and TLR9-induced phosphorylation of IκBα were still retained in
IRAK1/2-DKO-BMDMs, which was completely abolished in IRAK1/2/M-TKO-BMDMs,
implicating the participation of IRAKM in TLR2- and TLR9-mediated signaling. However,
it is important to point out, while TLR9-induced IκBα phosphorylation in IRAK1/2-DKOBMDMs was comparable to that in wild-type cells, TLR2-induced IκBα phosphorylation
in IRAK1/2-DKO-BMDMs was substantially reduced compared to that in wild-type cells,
suggesting differential utilization of IRAKM by different TLRs (Fig. 7).
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Figure 6. IRAKM forms Myddosome with MyD88-IRAK4 to mediate signaling
through MEKK3 and TRAF6. A. IRAKM-deficient mouse embryonic fibroblast(MEFs)
infected with retroviruses containing empty vector construct (Vector) and FLAG-IRAKM
were treated with IL-1β (1ng/ml) for the indicated times, followed by immunoprecipitation
(IP) with anti-FLAG antibody and analyzed by Western blot analyses using antibodies
against MyD88, IRAK4, TRAF6, MEKK3, TAK1 and FLAG. The whole cell lysates
(WCL) were subjected to the same Western analyses, including actin as a control. The
experiments were repeated for five times with similar results. B. IRAK1/2/M-triple
deficient (IRAK1/2/M TKO) BMDMs infected with adenovirus containing empty vector
construct (Vector) and HA-tagged IRAKM (HA-IRAKM) were treated with R848 (1ng/ml)
for the indicated times, followed by immunoprecipitation (IP) with anti-HA antibody and
analyzed by Western blot analysis with antibody against MyD88, IRAK4, TRAF6,
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MEKK3, TAK1 and FLAG. The whole cell lysates (WCL) were subjected to the same
Western analyses, including actin as a control. The experiments were repeated for five
times with similar results

Figure 7. IRAKM mediates TLR2/9-induced NFκB activation in the absence of
IRAK1 and IRAK2. A. Cell lysates from wild-type (WT), IRAK1/2- double deficient
(IRAK1/2 DKO), IRAK1/2/M-triple deficient (IRAK1/2/3 TKO) bone marrow-derived
macrophages (BMDMs) untreated or treated with TLR2 ligand Pam3CSK4 (200ng/ml) for
the indicated times were analyzed by Western blot analysis with antibodies against pIKKα/β, p-IκBα, IκBα, and actin. The experiments were repeated for five times with
similar results. B. Cell lysates from wild-type (WT), IRAK1/2- double deficient (IRAK1/2
DKO), IRAK1/2/M-triple deficient (IRAK1/2/3 TKO) bone marrow-derived macrophages
(BMDMs) untreated or treated with TLR9 ligand CpG B (1μg/ml) for the indicated times
were analyzed by Western blot analysis with antibodies against p-IKKα/β, p-IκBα, IκBα,
and actin. The experiments were repeated for five times with similar results.
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IRAKM mediates IL-1R-induced NFκB activation through formation of Myddosome
with MyD88-IRAK4
Lin et al recently reported the crystal structure of the MyD88–IRAK4–IRAK2
death domain (DD) complex, which revealed a left-handed helical oligomer that consists
of 6 MyD88, 4 IRAK4 and 4 IRAK2 DDs[127]. This helical signaling tower is referred as
Myddosome complex and its assembly is sequential, in which MyD88 recruits IRAK4 and
the MyD88-IRAK4 complex recruits the IRAK4 substrates IRAK2 or the related IRAK1.
This study has provided great insight into how IL-1R and also TLRs utilize adaptor
molecule MyD88 to recruit IRAKs to mediate its signaling. The question here was how
TLR/IL-1R utilizes IRAKM to mediate signaling in the absence of IRAK1 and IRAK2.
Since MyD88- or IRAK4-deficient BMDMs had completely abolished TLR/IL-1Rmediated NFκB activation, indicating that TLR/IL-1R-induced IRAKM-mediated NFκB
activation in the IRAK1/2-DKO-BMDMs must be MyD88-IRAK4-dependent. In the light
of the crystal structure of MyD88-IRAK4-IRAK2 DD Myddosome, we hypothesized that
IRAKM might also be capable of forming a complex with MyD88-IRAK4 to mediate
signaling. We indeed detected IL-1-induced interaction of IRAKM with MyD88, IRAK4,
TRAF6 and MEKK3, but not with TAK1 when we restored IRAKM-deficient MEFs with
tagged-IRAKM (Fig. 6A). Furthermore, TLR-induced interaction of IRAKM with
MyD88, IRAK4, TRAF6 and MEKK3 (but not with TAK1) can take place in the absence
of IRAK1 and IRAK2 when we introduced tagged-IRAKM into the IRAK1/2/M-TKOBMDMs (Fig. 6B). These data indicate the formation of IRAKM Myddosome (MyD88IRAK4-IRAKM), which is probably responsible for TLR-induced IRAKM-mediated
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NFκB activation in the absence of IRAK1 and IRAK2 through the MEKK3-dependent, but
not the TAK1-dependent pathway.
The N-terminal DD of IRAKM shares a considerable sequence identity to those of
other members of the IRAK family. The similarity of topologies within this region (DD)
of IRAKM to the region of IRAK2 suggested that this region of IRAKM may adopt a
similar protein fold. To test this prediction, we built a three-dimensional model of the
region of IRAKM DD (residues 14-105). The model has secondary structure elements
similar to those of other IRAK DDs with a hexahelical bundle [136]. The model places a
cluster of hydrophilic residues on the surface that is reminiscent to that of IRAK2 DD when
bound to IRAK4 DD[127]. IRAK4-binding residues with IRAK2 are highly conserved in
IRAKM DD, suggesting that IRAKM is assembled with IRAK4 DD in a similar manner
to IRAK2 (Fig. 8). In particular, the conserved W74 (W62 in IRAK2) in helix H4 of the
IRAKM DD is likely a key residue for interacting with IRAK4 DD. The model also a
conserved salt bridge between E71 (E59 in IRAK2) in helix H4 of the IRAKM and R54 in
IRAK4, suggesting a critical role of the helix H4 segment in IRAKM for recognizing
IRAK4. Interestingly, Q78 in IRAKM is a polar residue and distinct from the equivalent
residue in IRAK2 (M66) but the hydrophobic side chain portion of Q78 seems to make the
hydrophobic interaction with IRAK4 whereas the hydrophilic part of Q78 in IRAKM may
interact with the backbone oxygen atoms of F25, E92, and F93 in IRAK4.
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Figure 8. Computer modeling of IRAKM Myddosome complex. Conserved binding
interface in the interaction of IRAKM with IRAK4 (Left). A three-dimensional model of
the MyD88-IRAK4-IRAKM Myddosome complex (Middle). A putative binding interface
in the death domain (DD) between IRAKM (blue) and IRAK4 (yellow), as guided by
molecular modeling study. The helix H4 of IRAKM DD seems to be a critical element for
the interaction with IRAK4 DD. Putative binding residues in the helix H4 in the IRAKM
in the interaction with IRAK4 are highlighted. Specifically, the surface exposed E71 on the
helix H4 of IRAKM makes a salt bridge with R54 from one IRAK4 DD molecule, and this
salt bridge formation is conserved in the IRAK2 DD/IRAK4 DD interface. The E71mediated IRAKM DD/IRAK4 DD interaction is further stabilized by a hydrophilic
interaction with Q29 from another neighboring IRAK4 DD molecule upon the Myddosome
formation. W74 of IRAKM is situated in the center of the helix H4 and packs against a
hydrophobic environment that is created by two IRAK4 DD monomers upon Myddosome
formation. Q78 in IRAKM may play an important role both in the hydrophilic and
hydrophobic interactions with IRAK4 (see text). The significance of these side chains of
IRAKM in the interaction with IRAK4 was verified by our site-directed mutagenesis study
(Right). The interaction interface in the DD between IRAK2 (magenta) and IRAK4
(yellow), as evidenced by crystallographic study.

To test the proposed binding interface, we made individual and combined point
mutants of IRAKM in retroviral vector. We have previously shown that IRAKM was able
to restore IL-1-induced NFκB activation in 293-derived IRAK1-deficient cells (293-I1A
cells), in which IRAKM and IRAK2 expression were not detectable (absent or very low)
[125]. Therefore, this cell line was used to test the ability of IRAKM to form Myddosome
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in response to IL-1 stimulation. Fig 2C shows that E71A and Q78G each showed partial
defect whereas the combination of these two mutations (E71A/Q78G) drastically decreased
the binding of IRAKM to IRAK4. Furthermore, the W74A IRAKM mutant completely lost
the interaction with IRAK4 (Fig. 9A). We next used this cell line to examine the ability of
IRAKM mutants in mediatingIL-1-dependent NFκB activation. IRAKM wild-type and
mutants were co-transfected with NFκB-dependent luciferase reporter construct (Eselectin-Luc) into 293-I1A cells, followed by IL-1 treatment and luciferase assay. The
W74A IRAKM mutant completely lost the ability to activate NFκB in 293-I1A cells upon
IL-1 stimulation (Fig. 9B). On the other hand, while E71A and Q78G exhibited partial
defect, the combination of these two mutations (E71A/Q78G) greatly decreased the IL-1induced NFκB-dependent luciferase activity in 293-I1A cells (Fig. 9B). The same results
were obtained from the analysis of the IRAKM mutants in NFκB electrophoretic mobility
shift assay (Fig. 9C). Consistent with its ability in mediating IL-1-induced NFκB
activation, IRAKM was also able to restore IL-1-induced IL-8 and TNFα gene expression
in 293-I1A cells (Fig. 9D). Importantly, W74A and E71A/Q78G IRAKM mutants failed
to restore the IL-8 and TNFα gene expression in 293-I1A cells in response to IL-1
stimulation (Fig. 9D). Moreover, since we predict the hydrophilic part of Q78 in IRAKM
may interact with the backbone oxygen atoms of F25 in IRAK4, we generated the IRAK4
F25D mutant. When tested in IRAK4-deficient cells, this F25D mutant showed decreased
interaction with IRAKM compared with wild-type IRAK4 upon IL-1 stimulation (Fig. 10),
confirming the critical contact between Q78 in IRAKM and F25 in IRAK4.
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Figure 9. Restoration of IRAKM wild-type and mutants in 293-I1A cell. A. IRAK1deficient 293-IL1R (I1A) cells transfected with empty vector, FLAG-tagged wild-type
IRAKM (WT), FLAG-tagged IRAKM mutants (F18A, E71A, Q78A, W74A and
E71A/Q78G) were treated with IL-1β (1ng/ml) for the indicated times, followed by
immunoprecipitation (IP) with anti-IRAK4 antibody and analyzed by Western blot analysis
with antibody against FLAG to detect IRAKM. B. IRAKM wild-type and mutants (F18A,
E71A, Q78A, W74A and E71A/Q78G) were transiently co-transfected with NFκBdependent luciferase reporter construct (E-selectin-Luc) into IRAK1-deficient 293-IL1R
(293-I1A) cells, followed by IL-1 (1ng/ml) treatment for 6 hours and luciferase assay. The
experiment was repeated three times. Data represent mean ±SEM; *, p<0.05(two tailed ttest). C. Nuclear extracts prepared from 293-I1A cells transiently co-transfected with wildtype (WT), W74A and E71A/Q78A untreated or treated with IL-1β (1ng/ml) for the
indicated times were analyzed by electrophoretic mobility shift assay using an NFκB
specific probe. D. IRAK1-deficient 293-IL1R (I1A) cells transiently transfected with
empty expression vector, wild-type IRAKM, and IRAKM mutants (W74A and
E71A/Q78G) were treated with IL-1β (1ng/ml) for the indicated times. Total RNAs from
these cells were subjected to real-time PCR analysis for the levels of human IL-8 and TNFα
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mRNAs. The experiments were repeated three times. Data represent mean ± SEM; *,
p<0.05 (two tailed t-test).

Figure 10. F25 in IRAK4 is required for the interaction with IRAKM. IRAK4 wildtype (WT) and F25D mutant (F25D) were retrovirally expressed together with FLAGtagged IRAKM in IRAK4 deficient fibroblasts. Cells were treated with IL-1β (1ng/ml) for
the indicated times, followed by immunoprecipitation (IP) with IRAK4 antibody and
analyzed by Western blot analyses using antibodies against FLAG and IRAK4. WCL
(whole cell lysates). The experiments were repeated for five times with similar results.

We then confirmed the binding interface of IRAKM with IRAK4 in response to
TLR7 stimulation. IRAKM wild-type and mutants were expressed in IRAK1/2/M-TKOBMDMs by adenovirus infection. Consistent with the results for the IL-1 response, wildtype IRAKM was able to interact with IRAK4 and restored TLR7-induced NFκB activation
in IRAK1/2/M-TKO-BMDMs, whereas W74A mutant lost its ability to interact with
IRAK4 and failed to mediate NFκB activation. While E71 and Q78G showed partial
reduction, the combinational mutant E71A/Q78G was unable to interact with IRAK4 with
abolished TLR7-induced NFκB activation (Fig. 11A-B). Furthermore, W74A and
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E71A/Q78G mutants also failed to restore CXCL1, TNFα and IL-6 gene expression in
IRAK1/2/M-TKO-BMDMs upon TLR7 stimulation (Fig. 11C). Taken together, these
results provide strong supporting evidence for the interaction between DDs of IRAKM and
IRAK4 and demonstrate that this interaction is critical for IRAKM to mediate IL-1R/TLRinduced NFκB activation.

Figure 11. Restoration of wild-type and IRAKM mutants in IRAK1/2/M-triple
deficient cells. A. IRAK1/2/M-triple deficient (IRAK1/2/M TKO) BMDMs infected with
adenovirus expressing HA-tagged wild-type IRAKM (WT) and HA-tagged IRAKM
mutants (F18A, E71A, Q78A, W74A and E71A/Q78G) were treated with R848 (1ng/ml)
for the indicated times, followed by immunoprecipitation (IP) with anti-IRAK4 antibody
and analyzed by Western blot analysis with antibody against HA to detect IRAKM. The
experiments were repeated for five times with similar results. B. IRAK1/2/M-triple
deficient (IRAK1/2/M TKO) BMDMs infected with adenovirus expressing HA-tagged
wild-type IRAKM (WT) and HA-tagged IRAKM mutants (F18A, E71A, Q78A, W74A
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and E71A/Q78G) were treated with R848 (1ng/ml) for the indicated times, followed by
Western blot analyses with antibodies against p-p65 p-IκBα, IκBα, and actin. The
experiments were repeated for five times with similar results. C. IRAK1/2/M-triple
deficient (IRAK1/2/M TKO) BMDMs infected with adenovirus expressing HA-tagged
wild-type IRAKM (WT) and HA-tagged IRAKM mutants (F18A, E71A, Q78A, W74A
and E71A/Q78G) were treated with R848 (1ng/ml) for the indicated times. Total RNAs
from these cells were subjected to real-time PCR analysis for the levels of mouse CXCl1,
TNFα and IL-6 mRNAs. The experiment was repeated three times. Data represent mean ±
SEM; *, p<0.05(two tailed t-test).

IRAKM deficiency resulted in decreased second wave TLR7-induced NFκB
activation in the presence of IRAK1 and IRAK2
Previous studies suggested that IRAKM functions as a negative regulator that
prevents the dissociation of IRAKs from MyD88, thereby inhibits all downstream signaling
events including NFκB activation [128]. Considering how IRAKM can form Myddosome
and is capable of mediating TLR/IL-1R signaling in the absence of IRAK1/IRAK2, we
decided to re-investigate the impact of IRAKM single deficiency on TLR7-mediated
signaling. To our surprise, IRAKM deficiency decreased TLR7-induced late phase NFκB
activation (after 0.5h) in a gel-shift assay (Fig. 12A). The TAK1-dependent downstream
signaling events (phosphorylation of TAK1 and IKKα/β and IκBα degradation) were
similar or slightly enhanced in IRAKMKO-BMDMs compared to that in control cells.
However, whereas TLR7-induced IκBα and p65 phosphorylation were comparable at early
times (within 10min), they were substantially reduced at later times (after 30min) (Fig.
12B). These results suggest that IRAKM Myddosome contributes to the second wave of
TLR7-induced NFκB activation in the presence of IRAK1 and IRAK2, probably through
the TAK1-independent pathway.
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Figure 12. The role of IRAKM in second wave of TLR-mediated NFκB activation. A.
Nuclear extracts prepared from wild-type (WT), and IRAKM deficient (MKO) BMDMs
untreated or treated with R848 (1μg/ml) for the indicated times were analyzed by
electrophoretic mobility shift assay using an NFκB specific probe. The experiments were
repeated for five times with similar results. B. Cell lysates from wild-type (WT), and
IRAKM deficient (MKO) BMDMs untreated or treated with R848 (1μg/ml) for the
indicated times were analyzed by Western blot analyses with antibodies against TAK1,
MEKK3, p-IKKα/β, p-p65, p-IκBα, IκBα, p-JNK, p-ERK, p-p38 and actin. The
experiments were repeated for five times with similar results.
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Our previous studies showed MG132, which inhibits proteasome-dependent
protein degradation, can block TLR-mediated TAK1-depenent pathway (phosphorylation
of TAK1 and IKKα/β and IκBα degradation), since IRAK1 ubiquitination and degradation
is critical for TAK1-dependent downstream signaling [137] (Fig. 13A). On the other hand,
MG132 does not block the TLR-induced MEKK3-dependent pathway, as evident by intact
TLR-induced phosphorylation of MEKK3 and IκBα; and substantial residual JNK, p38 and
ERK activation after MG132 treatment. Therefore, to confirm the role of IRAKM in TLR7induced TAK1-independent MEKK3-dependent signaling, we examined the impact of
MG132 on TLR7-induced signaling in IRAKMKO BMDMs. We indeed found that
pretreatment of MG132 greatly reduced TLR7-induced phosphorylation of MEKK3, IκBα,
JNK, p38 and ERK in IRAKM-deficient BMDMs compared to its impact on wild-type
control cells. These results showed that IRAKM-mediated signaling becomes the dominant
pathway when the TAK1 pathway is blocked by MG132, supporting that IRAKM
Myddosome might mediate the second wave of TLR7-induced NFκB activation through
the TAK1-independent MEKK3-dependent pathway (Fig. 13B). To confirm the role of
MEKK3 in IRAKM-mediated NFκB activation, IRAKM was co-transfected with NFκBdependent luciferase reporter construct (E-selectin-Luc) into scramble shRNA-transfected
or MEKK3 knock-down 293-I1A cells, followed by IL-1 treatment and luciferase assay.
IL-1-induced IRAKM-mediated NFκB activation was greatly reduced in MEKK3 knockdown cells compared to that in the control cells (Fig. 14C&D). Taken together, these data
support that IRAKM Myddosome-mediated NFκB activation is through the MEKK3dependent pathway.
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Figure 13. IRAKM-mediated NFκB activation is dependent on MEKK3. A. BMDMs
from wild-type (WT) were pre-treated with/without MG132 (20μM) for 2 hours followed
by R848 (1μg/ml) treatment for the indicated time. B. BMDMs from wild-type (WT) and
IRAKM deficient (MKO) mice were pre-treated with MG132 (20μM) for 2 hours followed
by R848 (1μg/ml) treatment for the indicated time. Western blot analysis was performed
by antibodies againstTAK1, MEKK3, p-IKKα/β, p-IκBα, IκBα, p-JNK, p-ERK, p-p38 and
actin. The experiments were repeated for five times with similar results. C. MEKK3 knockdown (MEKK3 KD) cells and control (Scrambled) cells were transiently co-transfected
with IRAKM and NFκB-dependent luciferase reporter construct (E-selectin-Luc) followed
by IL-1 (1ng/ml) treatment for 6 hours and luciferase assay. The experiments were repeated
three times. Data represent mean ± SEM; *, p<0.05(two tailed t-test). D. FALG-tagged
IRAKM transfected MEKK3 knock-down (MEKK3 KD) cells and control (Scrambled)
cells were treated with IL-1 (1ng/ml) for indicated time, followed by Western blot
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analyses with antibodies against MEKK3, FLAG, p-IκBα, IκBα and actin. The experiments
were repeated for five times with similar results.

IRAKM is required for TLR7-induced expression of inhibitory molecules SHIP1,
SOCS1, A20 and IκBα
One important question is then whether TLR-induced IRAKM-mediated signaling
has any impact on gene expression.IRAK1/IRAK2 double deficiency results insubstantial
impairment of TLR-mediated production of pro-inflammatory cytokines and chemokines
[138]. It is important to note that the TLR-induced IRAKM-mediated signaling events in
IRAK1/2-DKO-BMDMs allowed the induction of cytokines and chemokines mRNAs at
early times (peak at 30min), such as TNFα and CXCL1 (KC), which was completely
abolished in IRAK1/2/M-TKO-BMDMs (Fig. 14A). However, since IRAK2 is required
for posttranscriptional control of the TNFα and CXCL1 (KC) mRNAs, we failed to detect
TNFα and CXCL1 (KC) mRNAs at later times (after 1 hour) and thus little protein
production of TNFα and CXCL1 (KC) in IRAK1/2-DKO-BMDMs (Fig. 14B).Therefore,
the IRAK1/IRAK2-mediated coupling of the TAK1-dependent NFκB activation and
posttranscriptional regulation plays an essential role in the production of these proinflammatory cytokines and chemokines. Although TLR7-induced IRAKM-mediated
signaling in IRAK1/2 DKO-BMDMs can mediate the induction of cytokines and
chemokines mRNAs at early times, this IRAKM-mediated pathway alone in the absence
of IRAK1 and IRAK2 is insufficient to induce the production of cytokines and chemokines
that are under the posttranscriptional control. Similar results were obtained for TLR2 and
TLR9 signaling pathways (Fig. 15).
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Fig. 14. IRAK1 and IRAK2 are required for TLR7-induced pro-inflammatory gene
expression. A. Total mRNAs from BMDMs of wild-type (WT), IRAK1/2-double deficient
(DKO) and IRAK1/2/M-triple deficient (TKO) mice treated with R848 (1μg/ml) for the
indicated times, were subjected to RT-PCR analyses for the levels of CXCL1, IL-6 and
TNFα expression. B. BMDMs from wild-type (WT), IRAK1/2 double deficient (DKO)
and IRAK1/2/M triple deficient (TKO) mice were treated with R848 (1μg/ml) for the
indicated time. CXCL1, IL-6 and TNFα concentrations in the supernatant were measured
by ELISA. The experiments were repeated three times. Data represent mean ± SEM; **,
P<0.01; *, p<0.05(two tailed t-test).
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Figure 15. IRAK1 and IRAK2 are required for TLR2/9-induced pro-inflammatory
gene expression. A. Total mRNAs from BMDMs of wild-type (WT), IRAK1/2-double
deficient (DKO) and IRAK1/2/M-triple deficient (TKO) mice treated with Pam3CSK4
(200ng/ml) for the indicated times, were subjected to RT-PCR analyses for the levels of
CXCL1, IL-6 and TNFα expression. B. Total mRNAs from BMDMs of wild-type (WT),
IRAK1/2-double deficient (DKO) and IRAK1/2/M-triple deficient (TKO) mice treated
with CpG B (1μg/ml) for the indicated times, were subjected to RT-PCR analyses for the
levels of CXCL1, IL-6 and TNFα expression. The experiments were repeated three times.
Data represent mean ±SEM; **p<0.01, *p<0.05 (two tailed t-test).
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We have previously also identified a group of TLR-induced genes that are not
regulated at posttranscriptional levels [131]. The TLR7-induced IRAKM-mediated
signaling events in IRAK1/2-DKO-BMDMs allowed sustained induction of these genes,
which was completely abolished in IRAK1/2/M-TKO-BMDMs (Fig. 16A).Furthermore,
the expression of these genes was also substantially reduced in IRAKM-KO-BMDMs
compared to that in wild-type cells (Fig. 16B). Several of the genes are important for the
activation and homeostasis of the macrophages (including ETS2, SOD2, Bcl-2A1D and
GPR84) (Fig. 16A-B). Another group of IRAKM-dependent genes is inhibitory molecules,
including A20, SOCS1, SHIP1 and IκBα (Fig. 16A-B, Fig. 17). The gene expression data
were consistent with the role of IRAKM in TLR7-induced second wave NFκB activation,
since most of the IRAKM-dependent genes were late genes (induced after 1 hour).
Although A20 was readily induced at 30 min, its expression peaked at 4 hours of treatment.
Taken together, these results suggest that at least one potential importance of TLR7induced IRAKM-mediated signaling is to induce the expression of several inhibitory
molecules (SHIP1, SOCS1, A20 and IκBα, which might serve as a negative feedback
control, implicating a novel inhibitory mechanism by which IRAKM modulates TLR
signaling.
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Figure 16. IRAKM is required for TLR7-induced expression of inhibitory molecules
SHIP-1, SOCS1, A20 and IκBα. A. Total mRNAs from BMDMs of wild-type (WT),
IRAK1/2-double deficient (DKO) and IRAK1/2/M-triple deficient (TKO) mice treated
with R848 (1μg/ml) for the indicated times, were subjected to RT-PCR analyses for the
levels of ETS2, SOD2, Bcl-2A1D, GPR84, SHIP-1, SOCS1, A20 and IκB expression. B.
Total mRNAs from BMDMs of wild-type (WT) and IRAKM-deficient (MKO) mice
treated with R848 (1μg/ml) for the indicated times, were subjected to RT-PCR analyses for
the levels of ETS2, SOD2, Bcl-2A1D, GPR84, SHIP-1, SOCS1, A20 and IκBαexpression.
The experiments were repeated three times. Data represent mean ± SEM; **, P<0.01;*,
p<0.05(two tailed t-test).
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Figure 17. IRAKM is required for TLR7-induced protein translation of SHIP1 and
SOCS1. A. Cell lysates from wild-type (WT), IRAK1/2- double deficient (IRAK1/2 DKO),
IRAK1/2/M-triple deficient (IRAK1/2/3 TKO) bone marrow-derived macrophages
(BMDMs) untreated or treated with R848 (1μg/ml) for the indicated times were analyzed
by Western blot analysis with antibodies against SHIP1, SOCS1, and actin. The
experiments were repeated for five times with similar results. B. Cell lysates from wildtype (WT), and IRAKM deficient (MKO) BMDMs untreated or treated with R848 (1μg/ml)
for the indicated times were analyzed by Western blot analyses with antibodies against
SHIP1, SOCS1, and actin. The experiments were repeated for five times with similar
results.

IRAKM inhibits translational control of proinflammatory cytokines via its
interaction with IRAK2
Although it is clear that IRAKM contributes to TLR7-induced gene transcription
through the activation of second wave of NFκB activation, the production of someproinflammatory cytokines and chemokines(including CXCL1, TNFα and IL-6) was actually
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enhanced in the IRAKMKO-BMDMs compared to that in the control cells [128](Fig. 18B).
Since the mRNAs of these pro-inflammatory genes were induced at similar or reduced
levels in IRAKMKO-BMDMs as compared to wild-type cells (Fig. 18A), we investigated
the possible role of IRAKM in regulation of cytokine and chemokine translation. BMDMs
from IRAKM-deficient mice and wild-type mice were treated with TLR7 ligand R848 for
1.5 hours and a sucrose gradient was used to separate the mRNA translation-inactive pool
(free ribosome) and translation-active pool (poly-ribosomes) (Fig. 19A). Compared with
wild-type BMDMs, IRAKM KO BMDMs had more cytokine and chemokine mRNAs (IL6, KC and TNFα) in the translation-active pool. IRAKM deficiency thus resulted in the
increased ratios of TLR-induced cytokine and chemokine mRNAs in translation-active
pool versus translation-inactive pool (Fig. 19B&E). On the other hand, IRAKM deficiency
had no impact on the translation of mRNAs that are not regulated at the post-transcriptional
levels, including the inhibitory molecules (ETS2, SOD2, Bcl-2A1D, GPR84, SHIP1,
SOCS1, A20 and IκBα (Fig. 19C-D&E).
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Figure 18. IRAKM inhibits TLR7-induced pro-inflammatory gene expression. A.
Total mRNAs from BMDMs of wild-type (WT) and IRAKM-deficient (MKO) mice
treated with R848 (1μg/ml) for the indicated times, were subjected to RT-PCR analyses for
the levels of CXCL1, IL-6 and TNFα expression. B. BMDMs from wild-type (WT) and
IRAKM-deficient (MKO) mice were treated with R848 (1μg/ml) for the indicated time.
CXCL1, IL-6 and TNFα concentrations in the supernatant were measured by ELISA. The
experiments were repeated three times. Data represent mean ± SEM; **P<0.01.
*p<0.05(two tailed t-test).
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Figure 19. IRAKM inhibits the translation of TLR7-induced pro-inflammatory genes.
A. Translation-active and –inactive mRNAs from R848-treated BMDMs were isolated by
sucrose gradient fraction. B-D.BMDMs from wild-type (WT) and IRAKM deficient (MKO)
mice were treated with R848 (1μg/ml) for 90 min. (B) IL-6, KC and TNFα; (C)ETS2,
SOD2, Bcl2A1D and GPR84; (D)A20, SOCS1, SHIP1 and IκBα and glyceraldehyde-3phosphate dehydrogenase (GAPDH) mRNAs from unfractionated cell lysates, translationactive pools, and translation-inactive pools were analyzed by quantitative RT-PCR and
normalized to β-actin (see supple. Fig. 4). The ratios of mRNAs from R848-treated
translation-active and –inactive pools are shown in B-D. The experiments were repeated
three times. Data represent mean±SEM; **P<0.01. *p<0.05(two tailed t-test). E.IL-6, KC,
TNFα, A20, SOCS1, SHIP1, IκBα and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNAs from unfractionated cell lysates, translation-active pools, and
translation-inactive pools were analyzed by quantitative RT-PCR and normalized to β-actin.
Similar results were obtained in three independent experiments. One representative is
shown.

We previously reported that IRAK2 plays an important role in the regulation of
TLR-mediated protein translation of cytokines and chemokines, including IL-6, CXCL1
(KC) and TNFα. Through co-immunoprecipitation experiment, we found that IRAKM
specifically bound to IRAK2, not IRAK1 (Fig. 20A). Furthermore, we have previously
reported that IRAK2 is required for TLR-induced phosphorylation of MNK1, MK2 and
eIF4e, which are involved in protein translational control. Interestingly, IRAKM
deficiency resulted in increased TLR7-induced phosphorylation of MNK1, MK2 and eIF4e
(Fig. 20B), supporting the role of IRAKM in inhibition of TLR7-induced proinflammatory
cytokine and chemokine translation through its interaction with IRAK2.
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Figure 20. IRAKM inhibits the translation of TLR7-induced pro-inflammatory genes
through its interaction with IRAK2. A. IRAKM-deficient mouse embryonic fibroblast
(MEFs) infected with retroviruses containing empty vector construct (Vector) and FLAGIRAKM were treated with IL-1β (1ng/ml) for the indicated times, followed by
immunoprecipitation (IP) with anti-FLAG antibody and analyzed by Western blot analyses
using antibodies againstIRAK1, IRAK2 and FLAG. WCL (whole cell lysates). The
experiments were repeated for five times with similar results. B. Cell lysates from wildtype (WT), and IRAKM deficient (MKO) BMDMs untreated or treated with R848 (1μg/ml)
for the indicated times were analyzed by Western blot analyses with antibodies against pMKK3/6, p-MNK1, p-MK2, p-eIF4F and actin. The levels of the phosphorylated proteins
were analyzed by ImageJ 1.43u and normalized to actin. * indicates non-specific band. The
experiments were repeated for five times with similar results.
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Figure 21. Model for the regulatory role of IRAKM in TLR-IL-1R signaling. IRAKM
is able to function as an intermediate signaling component to transmit signaling upon TLRIL-1R activation. IRAKM interacts with MyD88-IRAK4 to form IRAKM Myddosome to
mediate TLR-IL-1R-induced MEKK3-dependent second wave NFκB activation. However,
this IRAKM-dependent pathway only induces expression of genes that are not regulated at
the posttranscriptional levels (including inhibitory molecules SOCS-1, SHIP-1, A20 and
r hand,
IRAKM specifically interacts with IRAK2, but not IRAK1, and suppresses TLR-IL-1Rinduced IRAK2-mediated translation of cytokines and chemokines.
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D. Discussion
Although previous studies suggested that IRAKM prevents the dissociation of
IRAKs from MyD88, suppressing all downstream signaling, there have not been sufficient
experimental evidences to fully support this hypothesis. In this manuscript, we provided
two novel mechanisms for the regulatory role of IRAKM in TLR signaling (Fig. 21). First,
IRAKM is able to function as an intermediate signaling component to transmit signaling
upon TLR activation. IRAKM interacts with MyD88-IRAK4 to form IRAKM Myddosome
to mediate TLR7-induced MEKK3-dependent second wave NFκB activation. However,
this IRAKM-dependent pathway only induces expression of genes that are not regulated at
the posttranscriptional levels (including inhibitory molecules SOCS-1, SHIP-1, A20 and
IκBα), exerting an overall inhibitory effect on inflammatory response. The second novel
mechanism is that IRAKM specifically interacts with IRAK2, but not IRAK1, and
suppressesTLR7-induced IRAK2-mediated translation of cytokines and chemokines.
These findings present a new outlook for how IRAKM modulates TLR signaling and TLRmediated inflammatory responses.
The role of IRAKM in MEKK3-dependent NFκB activation was best demonstrated
in IRAK1/2-DKO- versus IRAK1/2/M-TKO-BMDMs. While IRAK1/2 double deficiency
abolished TAK1-, but not MEKK3-dependent pathway, TLR7-induced NFκB activation
was no longer detectable in IRAK1/2/M-TKO-BMDMs. It is intriguing that IRAKM single
deficiency resulted in loss of TLR7-induced late NFκB activation (after 30min),
implicating the role of the IRAKM-MEKK3 pathway in second wave of NFκB activation
in the presence of IRAK1/2. The importance of IRAKM in NFκB activation was further
demonstrated in the MG132 treatment experiment, in which IRAKM deficiency greatly
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diminished TLR7-induced NFκB activation, since MG132 treatment was shown to block
the TAK1-dependent pathway, mimicking IRAK1/2 deficiency [137]. These mouse
genetic experiments on the novel role of IRAKM were nicely supported by biochemical
studies. IRAKM-mediated NFκB activation was almost abolished in MEKK3 knock-down
cells and IRAKM specifically interacted with MEKK3, but not TAK1, providing direct
biochemical evidence for the role of IRAKM in MEKK3-, but not TAK1-dependent
pathway. IRAK1 and IRAK2 are known to form Myddosomes with MyD88-IRAK4 to
mediate TLR7-induced TAK1-dependent NFκB activation. Since IRAKM was able to
mediate NFκB activation in the absence of IRAK1 and IRAK2, and interacted with MyD88
and IRAK4, we proposed the formation of IRAKM Myddosome. Through protein
modeling, we predicted the critical residues for interaction interface between death
domains of IRAKM and IRAK4. Mutations in the conserved W74, E71 and Q78 in helix
H4 of the IRAKM DD greatly reduced the interaction of IRAKM with IRAK4 and also
diminished the ability of IRAKM to mediate NFκB activation. These results strongly
suggest that IRAKM probably indeed has the ability to directly interact with MyD88IRAK4, like IRAK1/2, acting as an intermediate signaling component to transmit signal
from the receptor to downstream signaling cascade (interaction with TRAF6-MEKK3) to
mediate NFκB activation.
One important question is what is the biological significance of the IRAK1/2mediated TAK1- versus IRAKM-mediated MEKK3-dependent pathway? We have
previously shown that the kinase activity of IRAK4 is required TAK1-, but not MEKK3dependent NFκB activation [131, 132]. Furthermore, IRAK4 coordinately regulates
TAK1-dependent NFκB activation and mRNA stabilization pathways to ensure robust
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production of cytokines and chemokines during inflammatory response [139]. In addition
to mRNA stabilization, TLR signaling is also necessary for efficient and sustained
translation of cytokine and chemokine mRNAs. We have previously reported that IRAK2
is essential for sustained translation of TLR-induced cytokine and chemokine mRNAs
[135].Therefore, it is logical to find that IRAK1/2 (substrates of IRAK4) are required for
TAK1- (not MEKK3-) dependent NFκB activation, which is coupled with
posttranscriptional control to promote the production of pro-inflammatory cytokines and
chemokines. On the other hand, the IRAKM-induced MEKK3-dependent pathway is
uncoupled from posttranscriptional regulation. Therefore, the IRAKM-dependent pathway
only induced expression of IRAK4-kinase-independent genes that are not regulated at the
posttranscriptional levels, including inhibitory molecules SOCS1, SHIP1, A20 and IκBα.
The important concept is that IRAKM is wired to engage an alternative NFκB activation
pathway to produce inhibitory molecules, which can in turn to exert an overall inhibitory
effect on inflammatory response. The advantage for such inhibitory mechanism could be
that through the production of these inhibitory molecules, IRAKM could exert broader
inhibitory effects not just on TLR-IL-1R but also on other cytokine signaling cascades, so
that the inflammatory response can be effectively controlled.
It is important to point out that IRAKM also has the ability to directly impact on
TLR-induced production of cytokines and chemokines. Although IRAKM deficiency did
not have much impact on TLR-induced mRNA levels of cytokines and chemokines, their
protein production was enhanced in IRAKM-KO-BMDMs as early as 1 hour after
stimulation. Through polysomal fractionation, we found that the mRNAs of cytokines and
chemokines were more actively translated in the absence of IRAKM, indicating the critical
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role of IRAKM in translational control. Consistent with the previous finding about the
essential role of IRAK2 in TLR-mediated translational control, we found IRAKM specially
interacts with IRAK2, but not IRAK1. These results suggest that in addition to the
formation of IRAKM Myddosome, IRAKM probably has the ability to dock onto IRAK2
Myddosome, thereby interfering IRAK2-dependent downstream signaling.
While this study has provided important insight into the mechanistic roles of
IRAKM in TLR signaling, many questions still remain regarding the functional
relationship of the IRAK family members. Future studies are needed to determine how
IRAKM specifically interacts with IRAK2, but not IRAK1 and what determines the
distribution and dynamics of IRAKM in IRAKM Myddosome versus IRAK2 Myddosome.
It will be important to determine how the newly found functions of IRAKM will impact on
the interpretation of the role of IRAKM in inflammatory responses in vivo and the drug
development of inhibitors for different IRAKs.
E. Materials and Methods
Biological reagents and cell Culture—Recombinant human IL-1 was purchased
from R&D system. CpG Boligodeoxynucleotide (ODN) and Pam3CSK4 were purchased
from Invivogen. LPS (Escherichia coli 055:B5) was purchased from Sigma-Aldrich and
R848 was obtained from GLSynthesis company. Antibodies against phosphorylated
IκB(Ser32/S36), JNK, IKK/(Ser176/180), Mnk1 (Thr179/202), MK2 (Thr334),
eIF4E(Thr70), MKK3(Ser189)/MKK6(Ser207), total IκB and SOCS1 were purchased
from Cell signaling. Antibody to IRAK2 was purchased from Abcam. Antibody to IRAK4
was purchased from Enzo. Antibody to FLAG (anti-FLAG) and hemagglutinin (anti-HA)
were purchased from Sigma. Antibody to MEKK3 was purchased from BD Bio-sciences
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Pharmingen. Antibodies against IRAK, TAK1, SHIP1 and Actin were from Santa Cruz
Biotechnologies. MG132 was purchased from Calbiochem. 293-derived IRAK1-deficient
cells (293-I1A cells), and mouse embryonic fibroblast (MEFs) were maintained in
Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum,
penicillin G (100 µg/ml), and streptomycin (100 µg/ml).

Bone-marrow derived

macrophages were obtained from the bone marrow of tibia and femur by flushing with
DMEM. The cells were cultured in DMEM supplemented with 20% fetal bovine serum
(FBS), and 30% L929 supernatant for 5 days.
Knock-down of MEKK3— Oligonucleotides encoding either scrambled or
MEKK3-specific small hairpin RNAs were cloned into pSUPER to generate pSUPERscrambled or pSUPER-MEKK3 respectively. 1 μg of pSUPER-scrambled or pSuperMEKK3 was transfected into 293-I1A cells along with 0.1 μg of pBabe-puromycin by
FuGENE 6 (Roche Applied Science). Two days after transfection, puromycin (1 μg/ml)
containing DMEM was added to the cells to select for puromycin-resistant clones. After
10 days of puromycin selection, single clones were picked and subjected to Western
analysis to determine the levels of MEKK3. Clones with over 85% knock-down of MEKK3
were pooled as MEKK3 knock down cells and used for experiments.
Transfection and luciferase assay—Transfection of the 293-I1A cells was
performed using the FuGENE 6 transfection reagent as recommended by the manufacturer
(Roche Diagnostics). After 24 h, the cells were stimulated with IL-1β or left untreated for
6 h before harvest. Luciferase activity was determined by using the luciferase assay system
and chemiluminescent reagents from Promega.
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Plasmids and retroviruses—Mouse IRAKM and IRAK4 cDNA were purchased
from Open Biosystems. The IRAKM mutants and IRAK4 mutant were generated by sitedirected mutagenesis polymerase chain reaction (PCR). The wild-type and mutants of
IRAKM and IRAK4 were cloned into pMX retroviral expression vector and transfected
into phoenix cell for viral packaging. Cells were infected by the packaged retrovirus for 3
days and selected by puromycin (2μg/ml) for 2days for stable viral integration. For all PCR
reactions high fidelity Pfu Turbo polymerase was used (Stratagene).
Adenovirus infection—IRAKM wild-type and mutants were cloned into
pENTR™⁄D-TOPO® Vector (Invitrogen). The pENTER clones were packaged into an
adenovirus destination vector pAd/CMV/V5-DEST™ using Gateway® Vector Kit
according to manufacturer’s guidelines (Invitrogen). The adenoviral stocks were prepared
using ViraPower™ Adenoviral Expression System according to manufacturer’s guidelines
(Invitrogen). The BMDMs were infected at multiplicity of infection (MOI) of 200. After
sixteen hours of infection, the cells were changed to fresh L929 conditioned medium.
Forty-eight hours after infection, the cells were used for experiments.
Immunoblotting—Cell were harvested and lysed in a Triton-containing lysis
buffer (0.5% Triton X-100, 20 mM HEPES (pH 7.4), 150 mM NaCl, 12.5 mM glycerophosphate, 1.5 mM MgCl2, 10 mM NaF, 2 mM dithiothreitol, 1 mM sodium
orthovanadate, 2mM EGTA, 1 mM phenylmethylsulfonyl fluoride and complete protease
inhibitor cocktail from Roche). Cell lysates were then separated by 10% SDS-PAGE,
transferred to Immobilon-P membranes (Millipore), and subjected to immunoblotting.
Quantitative real-time PCR—Total RNA was isolated using TRIzol reagent
(Invitrogen). 3μg of total RNA was then used for reverse transcription reaction using
60

SuperScript-reverse transcriptase (Invitrogen). Q-PCR was performed in AB 7300
RealTime PCR System, and the gene expression of human IL-8, TNFα, actin and mouse
CXCL1 (KC), TNFα, IL-6, A20, SHIP1, SOCS1, IκBα, GPR84, ETS2, SOD2, Bcl-2AD1
was examined by SYBR® GREEN PCR Master Mix (Applied Biosystems). PCR
amplification was performed in triplicate, and water was used to replace cDNA in each run
as a negative control. The reaction protocol included preincubation at 95°C to activate
FastStart DNA polymerase for 10 min, amplification of 40 cycles that was set for 15 s at
95°C, and annealing for 60 s at 60°C. The results were normalized with the housekeeping
gene human or mouse β-Actin. Primer sequences were designed using AlleleID 6.0. The
following primers were used: mouse TNFα forward, CAAAGGGAGAGTGGTCAGGT;
mouse TNFα reverse, ATTGCACCTCAGGGAAGAGT; mouse actin forward,
GGTCATCACTATTGGCAACG;

mouse

actin

reverse,

ACGGATGTCAACGTCACACT;

mouse

CXCL1

forward,

TAGGGTGAGGACATGTGTGG;

mouse

CXCL1

reverse,

AAATGTCCAAGGGAAGCGT;

mouse

IL-6

forward,

GGACCAAGACCATCCAATTC;
ACCACAGTGAGGAATGTCCA;

mouse
mouse

IL-6

reverse,

SOCS1

forward,

TGACTACCTGAGTTCCTTCC; mouse SOCS1 reverse, ATCTCACCCTCCACAACC;
mouse SHIP1 forward, GAGGAGACAGGCAACATC; mouse SHIP1 reverse,
TCTTGACACTGAAGGAACC; mouse GPR84 forward, TCAACCCTGTGCTCTATGC;
mouse GPR84 reverse, GCCTGTCCTGGTGAATGG; mouse Bcl2A1D forward,
GGAATGGAGGTTGGGAAGATGG;

mouse

CTGGTCCGTAGTGTTACTTGAGG;

mouse
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Bcl2A1D

reverse,

SOD2

forward,

ACAACTCAGGTCGCTCTTCAG;

mouse

SOD2

reverse,

GATAGCCTCCAGCAACTCTCC;

mouse

ETS2

forward,

AGTGTGGTGCTTCCTGTCTTG;

mouse

ETS2

reverse,

TTGCTCTGTCTGTGCTTCTGG; A20 forward, TGAGCAAGTAGGCAAGATAAG;
A20

reverse,

GTAGACGAGCAGCAATAGC;

mouse

IκBα

forward,

TGGAAGTCATTGGTCAGG; mouse IκBα reverse, ACAGGCAAGATGTAGAGG;
human

IL-8

forward,

AGAGACAGCAGAGCACAC;

human

IL-8

reverse,

GTTCTTTAGCACTCCTTGGC; human TNFα forward, TCAGCAAGGACAGCAGAG;
human TNFα reverse, GTATGTGAGAGGAAGAGAACC; human actin forward,
GTCGGTATGGGTCAGAAAG; human actin reverse, CTCGTTGTAGAAGGTGTGG.
ELISA assay—Supernatants from cell cultures were collected and measured for
the level of mouse cytokines CXCL1, IL-6 and TNFα using Duoset ELISA kits (R&D
system) according to manufacturer’s instructions.
Molecular modeling—A theoretical three-dimensional model of the IRAKM DD
region (residues 14-105) was generated via a web-based molecular modeling server [140].
The crystal structure of the IRAK2 DD segment (PDB 3MOP) was used as a template
because it shares a considerable sequence identity (30%) and topology with IRAKM DD,
as analyzed by the structure prediction. The complex of the MyD88 DD-IRAK4 DDIRAKM DD was constructed via two steps. First, four homology models of the IRAKM
DD were superposed onto each IRAK2 DD segment (chains K to N) in the Myddosome
complex (PDB 3MOP) using the secondary structure matching algorism [141], as
implemented in COOT [142]. Second, these four IRAKM DD models were assembled into
the coordinates of the MyD88 DD-IRAK4 DD complex in the Myddosome complex after
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removal of the regions of IRAK2 DD. Thus, the integrity and physicochemical property of
the MyD88 DD-IRAK4 MM complex were maintained. The hypothetical IRAK4 DDIRAKM DD interface was examined by the server PISA [143] and inspected by the
program PYMOL (www.pymol.org).
Co-immunoprecipitation

and

immunoblotting—Bone

marrow-derived

macrophages and 293-I1A cells were cultured as indicated above. After stimulation with
R848 (1μg/ml) or IL-1β (1ng/ml), the cells were harvested and co-immunoprecipitation
and immunoblotting were performed as previously descried [144].
Electrophoretic mobility shift assay (EMSA) — Bone marrow-derived
macrophages and 293-I1A cells were cultured as indicated above. After stimulation with
R848 (1 μg/ml) or IL-1β (1 ng/ml), the cells were harvested and nuclear extracts were
prepared with the NE-PER Nuclear and Cytoplasmic Extraction Reagent (Thermo).
Labeling of NFκB specific oligonucleotides (Santa Cruz) was performed with [γ-32P]-ATP
(PerkinElmer) by using T4 polynucleotide kinase (NEB) following manufacturer’s
guideline. After purification over a Sephadex G-25 column (Amersham), radiolabelled
oligonucleotides (around 20,000 cpm) were incubated with nuclear extracts at room
temperature for 30 min in binding buffer containing 12 mM HEPES (pH 7.9), 4 mM Tris
HCl (pH 7.8), 60 mM KCl, 1 mM ethylenediamine tetraacetic acid (EDTA), 1 mM
dithiothreitol (DTT), 1 mM PMSF, 12% glycerol, 5 μg of bovine serum albumin (BSA)
and 2 μg poly(dI-dC) (Sigma). The same amount of nuclear protein (around 5 μg) was used
in each experiment. The protein concerntraction was measured using Quick Start Bradford
Protein Assay Kit (Biorad) following manufacturer’s guideline. DNA–protein complexes
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were separated using 6% non-denaturing polyacrylamide gel electrophoresis. Signals were
visualized by exposing the dried gel to autoradiography film.
Polysome fractionation analysis—Wild-type and IRAKM deficient macrophages
were stimulated with R848 (1μg/ml) for 1.5h. Cytoplasmic extracts were prepared from
BM-derived macrophages stimulated with R848 (1μg/ml) as described [144]. Cytoplasmic
exacts were carefully layered over 10–50% linear sucrose gradients in polysome buffer (10
mM HEPES, pH 7.5, 100 mMKCl, 2.5 mM MgCl2, 1 mM dithiothreitol, 50 units of
recombinant RNasin (Promega), and 0.1% Igepal-CA630 (Sigma)) and centrifuged at
17,000 rpm in a Beckman SW32.1 Ti rotor for 4h at 4C. Gradients were fractioned by
using an ISCO gradient fractionation system equipped with a UA-6 detector. Light RNP
fractions, 40S, 60S, and 80S and heavy polysome fractions were monitored by the
continuous UV absorption profile at A254, and 12 tubes of 750 μl fractions were collected.
The fractions representing light RNP and free ribosomes were used to isolate the
translation-inactive pool of mRNAs, and the fractions presenting heavy polysomes were
used to isolate the translation-active mRNAs. RNAs were isolated from these fractions by
extraction with TRIzol.
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CHAPTER III
IRAKM-MINCLE AXIS CONTRIBUTES TO ALCOHOL-INDUCED LIVER
INJURY VIA INFLAMMASOME ACTIVATION

Hao Zhou1,2, Minjia Yu1, Junjie Zhao1, Bradly N. Martin1, Sanjoy Roychowdhurya3,
Megan R. McMullen3, Jazmine Dannera3, Doug Czarnecki3, Christine A. Wells4, Sho
Yamasaki5, Laura E. Nagy3,6, Xiaoxia Li1,
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A. Abstract
Alcohol-induced liver injury is induced by necrosis of hepatocytes and increased
translocation of endotoxin from the intestinal tract into hepatic portal system, which trigger
chronic inflammation that is damaging to the liver together. In this study, we found that
mice deficient of a Toll-like receptor proximal molecule, IRAKM, are protected from
alcohol-induced liver injury. IRAKM mediates the up-regulation of Mincle, a receptor for
danger signals release by damaged cells, in response to low dose of LPS. Biochemical
analysis revealed that low-dose LPS preferentially induces the formation of IRAKM
Myddosome, leading to MEKK3-dependent NFκB activation. Mincle-deficient mice are
also protected from alcohol-induced liver injury. We found IRAKM deficiency and Mincle
deficiency drastically reduced alcohol feeding induced inflammasome activation in the
mouse liver. Ex vivo studies showed that both IRAKM and Mincle are required for
inflammasome activation by endogenous Mincle ligand, SAP130, which is a danger signal
release by damaged hepatocytes. Taken together, this study identifies an IRAKM-Mincle
axis critical for the pathogenesis of alcohol induced liver disease through the activation of
inflammasome.
B. Introduction
Alcoholic liver disease (ALD) ranges from simple steatosis to alcoholic hepatitis,
fibrosis, cirrhosis and hepatocellular carcinoma [105-108]. Alcohol exposure induces
endoplasmic reticulum (ER) stress and mitochondrial dysfunction in hepatocytes, which
leads to hepatocyte apoptosis, necrosis and inflammation [145-147]. Alcohol disrupts the
balance gut microflora associated with an increased intestinal permeability, resulting in
increased translocation of bacterial products into the circulation [46, 51, 106, 114].
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Increased levels of LPS were indeed detected in alcoholic patients and alcohol-treated
experimental animals [113, 148]. The activation of hepatic macrophages (Kupffer cells) to
portal endotoxin/lipopolysaccharide (LPS) plays a key role in the early pathogenesis of
alcohol-induced liver injury. LPS recognition by Toll-like receptor 4 (TLR4) on hepatic
macrophages results in the release of inflammatory cytokines such as TNF and IL-1 that
can impact on the function of hepatocytes. Mice deficient in TLR4 or IL-1R indeed showed
reduced alcohol-induced liver diseases [115-117]. Conversely, previous studies have
shown that signals from injured hepatocytes induced by alcohol are also critical to the
activation of hepatic macrophages. Thus, one important question is how TLR-dependent
inflammatory response and alcohol-induced cell damage coordinately lead to the
pathogenesis of ALD.
Toll-like receptors (TLRs) are molecules of the innate immune system that detect
invading pathogens and protect multicellular organisms against infection by using
proinflammatory chemokines and cytokines [149]. TLRs transduce signals through the
adaptor molecule MyD88 and IL-1R-associated kinase (IRAK) family members, which
include: IRAK1, IRAK2, IRAKM (also known as IRAK3) and IRAK4 [123-126]. The
MyD88–IRAK4–IRAK2 death domain (DD) complex’s crystal structure, referred to as the
Myddosome complex, is constructed in a sequential manner, in which MyD88 recruits first
IRAK4 and then MyD88-IRAK4 complex recruits the IRAK4 substrates IRAK2 or the
related IRAK1[127]. Subsequently, the IRAK1/2 creates a complex with TRAF6 and
dissociates from the receptor complex, activating cascades of downstream kinases, thus
resulting in the activation of the transcription factor NFκB [69]. However, on the other
hand, IRAKM is believed to act as a negative regulator that suppress Myddosome
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complexes from disassociating with the receptor complex, therefore preventing signaling
downstream [128].
Previously, we had reported the presence of two parallel TLR/IL-1R-mediated
NFκB activation pathways: TAK1-dependent and MEKK3-dependent. The activation of
TAK1-dependent pathway results in IKKα/β phosphorylation and IKKγ activation, leading
to classical NFκB activation via IκBα phosphorylation and degradation. The TAK1independent MEKK3-dependent pathway entails IKKγ phosphorylation and IKKα
activation, which leads to NFκB activation by IκBα phosphorylation and its subsequent
dissociation from NFκB, but without IκBα degradation [73, 129, 132]. We have recently
been researching the functional relationships among IRAK family members and their roles
in TLR signaling by analyzing mice with deficiencies in IRAK1, IRAK2 and/or IRAKM.
We discovered that certain substrates of IRAK-4, specifically IRAK1 and IRAK2, are
necessary for TAK1-dependent NFκB activation and mRNA stabilization of chemokines
and cytokines, but not for MEKK3-dependent NFκB activation [135, 150-152]. IRAKM is
able to interact with MyD88-IRAK4 to form IRAKM Myddosome, allowing it to control
TAK1-independent MEKK3-dependent NFκB activation [153]. This IRAKM-dependent
pathway is necessary for the second wave of TLR-induced NFκB activation in the company
of IRAK1/IRAK2, a process which is independent on posttranscriptional regulation. Thus,
the IRAKM-dependent pathway only induces expression of genes which are not controlled
at posttranscriptional levels (including the inhibitory molecules SOCS1, SHIP1, A20 and
IκBα), exerting an overall inhibitory effect on responses of inflammation.
In this study, we were surprised to discover that IRAKM-deficient mice were
protected from ethanol-induced liver injury and inflammation. Mechanistically, we found
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that with low doses of LPS (100pg-1ng/ml), IRAKM-MEKK3-dependent NFκB activation
is the dominant pathway in macrophages; the IRAK1-mediated TAK1 pathway is not
activated. These results suggest that this IRAKM-dependent pathway induced by low
concentration of TLR ligands might contribute to the pathogenesis of ALD, since alcoholinduced increases in gut permeability result in low concentrations of TLR ligands in the
circulation and liver. One of TLR4-induced IRAKM-dependent genes was Mincle (a Ctype lectin receptor) that senses non-homeostatic cell death [52]. Spliceosome-associated
protein (SAP) 130, which was identified as the endogenous ligand of Mincle, was released
from hepatocytes after exposing to alcohol, while recombinant SAP130 was able to activate
the inflammasome and IL-1 production in macrophages. Importantly, we found Mincle
expression was induced in liver of ALD patients, as well as in mice after ethanol feeding.
Induction of Mincle was ablated in liver of IRAKM-deficient mice and Mincle-deficient
mice were protected from ethanol-induced liver injury, accompanied by reduced
inflammasome activation and IL-1 production. Since Mincle is a sensor for cell death and
its expression is IRAKM-dependent, these results suggest that TLR-induced IRAKMdependent Mincle up-regulation in macrophages provides a critical link between alcoholinduced cell death and onset of inflammatory responses, contributing to the pathogenesis
of ALD.

70

C. Results
IRAKM is required for low concentration LPS-mediated NFκB activation
IRAKM has been known as a negative regulator of innate immune response. Our
recent studies showed that IRAKM also interacts with MyD88-IRAK4 to form an IRAKM
Myddosome to mediate TLR-induced MEKK3-dependent second wave NFκB activation.
In response to normal does LPS (1 µg/ml), MEKK3 modification and second wave of IκBα
phosphorylation were ablated in IRAKM-deficient macrophages, whereas LPS-induced
IRAK1 and TAK1 modification and IKKα/β phosphorylation were not affected ([153] and
Fig. 22).

Figure 22. IRAKM is required for late phase high dose LPS-mediated NFκB
activation. Cell lysates from wild-type (WT) and IRAKM KO bone marrow-derived
macrophages (BMDMs) untreated or treated with high dose LPS (1 µg/ml) for the indicated
times were analyzed by Western blot analysis with antibodies against, MEKK3, p-IκBα,
IκBα, and actin.
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This IRAKM-dependent second wave of NFκB activation only induces expression
of genes that are not regulated at the posttranscriptional levels (including inhibitory
molecules SOCS-1, SHIP-1, A20 and IκBα), further exerting an overall inhibitory effect
on inflammatory response.
Interestingly, we now found that upon stimulation with low dose LPS (100pg1ng/ml versus 1ug/ml, the commonly used dosage), the IRAKM-MEKK3-dependent
NFκB activation is the dominant pathway. In bone marrow derived macrophages (BMDMs)
treated with low dose LPS (100pg/ml), IRAK1 modification/degradation and IKKα/β
phosphorylation were not observed, accompanied by the typical of MEKK3-dependent
NFκB activation, evident by IκBα phosphorylation without IκBa degradation. Importantly,
IκBα phosphorylation and MEKK3 modification induced by low LPS were completely
abolished in IRAKM-deficient cells (Fig. 23A). Based on these results, we hypothesized
that IRAKM is dominantly activated to mediate the MEKK3-dependent NFκB activation,
whereas IRAK1-TAK1-dependent pathway was not activated by low dose of LPS
(100pg/ml). In support of this, we found that inflammatory genes CXCL1, TNFα and IL-6
mRNA induction in response to low dose of LPS (100pg/ml) was not affected in IRAK1/2
double KO macrophages, but greatly reduced in IRAKM-deficient cells (Fig. 23B). Thus,
these data suggest that low-dose LPS preferentially induces the formation of IRAKM
Myddosome, leading to MEKK3-dependent NFκB activation.
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Figure 23. IRAKM is required for low dose LPS-mediated NFκB activation. A. Cell
lysates from wild-type (WT) and IRAKM KO bone marrow-derived macrophages
(BMDMs) untreated or treated with low dose LPS (100 pg/ml) for the indicated times were
analyzed by Western blot analysis with antibodies against IRAK1, p-IKKα/β, MEKK3, pIκBα, IκBα, and actin. B. Total mRNAs from BMDMs of WT, IRAK1/2-DKO and
IRAKM KO mice treated with low dose LPS (1μg/ml) for the indicated times, were
subjected to RT-PCR analyses for the levels of CXCL1, IL-6 and TNFα expression. Data
represent mean ±SEM; *, P<0.05.

Low-dose LPS preferentially induces the formation of IRAKM Myddosome via the
death domain of IRAKM
One important question is how low dose LPS activates the IRAKM-MEKK3
pathway. We previously reported that upon high dose ligand stimulation, the kinase activity
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of IRAK4 is required for TLR-induced TAK1-, but not MEKK3-dependent NFκB
activation [73, 132]. IRAK1 and its phosphorylation is required for TLR-induced TAK1-,
but not MEKK3-dependent NFκB activation [150, 151]. These results suggest that high
dose of LPS might lead to quick clustering/aggregation of the TLR-MyD88-IRAK4
complex and activation of IRAK4, which then recruits and phosphorylates IRAK1 thereby
stabilizing the IRAK1 Myddosome, leading to TAK1-dependent NFκB activation. In
support of this, our recent study showed that IRAK4 dimerization is required for its
autophosphorylation and activation of the kinase activity. Thus, we hypothesize that the
formation of TLR4 receptor complex induced by low dose LPS may not trigger the
aggregation of IRAK4, which can then only attract IRAKM, but not IRAK1, leading to
specific formation of IRAKM Myddosome and subsequent MEKK3-dependent NFκB
activation. We indeed found that upon low dose LPS stimulation (100pg/ml), IRAKM, but
not IRAK1 was recruited to IRAK4-MyD88 complex, whereas both IRAK1 and IRAKM
interacted with IRAK4 upon high dose LPS stimulation (1ug/ml) (Fig. 25A). Furthermore,
compared to BMDMs from wild-type control mice, low dose LPS-induced MEKK3
modification and NFκB activation were not affected in IRAK4 kinase inactive knock-in
macrophages (Fig. 24). Taken together, these data suggest that although IRAK4 kinase
activity was required for recruiting IRAK1 to mediate TAK1-dependent NFκB activation,
IRAKM-dependent MEKK3-mediated NFκB activation does not require IRAK4 kinase
activity.
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Figure 24. IRAK4 kinase activity is not required for low dose LPS-mediated NFκB
activation. Cell lysates from wild-type (WT) and IRAK4 kinase activity dead knock in
(IRAK4 KI) bone marrow-derived macrophages (BMDMs) untreated or treated with high
dose LPS (100 pg/ml) for the indicated times were analyzed by Western blot analysis with
antibodies against, MEKK3, p-IκBα, IκBα, and actin.
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Figure 25. Low-dose LPS preferentially induces the formation of IRAKM
Myddosome via the death domain of IRAKM. A. Wild-type BMDMs were treated with
high dose LPS (1 µg/ml) and low dose LPS (100 pg/ml) for the indicated times, followed
by immunoprecipitation (IP) with anti-IRAK-4 antibody and analyzed by Western blot
analysis with antibody against IRAK1, IRAKM and MyD88. B-D. IRAK-1/2/M-triple
deficient immortalized BMDMs infected with adenovirus expressing FLAG-tagged
IRAK1, FLAG-tagged chimeric IRAKM death domain with IRAK1 kinase domain
(DD(M)+IRAK1) and FLAG-tagged IRAKM were treated with low dose LPS (100 pg/ml)
for indicated times. B. Cell lysates were analyzed by Western blot analysis with antibodies
against FLAG, p-IκBα, IκBα, and actin. C. followeing by immunoprecipitation (IP) with
anti-IRAK-4 antibody and analyzed by Western blot analysis with antibody against FLAG
and MyD88. D. Total mRNAs were subjected to RT-PCR analyses for the levels of CXCL1,
IL-6 and TNFα expression. Data represent mean ± SEM; *, P<0.05.

To further elucidate the mechanism for the specific activation of IRAKM-MEKK3dependent pathway by low dose LPS, we compared IRAKM versus IRAK1 in their
differential recruitment to the TLR-MyD88-IRAK4 complex. The crystal structure of
Myddosome complex suggests the assembly of MyD88-IRAK4 with IRAK1, IRAK2 or
IRAKM via the interaction of their death domains. We thus hypothesized that the
specificity lies in the death domain of IRAKM versus IRAK1 in their formation of
Myddosome in response to receptor activation by low versus high dose of ligands. To test
this hypothesis, we generated a chimera protein by replacing the IRAK1 death domain with
IRAKM death domain: DD(M)-IRAK1. Flag-tagged wild-type IRAK1, IRAKM, and
DD(M)-IRAK1 in retroviral vectors were infected into IRAK1/2/M-TKO macrophages,
followed by stimulation with low or high dose of LPS. We found that wild-type IRAKM
and DD(M)-IRAK1 were able to interact with MyD88-IRAK4 and restore the low dose
LPS-induced IκBα phosphorylation and gene expression, whereas wild-type IRAK1 failed
to rescue the low dose LPS-mediated signaling (Fig. 25B-D). Taken together, our results
suggest that the death domain of IRAKM is responsible for the specific recruitment to the
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TLR-MyD88-IRAK4 complex in response to low dose LPS, leading to MEKK3-dependent
NFκB activation.

IRAKM-dependent pathway is required for the development of alcohol-induced liver
disease
Alcohol intake increases gut permeability, which allows accumulation of low levels
of TLR ligands in the circulation and liver. The activation of hepatic macrophages (Kupffer
cells) to portal endotoxin/LPS plays a key role in the early pathogenesis of ALD [115, 116,
148, 154, 155]. Thus, we propose that engagement of IRAKM-dependent signaling might
be the dominant TLR-activated pathway during the development of ALD. To test this
hypothesis, we subjected female IRAKM-deficient and littermate control wild-type mice
to chronic ethanol feeding via the Lieber-DeCarli liquid diet to model steatosis and mild
inflammation. Briefly, the ethanol-fed group was allowed free access to an ethanolcontaining diet with increasing concentrations of ethanol as part of a complete liquid diet
for 25 days. Control mice were pair-fed a diet that isocalorically substituted maltose dextrin
for ethanol. Compared to pair-fed control mice, the alcohol-fed WT mice had significant
increase in hepatocyte injury [assessed by serum aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) levels, Fig. 26A], steatosis [lipid droplets in hepatocytes
(H&E and oil red staining), Fig. 26B and D] and hepatic triglyceride levels (Fig. 26C).
Compared to WT mice, IRAKM-deficient mice had attenuated alcohol-induced
hepatocelullar injury as evident by reduced serum AST and ALT levels (Fig. 26A). Notably,
hepatic steatosis and triglyceride levels in alcohol-fed IRAKM-deficient mice were also
significantly decreased compared with those in WT mice (Fig. 26B-D). Moreover, IRAKM
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deficiency prevented the alcohol-induced upregulation of TNF-α, IL-6, and MCP-1 mRNA
in the liver of alcohol-fed mice (Fig. 26E). Taken together, these data support the crucial
role of IRAKM in the pathogenesis of alcohol-induced inflammatory responses in the liver.

Figure 26. IRAKM-dependent pathway is required for the development of alcoholinduced liver disease. Wild-type and IRAKM KO mice were allowed free access to
ethanol (EtOH) or pair-fed control diets. A. AST and ALT activity was determined in
plasma. B. Paraffin-embedded liver sections were stained with hematoxylin and eosin. C.
Hepatic triglyceride content was measured in whole liver homogenates. D. Frozen liver
sections were subjected to Oil Red O staining. All images were acquired using a 10X
objective. E. Total mRNAs from livers of WT and IRAKM KO mice (pair-fed and EtOHfed) were subjected to RT-PCR analysis for the levels of MCP1, TNFα and IL-6 and
normalized to 18sRNA. Data represent mean ±SEM; *, P<0.05.
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IRAKM is required for TLR-mediated Mincle expression
The next question was how IRAKM-mediated pathway contributes to pathogenesis
of ALD. Since low dose of LPS only induced minute amount of inflammatory cytokines
and chemokines in wild-type BMDMs (Fig. III-6), we suspected that the impact of
IRAKM on ALD might not due to its direct role in TLR-mediated inflammatory gene
expression. Through a search for novel IRAKM-dependent genes, we found that Mincle, a
sensor for cell death, is strongly induced by low does LPS, which was greatly reduced in
IRAKM-deficient cells (Fig. 28A). It is important to note that the induction of Mincle
mRNA was not affected in IRAK1/2 double deficient macrophages (data not shown).
Similarly, low LPS-induced Mincle protein levels were not reduced in IRAK1/2-deficient
cells, but greatly reduced in IRAKM-deficient macrophages, indicating that Mincle
expression is mostly dependent on IRAKM (Fig. 28B and data not shown). We then
examined the expression of Mincle in the liver tissue in pair-fed and alcohol-fed WT and
IRAKM-deficient mice. Interestingly, by immune fluorescent staining, we found that
Mincle expression was increased in the liver of alcohol-fed wild-type mice, which was colocalized with liver resident macrophage marker F4/80 (Fig. 28C). Importantly, ethanolinduced expression of Mincle was attenuated in IRAKM-deficient mice, implicating the
potential importance of Mincle in IRAKM-mediated impact on ALD.
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Figure 27. Low dose of LPS induced minute amount of inflammatory cytokines and
chemokines production. Bone marrow-derived macrophages (BMDMs) were treated with
high dose LPS (1 µg/ml) or low dose LPS (100 pg/ml) for 24 hours. Cell-free supernatants
were collected and CXCL1, TNFα and IL-6 concentrations were measured by ELISA assay.
Data represent mean ±SEM; *, P<0.05.
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Figure 28. IRAKM is required for TLR and alcohol-induced Mincle upregulation.
A. Cell lysates from wild-type (WT) and IRAKM KO bone marrow-derived macrophages
(BMDMs) untreated or treated with low dose LPS (100 pg/ml) for the indicated times were
analyzed by Western blot analysis with antibodies against Mincle and actin. B. Cell lysates
from wild-type (WT) and IRAK1/2 double knock out (IRAK1/2 DKO) bone marrowderived macrophages (BMDMs) untreated or treated with low dose LPS (100 pg/ml) for
the indicated times were analyzed by Western blot analysis with antibodies against Mincle
and actin. C. Immunostaining of F4/80 (green) and Mincle (red) was performed on frozen
sections of liver from of WT and IRAKM KO mice (pair-fed and EtOH-fed). Confocal
images are representative of five mice per group.
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Mincle-mediated pathway is required for the development of alcohol-induced liver
disease
Mincle was originally discovered based on its strong induction in macrophages by
inflammatory stimuli, including TLR ligands [156]. One of the identified ligands for
Mincle is spliceosome-associated protein (SAP) 130, a component of small nuclear
ribonucloprotein, that diffuses out of dying cells, leading to onset of inflammation [52]. It
is well documented that alcohol exposure induces endoplasmic reticulum (ER) stress and
mitochondrial dysfunction in hepatocytes, which results in hepatocyte apoptosis and
necrosis. Interestingly, upon challenge with ethanol and low dose LPS, hepatocytes
released SAP130 to the culture media (Fig. 29A), implicating SAP130 as an endogenous
ligand in the ALD model. Since Mincle expression was induced in myeloid cells in the
liver of ethanol-fed mice in an IRAKM-dependent manner, we hypothesized TLR-induced
IRAKM-dependent Mincle upregulation in liver resident macrophages provides a critical
link between alcohol-induced cell death and onset of inflammation, contributing to the
pathogenesis of ALD. To test this hypothesis, female Mincle-deficient and C57BL/6 mice
were exposed to chronic ethanol feeding via the Lieber-DeCarli liquid diet, as described
above. In contrast to wild-type control mice, Mincle-deficient mice had reduced alcoholinduced hepatocyte injury and steatosis, demonstrated by the levels of ALT/AST in the
plasma, lipid drops in the hepatocytes (H & E and oil red staining), and TG levels in the
liver (Fig. 29B-E). Moreover, Mincle deficiency attenuated the upregulation of TNF-α, IL6, and MCP-1 in the liver of alcohol-fed mice, supporting the crucial role of Mincle in the
pathogenesis of alcohol-induced inflammatory responses in the liver (Fig. 29F).
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Figure 29. Mincle-dependent pathway is required for the development of alcoholinduced liver disease. A. Primary hepatocytes from WT mice were treated with EtOH (50
mM) with/without TNFα (30 ng/ml) for 24 hours. Cell-free supernatants were collected
and SAP130 was measured by Western blot analysis with anti-SAP130 antibody. Band
densities from three independent experiments were measured by ImageJ software and
normalized to actin. Data represent mean ± SEM; *, P<0.05. Wild-type and Mincle KO
mice were allowed free access to ethanol (EtOH) or pair-fed control diets. B. AST and
ALT activity was determined in plasma. C. Paraffin-embedded liver sections were stained
with hematoxylin and eosin. D. Hepatic triglyceride content was measured in whole liver
homogenates. E. Frozen liver sections were subjected to Oil Red O staining. All images
were acquired using a 10X objective. F. Total mRNAs from livers of WT and IRAKM KO
mice (pair-fed and EtOH-fed) were subjected to RT-PCR analysis for the levels of MCP1,
TNFα and IL-6 and normalized to 18sRNA. Data represent mean ±SEM; *, P<0.05.
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SAP130-mediated Mincle activation is required for low concentration LPS induced
inflammation through inflammasome activation
Since Mincle plays a critical in the pathogenesis of ALD, we then aimed to
investigate how Mincle exerts its impact on the disease process. In addition to necrotic cell
ligands, fungal and mycobacterial ligands for Mincle have been identified. Mincle is
essential for recognition of the mycobacterial cord factor and its synthetic analog
Trehalose-Dibehenate (TDB) [157]. Interestingly, while TDB has been shown to activate
NLRP3 inflammasome [158, 159], Dectin-1, another member of C-type lectin receptors,
activates processing of IL-1β via a noncanonical caspase-8 inflammasome [160]. Since we
detected SAP130 in the culture media of hepatocytes treated with alcohol (Fig. 29A), it
suggests that SAP130 might be an endogenous ligand in the ALD model. Thus, we
examined whether SAP130 can also engage Mincle for inflammasome activation.
Importantly, recombinant SAP130 indeed induced caspase-1 cleavage and IL-1β
production in macrophages primed with low dose LPS (to up-regulate Mincle), which were
abolished in Mincle-, ASC- and NLRP3-deficient macrophages (Fig. 30A-B). These
results suggest that Mincle activation in macrophages results in activation of ASCdependent inflammasomes.
Importantly, recent studies have shown that mice deficient in inflammasome
components (adaptor ASC and caspase 1) or IL-1R are protected from ALD [117].
However, it remains unclear how inflammasome is activated in the liver of alcohol-fed
mice. Based on the ability of SAP130 in activation of inflammasome, we hypothesized that
Mincle senses necrotic cells induced by alcohol and subsequently activates ASC-dependent
inflammasome(s), leading to caspase1 activation and IL-1β production. Importantly, we
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indeed detected increased caspase-1 activity (shown as cleaved caspase 1 and processed
IL-1β) in the liver of ethanol-fed mice, which was much reduced in IRAKM- and Mincledeficient mice (Fig. 30C-D). Taken together, these results suggest that while low
circulating LPS upregulates Mincle expression in macrophages/Kupffer cells in an
IRAKM-dependent manner, SAP130 released from hepatocytes injured by ethanol triggers
Mincle activation, leading to inflammasome activation and IL-1β production.
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Figure 30. SAP130-mediated mincle activation is required for low concentration LPS
induced inflammation through inflammasome activation. A. BMDMs from WT and
Mincle KO mice B. BMDMs from WT, NLRP3 KO and ASC KO mice were treated with
PBS (NT), LPS (100 pg/ml) for 24 hours (L), LPS (100 pg/ml, 24 hours) + SAP130 (5
µg/ml, 6 hours) (LS) or LPS (100 pg/ml, 24 hours) + TDB (100 µg/ml, 6 hours). Cell
lysates and supernatants were collected together and were immunoblotted with the
antibodies against caspase1, cleaved caspase1 (p20) and actin. Cell-free supernatants were
collected and IL-1β was measured by ELISA. Data represent mean ± SEM; *, P<0.05. C.
Tissue lysates from the whole liver of WT and IRAKM KO mice (pair-fed and EtOH-fed)
were analyzed by Western blot analysis with antibodies against cleaved IL-1β, cleaved
caspase1 (p20) and actin. Band densities were measured by ImageJ software and
normalized to actin. Data represent mean ± SEM; *, P<0.05. D. Tissue lysates from the
whole liver of WT and Mincle KO mice (pair-fed and EtOH-fed) were analyzed by Western
blot analysis with antibodies against cleaved IL-1β, cleaved caspase1 (p20) and actin.
Band densities were measured by ImageJ software and normalized to actin. Data represent
mean ±SEM; *, P<0.05.
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D. Discussion
Emerging evidence indicates that activation of innate immunity in response to
alcohol exposure plays a key role in the development and progression of ALD [110-115,
117, 154, 161-166]. Here we report a novel TLR4-IRAKM-dependent signaling pathway
that contributes to the pathogenesis of ALD. While alcohol intake increases gut
permeability and accumulation of low levels of LPS in the circulation and liver, we found
that low dose of LPS preferentially induces the formation of IRAKM Myddosome, leading
to MEKK3-dependent NFκB activation in macrophages. Importantly, this novel IRAKMdependent signaling pathway leads to inflammsome activation during ALD through the
upregulation of Mincle, a sensor for cell death. While SAP130, the endogenous ligand of
Mincle, was released from hepatocytes after exposing to alcohol, recombinant SAP130
activated ASC-dependent inflammasomes and IL-1 production in macrophages (Fig. 31).
Induction of Mincle was ablated in liver of IRAKM-deficient mice and Mincle deficiency
protected mice from ethanol-induced liver injury, accompanied by reduced inflammasome
activation and IL-1β production. These results suggest that IRAKM-Mincle axis might
provide a critical link for the cross-talks between alcohol-induced cell damage and innate
immune activation during the development and pathogenesis of ALD.
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Figure 31. IRAKM-Mincle axis contributes to the pathogenesis and development of
ALD. Chronic alcohol exposure results in increased intestinal permeability and changes in
bacterial microflora increase levels of bacterial products in alcoholic patients and animal
models of ALD. Further, alcohol exposure can induce endoplasmic reticulum (ER) stress
and mitochondrial dysfunction in hepatocytes, contributing to hepatocellular injury and
death. TLR4- induced IRAKM-mediated MEKK3-dependent NFκB activation is required
for the up-regulation of Minlce in hepatic macrophages. Mincle sense the necroptotic
hepatocytes-released nuclear protein, SAP130, which in turn activates the inflammasome
activation in macrophages. Secreted IL-1β may further act on hepatocytes inducing
pyroptosis or on Stellate cells which leads to fibrosis.
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While low levels of LPS were detected in alcoholic patients and alcohol-treated
experimental animals, mice deficient in TLR4 showed reduced alcohol-induced liver
diseases [111, 112, 115, 116, 161, 162, 166]. TLR4 has ability to activate two distinct
pathways: MyD88-dependent and MyD88-independent. MyD88-dependent pathway is
activated by the adaptors TIRAP and MyD88, which leads to activation of NF-kB and to
the induction of inflammatory cytokines. The second pathway (MyD88-independent) is
activated by adaptors TRIF and TRAM, which activates IRF3 to induce Type I interferons
(IFNs), as well as NF-kB activation [26, 122]. The TLR4-induced MyD88-independent
TRIF/IRF3-dependent cascade has been directly implicated in steatosis and inflammation
in ALD [166]. However, it remains unclear how MyD88-dependent pathway participates
and contributes to the development and pathogenesis of ALD. This is the first study to
show that MyD88 downstream component IRAKM is required for development and
pathogenesis of ALD. Although the IRAK4 kinase activity was not required for IRAKMdependent pathway, IRAK4 was recruited to MyD88 upon low dose LPS stimulation,
which in turn recruits IRAKM for the formation of IRAKM Myddosome. Thus, IRAK4
probably functions as a structural protein in the IRAKM pathway. One important question
is how the IRAKM Myddosome activates MEKK3. Since IRAKM does not have kinase
activity, it is possible that MEKK3 is recruited to the IRAKM Myddosome for its activation,
leading to the phosphorylation of IRAKM and consequent release of IRAKM-MEKK3
from the receptor complex to activate the IκB kinase complex for NFκB activation. Future
studies are required to elucidate the IRAKM-MEKK3 NFκB activation mechanism.
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IRAKM is well known as a negative regulator of inflammatory response during acute
inflammation. Our previous study shows that IRAKM is capable to form Myddosome
complex with MyD88 and IRAK4 in response to TLR ligands stimulation as IRAK1/2.
IRAKM Myddosome is required for late phase NFκB activation through MEKK3
dependent pathway. This IRAKM-dependent pathway only induces expression of genes
that are not regulated at the posttranscriptional levels (including inhibitory molecules
SOCS-1, SHIP-1, A20 and IκBα), exerting an overall inhibitory effect on inflammatory
response. Further, IRAKM specifically interacts with IRAK2, but not IRAK1, to suppress
TLR-induced IRAK2 mediated translation of cytokines and chemokines [153]. Overall,
IRAKM functions as suppressor of inflammation during infectious diseases and is required
for the homeostasis. However, the role of IRAKM in low level chronic diseases has not
been reported. In this paper, our data suggests that TLR4-induced IRAKM Myddosome
dependent pathway plays as pathogenic role in ALD. Further biochemical analysis suggests
that IRAKM-dependent MEKK3-mediated NFκB activation does not require IRAK4
kinase activity. The death domain of IRAKM is responsible for the specific recruitment to
the TLR-MyD88-IRAK4 complex in response to low dose LPS, leading to MEKK3dependent NFκB activation.
Since IRAK1 is not activated upon low dose LPS stimulation, we do not anticipate
IRAK1 to be part of the receptor complex for the IRAKM pathway. We expect the death
domain determines the specific recruitment of IRAKM the receptor complex induced by
low dose ligands. Thus, we predict DD(M)-IRAK1, but not DD(1)-IRAKM, will restore
TLR signaling in response to low dose TLR ligands.
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Next important question we asked is that how IRAKM-dependent pathway
mediates the pathogenesis of ALD. Since low dose of LPS only induced minute amount of
inflammatory cytokines and chemokines in wild-type BMDMs, we suspect that the impact
of IRAKM on ALD might not due to its direct role in TLR-mediated inflammatory gene
expression. Through a search for novel IRAKM-dependent genes, we found that Mincle, a
sensor for cell death, is strongly induced by low does LPS, which was greatly reduced in
IRAKM-deficient cells. Mincle, a member of C-type lectin receptor, was discovered
because it is strongly induced in macrophages by inflammatory stimuli, including TLR
ligands [156]. Mincle-mediated pathway is critical for anti-fungal and anti-mycobacterial
immune response [46, 51, 167, 168]. Recent study found that Mincle functions as a sensor
non-homeostatic cell death which leads to sterile inflammation. Spliceosome-associated
protein (SAP)130 was identified as the endogenous ligand that was recognized by Mincle
following necrotic cell death [52]. In this study, we found that TLR-induced Mincle
expression is dependent on IRAKM in BMDMs. Also, the upregulation of Mincle is also
found in the liver of wild-type alcohol-fed mice and ablated in IRAKM deficient mice.
Consistently, the alcohol-fed Mincle deficient mice also had significant decrease in
hepatocyte injury, steatosis and liver inflammation levels.
Fungal, mycobacterial and necrotic cell ligands for Mincle have been identified,
implicating this receptor in anti-microbial immunity and homeostasis. Mincle is essential
for recognition of the mycobacterial cord factor and its synthetic analog TrehaloseDibehenate (TDB) [157, 168, 169]. Interestingly, TDB has been shown to be able to
activate NLRP3 inflammasome [158]. Further, Dectin-1, another member of C-type lectin
receptors, is also able to activate processing of IL-1β via a noncanonical caspase-8
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inflammasome [160]. Recent studies have shown that mice deficient in inflammasome
components or IL-1R are protected from ALD [117]. However, how inflammasome gets
activated in the alcohol-fed liver is still unclear. In this study, we found SAP130 is also
capable to activate caspase-1 inflammasome in BMDMs. Alcohol-feeding induced
caspase-1 and IL-1β activation was also decreased in the liver of IRAKM and Mincle
deficient mice. However, how Mincle-mediated pathway activates inflammasome in
cooperating with low dose LPS is still not unclear. This will be the future direction of this
study.
Overall, here we first report that IRAKM-dependent pathway induced by low
concentration of TLR ligands contributes to the pathogenesis of ALD by upregulating
Mincle expression in hepatic macrophages. Activation of Minlce-mediated pathway by
sensing SAP130 which released from necrotic hepatocytes leads to further liver
inflammation through inflammasome activation. It provides a novel mechanistic insight of
ALD and may be crucial for future pharmaceutical target design.

E. Materials and Methods
Biological reagents and cell culture—LPS (Escherichia coli 055:B5) and ATP
(A2383) were purchased from Sigma-Aldrich. TDB was purchased from Invivogen.
Antibodies against phosphorylated IκB(Ser32/S36), JNK, IKK/(Ser176/180), and total
IκB were purchased from Cell signaling. Antibody to IRAK-4 was purchased from Enzo
Life Science. Antibody to FLAG (anti-FLAG) and hemagglutinin (anti-HA) were
purchased from Sigma-Aldrich. Antibody to MEKK3 was purchased from BD Bio-
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sciences Pharmingen. Antibodies against IRAK1, TAK1 and Actin were from Santa Cruz
Biotechnologies. Anti-IL-1β antibody (3ZD) was obtained from the Biological Resources
Branch of the NIH. Anti-caspase-1 (p20) antibody was generated as previously described
by L. Franchi and G. Nunez [170]. Anti-Mincle antibodies were generated as previously
describes [52, 167].V5-tagged recombinant SAP130 was overexpressed in HEK-293 cells
and purified as previously described [52]. Bone-marrow derived macrophages were
obtained from the bone marrow of tibia and femur by flushing with DMEM. The cells were
cultured in DMEM supplemented with 20% fetal bovine serum (FBS), penicillin G (100
µg/ml), and streptomycin (100 µg/ml), and 30% L929 supernatant for 5 days.
Plasmids and retroviruses—Mouse IRAKM and IRAK1 cDNA were purchased
from Open Biosystems. IRAK1/IRAKM chimeric constructs were generated by
overlapping PCR. The wild-type IRAK1, IRAKM and IRAK1/IRAKM chimeric mutant
were cloned into pMX retroviral expression vector and transfected into phoenix cell for
viral packaging. Immortalized IRAK1/2/3 triple deficient BMDMs were infected by the
packaged retrovirus for 3 days and selected by puromycin (2μg/ml) for 2days for stable
viral integration. For all PCR reactions high fidelity Pfu Turbo polymerase was used
(Stratagene).
Immunoblotting—Cell were harvested and lysed in a Triton-containing lysis
buffer (0.5% Triton X-100, 20 mM HEPES (pH 7.4), 150 mM NaCl, 12.5 mM glycerophosphate, 1.5 mM MgCl2, 10 mM NaF, 2 mM dithiothreitol, 1 mM sodium
orthovanadate, 2mM EGTA, 1 mM phenylmethylsulfonyl fluoride and complete protease
inhibitor cocktail from Roche). Cell lysates were then separated by 10% SDS-PAGE,
transferred to Immobilon-P membranes (Millipore), and subjected to immunoblotting.
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Quantitative real-time PCR—Total RNA was isolated using TRIzol reagent
(Invitrogen). 3μg of total RNA was then used for reverse transcription reaction using
SuperScript-reverse transcriptase (Invitrogen). Q-PCR was performed in AB 7300
RealTime PCR System, and the gene expression of mouse CXCL1 (KC), TNFα, IL-6,
MCP-1 Mincle, 18s RNA and β-actin was examined by SYBR® GREEN PCR Master Mix
(Applied Biosystems). PCR amplification was performed in triplicate, and water was used
to replace cDNA in each run as a negative control. The reaction protocol included preincubation at 95°C to activate FastStart DNA polymerase for 10 min, amplification of 40
cycles that was set for 15 s at 95°C, and annealing for 60 s at 60°C. The results were
normalized with the housekeeping gene β-actin or 18s RNA. Primer sequences were
designed using AlleleID 6.0. The following primers were used: mouse TNFα forward,
CAAAGGGAGAGTGGTCAGGT;

mouse

TNFα

reverse,

ATTGCACCTCAGGGAAGAGT;

mouse

actin

forward,

GGTCATCACTATTGGCAACG;

mouse

actin

reverse,

ACGGATGTCAACGTCACACT;

mouse

CXCL1

forward,

TAGGGTGAGGACATGTGTGG;

mouse

CXCL1

reverse,

AAATGTCCAAGGGAAGCGT;

mouse

IL-6

forward,

GGACCAAGACCATCCAATTC;

mouse

IL-6

reverse,

ACCACAGTGAGGAATGTCCA.
ELISA assay—Supernatants from cell cultures were collected and measured for
the level of mouse cytokines IL-1β, CXCL1, IL-6 and TNFα using Duoset ELISA kits
(R&D system) according to manufacturer’s instructions.
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Mouse models and samples collection— IRAKM KO and Mincle deficient mice
were previously described [52, 128]. All procedures using animals were approved by the
Cleveland Clinic Institutional Animal Care and Use Committee. Female mice were housed
in shoe-box cages (2 animals/cage) with microisolator lids. Standard microisolator
handling procedures were used throughout the study. Mice were age-matched, randomized
into ethanol-fed and pair-fed groups and then adapted to a control liquid diet for 2 days.
The ethanol-fed groups were allowed free access to an ethanol containing diet. Control
mice were pair-fed a control diet which iso-calorically substituted maltose dextrins for
ethanol over the entire feeding period. Chronic ethanol-induced liver injury: 1% (vol/vol)
ethanol for 2 days followed by 2% ethanol (11% of total calories) for 2 days, 4% ethanol
for 1 week, 5% ethanol for 1 week followed by 6% ethanol for the final week . Sample
collection: At the end of the feeding protocols, mice were anesthetized, blood samples
taken into non-heparinized syringes from the posterior vena cava and livers excised.
Portions of each liver were then either fixed in formalin or frozen in optimal cutting
temperature (OCT) compound (Sakura Finetek U.S.A. Inc.) for histology, frozen in
RNAlater (Qiagen) or flash frozen in liquid nitrogen and stored at -80°C until further
analysis. Blood was transferred to EDTA-containing tubes for the isolation of plasma.
Plasma was then stored at -80°C. Histopathology and immunohistochemistry of mouse
liver: Formalin-fixed tissues were paraffin-embedded, sectioned, coded and stained with
hematoxylin and eosin. Frozen liver sections were used for staining F4/80 and Mincle. All
images presented in the results are representative of at least 3 images per liver and 4 mice
per experimental condition
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ALT/AST and triglyceride measurement—Plasma samples were assayed for
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) using commercially
available enzymatic assay kits (Diagnostic Chemicals) following the manufacturer’s
instructions. Total hepatic triglycerides were assayed using the Triglyceride Reagent Kit
from Pointe Scientific Inc. (Lincoln Park, MI).
Inflammasome activation—BMDMs were plated in 6-well plates at a
concentration of 2.0 X 106 cells per well the day before the experiment. The day of the
experiment, cells were primed with low concentration of LPS (100 pg/ml), SAP130 (10
µg/ml) or TDB (10 µg/ml) for the indicated time. Medium was then supplemented with
ATP (5 mM) for indicated time points. For all experiments, cell-free supernatant was then
either collected for ELISA analysis, or cell lysates and supernatants were collected together
for immunoblotting by the addition of 1% Nonidet-P40 supplemented with complete
protease inhibitor ‘cocktail’ (Roche) and 2 mM dithiothreitol directly to the well. Cells
were scraped and lysed on ice for 30 minutes, then spun at 13,000 rpm. Protein
concentration was measured. 4X Laemlli buffer was then added, samples were boiled and
approximately 20 µg of sample was run on a 12% or 15% SDS-PAGE gel.
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CHAPTER IV
GENERAL DISCUSSION AND FUTURE DIRECTIONS

With these studies, we have uncovered dual roles for IRAKM in TLR signaling
pathways. First, during acute inflammation, IRAKM functions as an important negative
regulator of inflammation. It forms an IRAKM Myddosome complex with MyD88-IRAK4
complex similar to IRAK1/2 myddosome. IRAKM Myddosome is required for the late
phase TLR-induced NFκB activation. This IRAKM Myddosome mediated TLR-induced
NFκB activation through TAK1-independent MEKK3-dependent pathway only induces
expression of genes that are not regulated at the posttranscriptional levels (including
inhibitory molecules SOCS-1, SHIP-1, A20 and IκBα), exerting an overall inhibitory effect
on inflammatory response. Further, IRAKM specifically interacts with IRAK2, but not
IRAK1, and suppresses TLR-induced IRAK2-mediated translation of cytokines and
chemokines.
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Second, in low grade inflammation scenario, we found that IRAKM-dependent
pathway is required for low dose TLR4 ligand-induced NFκB activation. Biochemical
studies suggested low dose LPS-induced IRAKM-dependent NFκB activation is
independent of IRAK4 kinase activity and the death domain of IRAKM is responsible for
the specific recruitment to the TLR-MyD88-IRAK4 complex in response to low dose LPS.
Ex-vivo experiments showed low dose of LPS only induced minute amounts of
inflammatory cytokines and chemokines in wild-type BMDMs. IRAKM-deficient mice
were protected from alcohol-induced liver injury. Through our analysis of low dose LPSinduced IRAKM-dependent gene expression, we found a novel IRAKM dependent gene
known as Mincle. As a sensor of cell death, Mincle is highly up-regulated upon low dose
LPS stimulation which is dependent on IRAKM. Mincle deficient mice were also protected
from alcohol-induced liver injury. Spliceosome-associated protein (SAP) 130 was
identified as the endogenous ligand that was recognized by Mincle following necrotic cell
death. Ex vivo studies showed that both IRAKM and Mincle are required for alcoholfeeding-induced inflammasome activation in the liver. Taken together, this study identifies
an IRAKM-Mincle axis is critical for the pathogenesis of alcohol induced liver disease
through the activation of inflammasome.
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A. The Role of IRAKM in Acute Inflammation
IRAKM, also named as IRAK3, was identified in 1999, as an indispensable element
of LPS-mediated signaling transduction [123]. It was found mainly expressed in cells of
monomyeloic origin and was, therefore, designated IRAKM. Following studies with
IRAKM deficient mice and cells suggest that IRAKM functions as a negative regulator of
TLR signaling. Since IRAKM expression is induced by TLR ligands stimulation, it was
thought to be a key component of a feedback regulatory system of innate immunity [128].
IRAKM deficient mice showed increased inflammatory cytokines and chemokines
production or bacterial clearance, compared to wild-type control mice. IRAKM was shown
to be required for endotoxin tolerance. On the molecular level, previous studies suggest
that IRAKM prevents the dissociation of IRAKs from the adaptor MyD88, therefore,
suppresses downstream signaling transduction. However, there has not been sufficient
experimental evidences to support this. In our study, we provide two novel mechanisms
for the regulatory role of IRAKM in TLR signaling.
IRAKM Myddosome
Myd88, an intracellular TIR domain containing protein, is utilized by IL-1R and all
TLRs as an adaptor molecule except for TLR3. It contains an N-terminal death domain
(DD) and a short intermediate domain (ID) [26, 122, 125, 171]. Through the DD, MyD88
interacts with IRAKs, a group of receptor proximal Ser/Ther kinases including IRAK1,
IRAK2, IRAKM and IRAK4. All of the IRAKs, except IRAK4, contain a TRAF binding
site at C-terminal motif which is required for binding to TRAF6 and subsequent NFκB
activation through the TAK1-IKK complex. Recent crystal structure study reveals that 6
MyD88 DDs, 4 IRAK4 DDs and 4 IRAK2 DDs form a left-handed helical complex [127].
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This helical signaling complex is referred as Myddosome complex and its assembly is
sequential, in which MyD88 recruits IRAK-4 and the MyD88-IRAK4 complex recruits
IRAK2 or the related IRAK1.
Our data suggested that IRAKM is also able to form a Myddosome complex with
MyD88 and IRAK4, as IRAK1 and IRAK2. The DD of IRAKM shares a considerable
sequence homology with IRAK2. By computational modeling, IRAKM DD has the
capacity to dock to MyD88-IRAK4 complex to form a relatively stable complex. Detailed
analysis suggested that IRAK4 binding residues with IRAK2 are highly conserved in
IRAKM DD. E71, W74 and Q78 in IRAKM DD were suggested to be critical for binding
with IRAK4 DD. By site-specific mutagenesis, we confirmed this TLR-induced binding
interface between IRAK4 and IRAKM DD. Following functional tests, we confirmed the
formation of IRAKM Myddosome complex is required for IRAKM-mediated signaling
transduction.
A recent study from Dr. Hao Wu’s group (the same group which resolved
Myddosome crystal structure complex) indicates that formation of IRAK4 kinase domain
(KD) dimers in Myddsosome complex is required for proximity-driven dimerization and
activation of IRAK4 kinase activity. Our study indicated that IRAK1/2-mediated pathway
is dependent on IRAK4 kinase activity, while IRAKM-mediated pathway is independent
of IRAK4 kinase activity. Therefore, it is possible that IRAKM Myddosome complex may
have a different structure with IRAK2 Myddosome. Future structural study on IRAKM
Myddosome will be required to test this possibility.
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TLR-induced IRAKM-mediated MEKK3-dependent NFκB activation
The previous work from our lab uncovered two parallel TLR/IL-1R-mediated
NFκB activation pathways: TAK1-dependent and MEKK3-dependent, respectively.
IRAK4 kinase activity and IRAK1 are required for TAK1-dependent pathway which leads
to IKKα/β phosphorylation and IKKγ activation, resulting in NFκB activation through
IκBα phosphorylation and degradation. The MEKK3-dependent pathway involves IKKα
activation and IKKγ phosphorylation, which only leads to IκBα phosphorylation without
degradation [65, 73, 129, 150, 151].
In this study, we found that IRAKM is required for TAK1-independent MEKK3pathway. In response to TLR ligand simulation, IRAKM specifically interacts with
MEKK3, not TAK1, through TRAF6, resulting in the phosphorylation of IKKγ and
activation of IKKα. Furthermore, IRAK4 kinase activity is not required for IRAKMmediated MEKK3 dependent pathway. One important question here is how the IRAKM
Myddosome activates MEKK3. In regards to this question, testing whether IRAKM has
kinase activity certainly warrants future study.
IRAKM has been considered to be a member of the pseudokinase family.
Overexpression of IRAKM in HEK 293 cells did not lead to robust autophosphorylation
as IRAK1 in in vitro kinase assay, rather an extremely weak autophosphorylation was
observed [123]. Structurally, IRAKM lacks an aspartic acid residue in HRD motif in the
catalytic loop which is crucial for the kinase activity. Interestingly, it was reported that
murine IRAKM does has a weak but detectable autophosphorylation in in vitro kinase
assay [172]. However, there was not enough experimental evidence to support this. Further
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detailed biochemical study is required to define whether IRAKM has kinase activity or not
and the potential role in IL-1R/TLR signaling.
Since IRAKM interacts with MEKK3, another possible scenario is that MEKK3
may directly phosphorylate IRAKM, leading to the activation of IRAKM and consequent
release of IRAKM-MEKK3 from the receptor complex. This will be the future direction to
study IRAKM-mediated MEKK3-dependent signaling pathway.
Post-translational modification of IRAKM
Among the four members of IRAK family, IRAK1 is the most characterized. Upon
IL-1 or TLR ligands stimulation, IRAK1 is phosphorylated, ubiquitinated and degraded.
Also it has been reported that IRAK1 may also undergo sumoylation besides
phosphorylation and ubiquitination in TLR signaling. IRAK1, through Lysine 48 and
Lysine K63-mediated ubiquination, is mediated by the E3 ligase β-TRCP and Pellino2,
respectively [150, 151].

Recent study suggests that IRAK2 also undergoes

phosphorylation and ubiquitination upon TLR ligand stimulation [173]. However, there is
no report has been published on IRAKM modification. An ongoing project in our lab aims
to find the phosphorylation sites of IRAKM in response to LPS treatment by mass
spectroscopy analysis.
IRAKM-dependent second wave of NFκB activation and gene expression
In the absence of IRAK1 and IRAK2 (in IRAK 1/2 double-deficient cells), IRAKM
is able to mediate prompt TLR-induced NFκB activation. This only indicates IRAKM
Myddosome has the capability to activate NFκB. To further determine its physiological
significance, we re-investigated TLR-induced NFκB activation in IRAKM single deficient
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cells. Surprisingly, the late phase of TLR7-induced late phase NFκB activation was
decreased in IRAKM deficient cells.
By analyzing pro-inflammatory genes expression and protein production, we found
that, although TLR-induced IRAKM-mediated signaling in IRAK1/2 double deficient cells
can mediate the induction of mRNAs expression of pro-inflammatory genes in early time
points, the protein production was total abolished. It suggests that IRAKM-mediated
pathway alone is not sufficient to induce the production of cytokines and chemokines. This
phenomenon indicates the critical role of TLR-induced IRAK1/2-dependent posttranscriptional regulation in innate immune response.
Our previous study about the role of IRAK4 kinase activity in TLR-induced gene
expression identified a group of genes which are not regulated on post-transcriptional
levels [73]. Consistently, the expression of these genes was also substantially reduced in
IRAKM deficient cells compared to that in wild-type cells. Several of the genes are
important for the activation and homeostasis of the macrophages (including ETS2, SOD2,
Bcl-2A1D and GPR84) Interestingly, we found another group of IRAK-M-dependent
genes including A20, SOCS1, SHIP1 and IκBα. These molecules are all well-known
inhibitory molecules of inflammation. They not only negatively regulate TLR-mediated
signaling pathway, but also control other critical inflammation-related signaling pathways,
such as JAK-STAT pathways, TNFα-activated pathway, PI3K-Akt pathway [174-177].
This study provided a novel mechanism which IRAKM exerts an overall inhibitory effect
in acute inflammatory response through producing inhibitory molecules as feedback
regulation system. The advantage for such an inhibitory mechanism could be that IRAKM

105

may exert broader inhibitory effects not just on TLR/IL-1R but also on other cytokine
signaling cascades, so that the inflammatory response can be effectively controlled.
The gene expression data were consistent with the role of IRAK-M in TLR7induced second wave NFκB activation, since most of the IRAK-M-dependent genes were
late genes (induced after 1 hour). However, it is still mysterious why IRAKM-MEKK3
pathway is important for the late phase NFκB activation and gene expression. One possible
answer is that IRAK1 is phosphorylated, ubiquinated and degraded upon TLR ligand
stimulation, while IRAKM expression is induced upon treatment. Only IRAKM is left at
late time points at which mediates second wave NKκB activation. Future detailed studies
on the dynamic and kinetic change of IRAK family members and their roles in TLR
signaling need to done to solve this question.
IRAKM suppresses IRAK2-mediated translational regulation
Previous studies from our lab found that IRAK-2 plays an important role in the
regulation of TLR-mediated protein translation of cytokines and chemokines, including IL6, CXCL1 (KC) and TNFα. Although the mRNAs of these pro-inflammatory genes were
induced at similar or reduced levels in IRAKM deficient BMDMs, their protein production
were actually increased in the IRAKM deficient cells. Based on these observations we
investigated the role of IRAK-M in the regulation of cytokine and chemokine translation.
By poly-ribosome fractionation experiments, we determined that the translational
efficiency of these genes were increased in the absence of IRAKM. Through coimmunoprecipitation experiments, we found that IRAKM specifically interacts with
IRAK2, not IRAK1. Therefore, we proposed that IRAKM suppress the pro-inflammatory
cytokines and chemokines production through the interaction with IRAK2. However, it is
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still unclear how IRAKM interacts with IRAK2 and inhibit its ability to mediate protein
translation. Future studies are needed to detail the molecular mechanism of IRAK2mediated post-transcriptional control of pro-inflammatory genes and how IRAKM binds
to and regulates IRAK2.

B. The Role of IRAKM in Low Grade Inflammation
It has been reported that IRAKM deficient macrophages/dendritic cells produce
more cytokines and chemokines compared to wild-type control cells in response to high
dose TLR agonists. Furthermore IRAKM expression in myeloid lineage cells is known to
impair host defense during infection. Infection or sepsis can induce IRAKM expression
which functions as negative feedback regulation of immune response. This is an important
mechanism which prevent sepsis-induced septic shock. However, the role of IRAKM in
low-grade inflammatory diseases has not been reported before, to the best of our
knowledge.
High-grade inflammation versus low-grade inflammation
High-level endotoxemia in human or experimental animals induces a robust, but
transient immune response. Both pro- and anti-inflammatory mediators are activated,
providing a compensatory mechanism to resolve inflammation and prevent further
damages. This is an important and strict regulatory mechanism to maintain host
homeostasis. Emerging evidence suggests that low-level endotoxemia-induced low-grade
inflammation plays a crucial role during the pathogenesis and development of in several
different chronic diseases. High-level endotoxemia-induced robust acute inflammation,
low-level endotoxemia-mediated mild but persist chronic inflammation. However, the
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molecular mechanisms of this persistent low-grade inflammation are still poorly
understood.
With our studies, we provide new mechanistic insight of low-grade chronic
inflammation. IRAKM-mediated pathway is crucial for low-dose TLR ligand-induced proinflammatory gene expression. Inflammation can be further amplified by IRAKMdependent Mincle expression on macrophages which can sense cell death. Mincle
expression is very low in resting cells. It is highly induced in response to different cell
stresses or danger signals, including TLR ligands. Recent study identified dead cellreleased SAP130, a nuclear protein, as the endogenous ligand for Mincle. Activation of
Mincle signaling leads to cytokine and chemokine production and neutrophils infiltration.
A recent study suggests that low-dose LPS treatment can lead to mitochondria dysfunction
and cell necroptosis. Here we provide a direct evidence linking un-regulated cell death to
inflammation. Also it provides a new angle to study chronic inflammatory disease.
Alcohol induced liver disease and inflammasome activation
The pathogenesis of ALD is multifactorial and current studies suggest that the
damage is the end result of the interplay among ethanol metabolism, inflammation and
innate immunity. TLR4 mediated TLR signaling activation has been shown to be critical
during the initiation and development of ALD. TLR4 has ability to activate two distinct
pathways: MyD88-dependent and MyD88-independent. MyD88-dependent pathway is
activated by the adaptors TIRAP and MyD88, which leads to activation of NFκB and to
the induction of inflammatory cytokines. The second pathway (MyD88-independent) is
activated by adaptors TRIF and TRAM, which activates IRF3 to induce Type I interferons
(IFNs), as well as NFκB activation. The TLR4-induced MyD88-independent TRIF/IRF3-
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dependent cascade has been directly implicated in steatosis and inflammation in ALD. It is
important to note that IL-1R, which exclusively signals through the MyD88 pathway, is
required for ALD pathogenesis. However, it remains unclear how the MyD88-dependent
pathway participates and contributes to the development and pathogenesis of ALD. Here
our preliminary studies identify that downstream signaling components of MyD88, the
IRAKM proteins, play a critical role in the development and pathogenesis of ALD. It has
also been reported that inflammasome activation was observed in the liver from alcoholfed mice. Mice deficient in inflammasome components or IL-1R are protected from ALD.
However, how inflammasome gets activated in the alcohol-fed liver is still unclear. In this
study, we found SAP130 is also capable to activate caspase-1 inflammasome in BMDMs.
Alcohol-feeding induced caspase-1 and IL-1β activation was also decreased in the liver of
IRAKM and Mincle deficient mice. However, how Mincle-mediated pathway activates
inflammasome in cooperating with low dose LPS is still not unclear. This will be the future
direction of this study.

C. IRAKM as a Target for Drug Development
Dysregulated immune responses are involved in many chronic diseases, such as
inflammatory bowel disease, atherosclerosis, rheumatoid arthritis and autism. TLRmediated inflammatory responses are suggested to be involved in the pathogenesis of some
of these diseases. Therefore, suppression of the inflammatory response mediated by TLRs
would be a direct and efficient treatment for these diseases. However, considering the
critical function of TLR-mediated signaling in innate immune response, the side effects of
such treatment might be detrimental and lead to susceptible to infection. The observation
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that IRAKM deficiency leads to increased pro-inflammatory cytokine and chemokine
production during acute inflammation. While our study indicates that IRAKM-mediated
MEKK3-dependent pathway is crucial in low-grade inflammation. IRAKM may be a better
drug targets than other IRAKs in preventing chronic inflammation.
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A. Abstract
Low grade systemic inflammation is often associated with metabolic syndrome
which plays a critical role in the development of the obesity-associated inflammatory
diseases including insulin resistance and atherosclerosis. Here we investigate how TLRMyD88 signaling in myeloid and endothelial cells coordinately participates in the initiation
and progression of high fat diet-induced systemic inflammation and metabolic
inflammatory diseases. MyD88 deficiency in myeloid cells inhibits macrophage
recruitment to adipose tissue and their switch to an M1-like phenotype. This is
accompanied by substantially reduced diet-induced systemic inflammation, insulin
resistance, and atherosclerosis. MyD88 deficiency in endothelial cells results in a moderate
reduction in diet-induced adipose macrophage infiltration and M1 polarization, selective
insulin sensitivity in adipose tissue, and amelioration of spontaneous atherosclerosis. Both
in vivo and ex vivo studies suggest that MyD88-dependent GM-CSF production from the
endothelial cells might play a critical role in the initiation of obesity-associated
inflammation and development of atherosclerosis by priming the monocytes in the adipose
and arterial tissues to differentiate into M1-like inflammatory macrophages. Taken
together, these results implicate a critical MyD88-dependent interplay between myeloid
and endothelial cells in the initiation and progression of obesity-associated inflammatory
diseases.
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B. Introduction
The metabolic syndrome is characterized by a cluster of physiological alterations
including glucose intolerance/insulin resistance, abdominal obesity, atherogenic
dyslipidemia (low concentration of plasma high-density lipoprotein cholesterol and high
concentration of plasma triglycerides), and elevated blood pressure. Occurring together,
these conditions increase the risk for atherosclerosis and type 2 diabetes mellitus (T2DM),
which are typical obesity-associated diseases that are endemic in developed countries,
currently affecting 25% of the population and growing [178]. Recent investigations have
increasingly shown that low grade systemic inflammation is often associated with
metabolic syndrome, which probably plays a critical role in the development of these
metabolic diseases [179-182]. Previous studies have shown that a high fat diet (HFD) can
increase the gut permeability, triggering the accumulation of systemic inflammatory
stimuli [183], including pathogen-associated molecular patterns (PAMPs), such as ligands
for Toll-like receptors (TLRs), endogenous TLR ligands such as fatty acids and
inflammatory cytokines, including Interleukin-1 (IL-1) [184-189]. Although inflammation
is generally considered to be a localized reaction, it is now understood that a “systemic
inflammatory response” can occur when inflammatory stimuli gain access to the circulation
[180].
Genetic studies and mouse disease models have shown the participation of TLR
and IL-1R in the development of HFD-induced systemic inflammation and obesityassociated inflammatory diseases. TLR4 deficiency reduced diet-induced insulin resistance
and systemic inflammation [189], while TLR2-deficient mice were partially protected from
diet-induced obesity [190]. Human TLR4 null mutations are associated with reduced risk
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of atherosclerosis [191]. ApoE-/- mice, a commonly used model, spontaneously develop
atherosclerosis; deficiency in TLR4, IL-1 and IL-1R each reduced vascular inflammation
and atherosclerosis in ApoE-/- mice [192-195]. These previous studies suggested that
exogenous/endogenous TLR ligands and the pro-inflammatory cytokine IL-1 can activate
IL-1R/TLRs in multiple tissues including adipose, liver, pancreas, aorta, heart and muscle.
As a consequence, a chronic systemic inflammatory response is established which is
strongly associated with the development of type II diabetes and atherosclerosis [183, 196,
197]. Much effort has been devoted towards the understanding of IL-1R/TLR-mediated
signaling mechanisms, with the long-term objective to identify new therapeutic targets and
develop more effective anti-inflammatory small molecule drugs. Upon ligand stimulation,
IL-1R and TLRs form either homo- or hetero oligomers. The adapter molecule MyD88 is
recruited to all IL-1R/TLR oligomers, except TLR3, followed by the recruitment of the
serine/threonine interleukin-1 receptor kinases (IRAKs) [127, 171, 198-200]. Genetic and
biochemical studies revealed that through activation of MyD88-IRAKs, downstream
kinases are organized by multiple adapter molecules into parallel and sequential signaling
cascades, leading to activation of the transcription factor nuclear factor κB (NFκB) and
MAPKs[129, 131, 132], resulting in the production of inflammatory cytokines and
chemokines.
Although TLR-MyD88 signaling has been implicated in obesity-associated
inflammatory diseases, the molecular and cellular mechanisms are not completely
understood. In this study, we investigated how TLR-MyD88 signaling in different cellular
compartments coordinately participates in the initiation of HFD-induced systemic
inflammation and metabolic inflammatory diseases. The cell-type specific MyD88-/- mice
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are crucial, since complete MyD88-/- mice (1) are immune compromised and prone to
infection; (2) do not adequately reflect specific role of MyD88 in different cell types [201].
Indeed, several previous studies using complete MyD88-/- mice produced conflicting
results regarding the role of MyD88 in obesity-associated inflammatory diseases, which
might be due to the immune deficiency of complete MyD88-/- mice and the housing
environment in different institutions [193, 195, 202]. Therefore, studies using cell-type
specific MyD88-/- mice are necessary and timely to elucidate the mechanistic role of TLRMyD88 signaling in obesity-associated inflammatory diseases.
Using cell-type specific MyD88-deficient mice, our findings for the first time
demonstrate the MyD88-dependent cooperative actions of myeloid and endothelial cells in
the development and progression of metabolic inflammatory diseases. MyD88 deficiency
in myeloid cells (MyD88MC-KO) substantially reduced diet-induced systemic inflammation,
insulin resistance, and atherosclerosis. Furthermore, deletion of MyD88 in myeloid cells
prevented macrophage infiltration into adipose tissue and aborted a switch in ATM
phenotype from M2-like to M1-like. Using an adipocyte-macrophage ex vivo co-culture
system and adipocyte-derived endogenous TLR ligand FFA, we demonstrated the
influence of adipocytes on MyD88-dependent induction of M1-associated genes in
macrophages, indicating the cross-talk between adipocytes and macrophages. On the other
hand, MyD88 deficiency in endothelial cells (MyD88EC-KO) showed moderate reduction in
diet-induced adipose M1-like macrophages with selective insulin sensitivity in adipose
tissue, and amelioration of spontaneous atherosclerosis. Both in vivo and ex vivo studies
suggest that MyD88-dependent GM-CSF production from the endothelial cells might play
a critical role in the initiation of obesity-associated inflammation and development of

151

atherosclerosis by priming the monocytes in the adipose and arterial tissues to M1-like
inflammatory macrophages. Taken together, these results implicate a critical MyD88dependent interplay among adipocytes, macrophages and endothelial cells in the initiation
of diet-induced systemic inflammatory state and metabolic diseases.

C. Results
Generation of myeloid- and endothelial-specific MyD88-deficient mice
Endothelial cell-specific MyD88-deficient mice created by cre-lox technology were
validated by PCR (Fig. 32A). Tie2eCre transgenic mice (generated using the Tie2 5’
promoter and first intron enhancer element) express Cre within endothelium of brain, heart,
and liver, among others [203, 204]. It is important to note that Tie2eCre (distinct from
Tie2Cre) is restricted to endothelium, and Cre expression is minimally leaky [203, 204].
MyD88 expression was abolished in CD31+ endothelial cells from the aortas of
Tie2eCreMyD88fl/fl (MyD88EC-KO) mice compared to control (Tie2eCreMyD88fl/+, Con ECKO

), but showed normal MyD88 expression in monocytes (Fig. 32A). To generate myeloid

specific MyD88-deficient mice, we utilized CD11bCre transgenic mice (generated with the
promoter for CD11b, an integrin expressed exclusively in the myeloid lineage) [204-206].
These mice express Cre in macrophages, microglia, as well as activated liver kupffer cells.
CD11bCreMyD88fl/+ mice were bred to MyD88fl/fl to generate control mice
(CD11bCreMyD88fl/+,

ConMC-KO)

and

myeloid-specific

MyD88-deficient

mice

(CD11bCreMyD88fl/fl, MyD88MC-KO). PCR analysis showed that MyD88 expression was
diminished in CD11b+ monocytes derived from CD11bCreMyD88fl/fl (MyD88MC-KO) mice
compared to that in ConMC-KO mice (Fig. 32A).
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Figure 32. MyD88 deficiency in myeloid and endothelial cells improves diet-induced
hyperglycemia and hyperinsulinemia. (A)PCR for MyD88 mRNA of mouse CD11b+
splenic monocytes (CD11b+ monocytes) and CD31+ primary aortic vascular endothelial
cells (MAVECs) from MyD88EC-KO, MyD88MC-KO and their respective littermate controls
(ConMC-KO and ConEC-KO). Data are presented as mean ± SD based on 5-7 for each group
and are representative of three independent experiments. Body weights of (B) MyD88MCKO
or (C) MyD88EC-KO male mice and their littermate controls (maintained on a chow diet
or HFD) were measured weekly from 6 to 26 weeks of age. (D) Serum fasting glucose and
(E) fasting insulin levels were measured in MyD88MC-KO, MyD88EC-KO male mice and
their respective littermate controls fed on chow diet (6 months of age) or HFD (for 6 weeks
or 3 months starting from 6 weeks old). (n = 9-11 mice per genotype). Data are
representative of two independent experiments.

153

MyD88 deficiency in myeloid and endothelial cells reduce diet-induced insulin
resistance
We first analyzed metabolic parameters of MyD88MC-KO and MyD88EC-KO mice on
chow diet or HFD. There were no substantial differences in weight gain over the course of
20 weeks (Fig. 32B-C) with similar levels of serum cholesterol, triglycerides and nonesterified fatty acids (data not shown) in MyD88MC-KO and MyD88EC-KO mice fed on chow
or high-fat diet compared to their respective littermate controls. These results indicate that
MyD88 deficiency in endothelial or myeloid cells did not affect diet-induced weight gain
and lipid homeostasis. We then examined glucose metabolism in the MyD88MC-KO and
MyD88EC-KO mice. Interestingly, after HFD (for 6 weeks and 3 months), fasting glucose
and fasting insulin levels were substantially decreased in MyD88MC-KO mice compared with
the littermate controls (Fig. 32D-E). By performing GTT, we found that HFD fed
MyD88MC-KO mice had much improved glucose tolerance compared with the littermate
controls (Fig. 33A-B). Endothelial MyD88 deficiency also improved insulin sensitivity,
but the impact was more dramatic at early phase (6 weeks) compared to that after 3 months
of HFD (Fig. 33C-D). As controls, we noticed that the glucose tolerance and insulin
sensitivity in chow diet fed MyD88MC-KO and MyD88EC-KO mice were comparable with
their respective littermate controls (Fig. 32D-E, data not shown).
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Figure 33. Deletion of MyD88 in myeloid cells and endothelial cells reduces dietinduced insulin resistance. GTTs (Glucose tolerance tests) in MyD88MC-KO male mice
and littermate controls on high fat diet (HFD) for (A) 6 weeks or (B) 3 months starting
from 6-week old (6 months old mice on chow diet as controls，data not shown). Area
under curve (AUC) was calculated. GTT in MyD88EC-KO mice and their littermate controls
on high fat diet (HFD) for (C) 6 weeks or (D) 3 months starting from 6-week old (6 months
old mice on chow diet as controls，data not shown). AUC was calculated. Data are
presented as mean ± S.E.M (n = 9-11 mice per genotype) and are representative of two
independent experiments. (*P < 0.05, **P < 0.01)
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Deletion of MyD88 in myeloid cells and endothelial cells preserves insulin signaling
in different tissues
Since MyD88 deficiency in myeloid and endothelial cells attenuated diet-induced
insulin resistance, we then examined insulin sensitivity in several tissues (including
adipose tissue, muscle and liver) by IP injecting HFD-fed mice with insulin or saline after
an overnight fast. As expected, compared with normal chow fed mice, insulin-induced
AKT phosphorylation, tyrosine phosphorylation of IRS1 (insulin receptor substrate 1) and
IRS1 interaction with PI3K (p85-phosphoinositide 3 kinase) were greatly reduced in
adipose tissue, liver and muscle of HFD-fed wild-type control mice (Fig. 34A-D),
demonstrating diet-induced insulin insensitivity of these tissues. Interestingly, while
insulin-induced AKT phosphorylation was preserved in all three tissues of HFD-fed
MyD88MC-KO mice, endothelial-specific MyD88 deficiency only rescued insulin signaling
substantially in adipose tissue(Fig. 34E-H). Consistently, insulin-induced IRS-1 tyrosine
phosphorylation and its association with PI3K (p85) were preserved in adipose tissue, liver
and muscle of HFD-fed MyD88MC-KO mice, but only restored in adipose tissue of HFD-fed
MyD88EC-KO mice, compared to that in their respective HFD-fed littermate controls(Fig.
34E-H). Thus, endothelial-derived MyD88 plays a more important role in HFD-induced
insulin resistance in the adipose tissue than that in liver and muscle.
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Figure 34. Deletion of MyD88 in myeloid cells and endothelial cells preserves insulin
signaling. After overnight fast, 5-month-old of control group (CD11bCreMyD88fl/+ and
Tie2eCreMyD88fl/+) male mice kept on chow diet or HFD were injected with either saline
(-) or 25 mU/kg of insulin (+). (A) white Adipose tissues (WAT), (B) muscles and (C)
livers were collected 5 minutes later. (E) white Adipose tissues (WAT), (F) muscles and
(G) livers of MyD88MC-KO, MyD88EC-KO and control group male mice kept on HFD for 3
months were collected at 5 minutes after saline or insulin injection. Protein extracts were
prepared, immunoprecipitated with anti-IRS-1, followed by western analysis with
antibodies for phosphotyrosine (PY20, pY) or p85-PI3K. The levels of IRS1, activated
AKT (pSer473, pAKT) and total AKT, were determined by immunoblotting of the original
lysates. (D and H) The levels of pAKT and AKT were quantified by densitometry. The
ratio of pAKT to AKT was expressed as a mean ± S.E.M. (*P < 0.05, **P < 0.01). (n = 4
mice per genotype). The results are representative of three independent experiments.
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Myeloid-

and

endothelial-specific

MyD88

deficiency

protect

mice

from

atherosclerosis in ApoE-/- mice
Atherosclerosis is a chronic inflammatory disease of the arteries, representing the
underlining cause of the majority of cardiovascular disease. Obesity is an independent risk
factor for the development of cardiovascular atherosclerosis. Obesity-induced insulin
resistance and impaired glucose metabolism can exacerbate atherosclerosis. To study the
impact of MyD88 deficiency in endothelial or myeloid cells on the pathogenesis of
atherosclerosis, we employed the ApoE-deficient mice, which spontaneously develop
hypercholesterolemia and atherosclerosis. Since female ApoE-/- mice were shown to
develop more severe phenotype than male ApoE-/-[207, 208], we decided to use the female
mice in this model. MyD88MC-KO, MyD88EC-KO mice and respective littermate controls
were crossed to ApoE-/- mice to generate MyD88MC-KOApoE-/-, MyD88EC-KOApoE-/- mice
and control mice (ConMC-KOApoE-/- and ConEC-KOApoE-/- mice). Total plasma cholesterol
levels and cholesterol distribution were similar among 18-week old female MyD88MC-KO
ApoE-/-, MyD88EC-KO ApoE-/- and their respective littermate controls either on chow diet
or HFD (data not shown).
We first compared the severity of atherosclerosis in chow fed MyD88MC-KOApoE/-

, MyD88EC-KOApoE-/- and their respective littermate controls at 18 weeks of age. En face

and aortic root section analysis of atherosclerotic lesions showed about 60-70% reduction
in both MyD88MC-KO ApoE-/- and MyD88EC-KO ApoE-/- mice compared to littermate controls
(Fig. 35A-D). Thus, MyD88 deficiency in endothelial or myeloid cells inhibited vascular
lesion formation in this model of spontaneous atherosclerosis. Consistently, under chow
diet MyD88 deficiency in myeloid or endothelial cells had similar impact on insulin
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sensitivity of aortas compared to that in their littermate controls (Fig. 35E). We then
examined expression of inflammatory genes in arterial tissue of both MyD88MC-KOApoE-/and MyD88EC-KOApoE-/-mice. The expression levels of M-CSF, MCP-1, iNOS, VCAM-1,
ICAM-1, and especially GM-CSF, were substantially reduced in the arterial tissue of
MyD88

EC-KO

ApoE-/-mice, whereas TNFα, IL-6 and IL-1 were similarly decreased in

arterial tissue of MyD88EC-KOApoE-/- and MyD88MC-KOApoE-/- mice compared to that of
littermate controls (Fig. 36A-B).
Since it is well known that the pathology of atherosclerosis in ApoE-/- mice is
further aggravated upon HFD feeding, we then compared diet-induced atherosclerotic
lesions of the endothelial- and myeloid-specific MyD88-deficient mice with their littermate
controls. En face and aortic root section analysis of atherosclerotic lesions showed about
70% versus 40% reduction respectively in lesion areas of MyD88MC-KO ApoE-/- mice and
MyD88EC-KO ApoE-/- mice compared to their littermate controls (Fig. 35A-D). It is
important to note that HFD substantially induced insulin resistance in the aortas of wildtype control mice. Both MyD88MC-KO ApoE-/- and MyD88EC-KO ApoE-/- mice showed
improved insulin sensitivity of aortas compared to their littermate controls (Fig. 35E). The
expression of inflammatory genes (CXCL1, TNFα, IL-6, IL-1) was more dramatically
decreased in arterial tissue of MyD88MC-KO ApoE-/- than that in MyD88EC-KOApoE-/-mice
compared to their respective littermate controls (Fig. 36C-D). On the other hand, the
expression of several inflammatory genes (M-CSF, MCP-1, iNOS, VCAM-1 and ICAM1) were equally decreased in arterial tissue of MyD88
KO

MC-KO

ApoE-/- and MyD88

EC-

ApoE-/-mice compared to littermate controls (Fig. 36C-D). It is important to note that

the expression of GM-CSF was more dramatically decreased in arterial tissue of MyD88EC-
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KO

ApoE-/- than that in MyD88MC-KOApoE-/-mice compared to that in littermate controls

(Fig. 36C-D). Lastly, through the analysis of gene expression in aorta, we did notice that
the expression of Arg1 and IL-10 were always enhanced in the arterial tissue of either chow
or HFD fed MyD88EC-KO ApoE-/- and MyD88MC-KOApoE-/- mice compared to that in their
respective littermate controls (Fig. 36A-D), which will be further discussed below.
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Figure 35. Myeloid - and endothelial-specific MyD88 deficiency protect mice from
atherosclerosis. (A)MyD88MC-KO ApoE-/-, (B) MyD88EC-KO ApoE-/- female mice and their
respective littermate controls (ConMC-KO ApoE-/- and ConEC-KO ApoE-/-), were fed on chow
diet or HFD for 12 weeks beginning at 6 weeks of age. Enface (oil-red O staining) analysis
was done for the whole aorta tree from end of the curvature of the aortic arch to the iliac
bifurcation from these mice. Total mean lesion area was quantified based on imageanalysis by Photoshop software shown. Data are presented as mean ±S.E.M (n = 9-12 mice
per genotype) and are representative of two independent experiments. (*P < 0.05, **P <
0.01). Cross-sections of aortic roots from (C) MyD88MC-KO ApoE-/-, (D) MyD88EC-KO
ApoE-/- female mice and their respective littermate controls fed on chow diet or HFD for
12 weeks were stained with oil red O (Scale bar=250μm). Total mean lesion area was
quantified by Photoshop software and shown as mean ± S.E.M and are representative of
three independent experiments.. (*P < 0.05, **P < 0.01). (n = 6-7 mice per genotype). (E)
Aortas of MyD88MC-KO ApoE-/-, MyD88EC-KO ApoE-/- and control group female mice kept
on either chow diet or HFD for 3 months were collected at 5 minutes after saline or insulin
injection. Protein extracts were analyzed as described in Fig. 2A-D. The levels of pAKT
and AKT were quantified by densitometry. The ratio of pAKT to AKT was expressed as a
mean ± S.E.M. (*P < 0.05, **P < 0.01). (n = 4 mice per genotype). The results are
representative of three independent experiments.
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Figure 36. MyD88 deficiency in myeloid and endothelial cells ameliorates arterial
tissues inflammation under hypercholesterolemia and diet-induced systemic
inflammation. Total RNA of aortas was isolated from MyD88MC-KO ApoE-/- female mice
and littermate control mice on chow diet (A) or HFD (B); MyD88EC-KO ApoE-/- female mice
and their respective littermate controls on chow diet (C) or HFD (D); and followed by
quantitative real-time PCR and normalized to β-actin for the indicated genes. The mean
value of each gene in control groups on chow diet was set to 1. The mean value of each
gene in mice on HFD was normalized to that in their respective controls on chow diet. Data
are presented as mean ± S.E.M (n = 9-12mice per genotype) and are representative of two
independent experiments. (E) Protein levels of IL-1β, IL-6, TNFα and CXCL1 in the serum
from MyD88MC-KO ApoE-/-, MyD88EC-KO ApoE-/- female mice and their respective
littermate controls were analyzed by ELISA. (n = 7-9 mice per genotyping). Data are
presented in as mean ± S.E.M. (*P < 0.05, **P < 0.01). The results are representative of
two independent experiments.
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Myeloid-derived MyD88 is required for HFD-induced systemic inflammation
Recent studies have shown a direct link between “chronic systemic inflammation”
and diet-induced metabolic syndrome and consequent obesity-associated inflammatory
diseases [180, 209-221]. Low-grade inflammation triggered by the HFD was indeed
detected in the circulation of control mice, whereas diet-induced serum pro-inflammatory
cytokines (IL-1, IL-6, TNF and CXCL1) were greatly reduced in MyD88MC-KO mice (Fig.
36E). On the other hand, the deletion of MyD88 in endothelial cells only moderately
reduced serum levels of these pro-inflammatory cytokines (Fig. 36E). As shown in Fig.
35A-D, myeloid MyD88 also plays a more critical role than endothelial MyD88 in HFDinduced atherosclerosis, suggesting that systemic inflammation might contribute to HFDinduced exacerbation on atherosclerosis. Under systemic inflammation, in addition to oxLDL and IL-1, the endothelium is probably also activated by other circulating
inflammatory stimuli through MyD88-independent pathways, including TNFα and IL6[222]. Taken together, our results suggest that while both myeloid and endothelial MyD88
participate in the initiation of obesity-induced inflammatory diseases, myeloid MyD88
might play a more dominant role in disease progression through its impact on systemic
inflammation.

Myeloid MyD88 participates in HFD-induced switching of adipose tissue
macrophages (ATM) from M2-like to M1-like
Metabolic-triggered inflammation in white adipose tissue plays a key role in
initiation of inflammatory diseases associated with metabolic syndrome, by directly
impacting local and systemic insulin signaling and consequent long-term systemic
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inflammation [223-227]. Obesity-induced adipose tissue inflammation is characterized by
the presence of an increased number of adipose tissue infiltrating macrophages [228].
Compared to littermate controls, MyD88MC-KO mice showed markedly reduced infiltration
of macrophages and fewer so called “crown-like structures (CLS)”, which are associated
with inflammation and apoptotic/necrotic adipocytes (Fig. 37A-B and F4/80 levels in
37D). In support of the histology, mRNA expression levels of inflammatory genes were
greatly decreased in adipose tissue of MyD88MC-KO mice compared to controls (Fig. 37C).
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Figure 37. Deletion of MyD88 in myeloid cells and endothelial cells reduces dietinduced adipose tissue inflammation. MyD88MC-KO, MyD88EC-KO male mice and their
respective littermate controls on HFD for 14 weeks were sacrificed and epididymal fat pad
was collected. (A) Paraffin sections of epididymal fat pad were stained with anti-F4/80
antibody (Scale bar=50μm). Arrowheads indicate F4/80 positive staining; representative
CLSs were enlarged and shown in the insert. (B) The number of CLSs was counted. Results
are shown as mean± S.E.M of five different sections per mouse and are representative of
five mice per genotype with similar results. The results are representative of two
independent experiments. (C-D) Total adipose tissue RNA from MyD88MC-KO, MyD88ECKO
and their respective littermate control mice were analyzed by quantitative real-time PCR
and normalized to β-actin for the indicated genes. Data are presented as mean ± S.E.M (n
= 9-11 per genotype) and are representative of two independent experiments. (*P<0.05,
**P < 0.01). MyD88MC-KO ApoE-/-, MyD88EC-KO ApoE-/- male mice and their respective
littermate controls fed on either chow diet (E) or HFD (F) for 12 weeks were sacrificed
and epididymal fat pad was collected. Total adipose tissue RNA were analyzed by
quantitative real-time PCR and normalized to β-actin for the indicated genes. Data are
presented as mean ± S.E.M (n = 5-6 per genotype) and are representative of two
independent experiments. (*P<0.05, **P < 0.01).

ATMs consist of at least two different phenotypes, classically activated M1-like
macrophages and alternatively activated, resident M2-like macrophages. In obesity,
infiltrating M1-like macrophages lead to an overall switch in adipose tissue phenotype,
associated with insulin resistance and chronic inflammation [224, 228-238]. Interestingly,
we found that gene markers for M2-like macrophages, including IL-10, C-type mannose
receptor 2(CD206), Arginase-1, and macrophage galactose N-acetyl-galactosamine–
specific lectin 1 (Mgl-1) were increased in adipose tissue of MyD88MC-KO, while M1-like
marker CD11c was decreased (Fig. 37D), which is consistent with the improved adipose
inflammatory status of these mice. When gated on CD11b+F4/80+ cells from adipose
tissue of HFD-fed mice, the elimination of MyD88 in myeloid cells increased the number
of M2-like macrophages (CD11c-CD206+) with decreased M1-like macrophages
(CD11c+CD206-), confirming the critical role of MyD88-dependent signaling in HFDinduced ATM switching from M2- to M1-like macrophages (Fig. 38A). We then sorted for
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M1-like (F4/80+CD11c+) and M2-like (F4/80+CD206+) macrophages from adipose
tissues of HFD-fed MyD88MC-KO and control mice, followed by gene expression analysis.
Inflammatory gene expression (iNOS and IL-6) was much higher in M1-like than that in
M2-like macrophages and substantially reduced in MyD88-deficient M1- and M2-like
macrophages compared to their corresponding control macrophages, respectively (Fig.
38B). On the other hand, M2-associated gene expression (Mgl1 and IL-10) was much
higher in M2-like than that in M1-like macrophages and significantly increased in MyD88deficient M2- and M1-like macrophages compared to their corresponding control
macrophages (Fig. 38B). These data indicate that deletion of MyD88 in myeloid cells
aborted HFD-induced switch of ATMs from M2- to M1-like subtype at cellular and
molecular levels.
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Figure 38. MyD88 participates in HFD-induced switching of adipose tissue
macrophages (ATM) from M2 to M1. (A) Stromal vascular fraction (SVF) cells from
epididymal fat pad of 6 month old MyD88MC-KO, MyD88EC-KO mice and their respective
littermate controls on HFD were analyzed by flow cytometry. CD11b+F4/80+ (ATMs)
were further analyzed with anti-CD11c and anti-CD206 antibodies. M1-like
(F4/80+CD11c+) cells and M2-like (F4/80+CD206+) subsets were shown as mean ±
S.E.M (n = 9-12 mice per genotype) and are representative of two independent experiments.
(*P<0.05, **P < 0.01). (B)Total RNA isolated from M1- or M2-like macrophages was
analyzed by quantitative real-time PCR and normalized to β-actin for the indicated genes.
The mean value of each gene in M1-like cells from control groups was set to 1. Data are
presented as mean ± S.E.M (n = 5-7 per genotype) and are representative of two
independent experiments. (C)Total RNA was isolated from M1-like (F4/80+CD11c+) cells
or M2-like (F4/80+ CD206+) cells in aortic lesions and analyzed by quantitative real-time
PCR and normalized to β-actin for the indicated genes. The mean value of each gene in
M1-like cells from control groups was set to 1. Data are presented as mean ± S.E.M (n =
5-6 mice per genotype and are representative of two independent experiments. (*P<0.05,
**P < 0.01).

Similar M1- and M2-associated gene expression patterns were observed in adipose tissues
of mice bred onto ApoE-/- background fed on HFD (Fig. 37D and Fig. AI-37E-F). It is
interesting to note MyD88 deficiency in myeloid cells also led to a shift from M1associated [iNOS; TNF, IL-1 and IL-6] to M2-like [Arg1 and IL-10] gene expression in
arterial tissue of chow and HFD fed mice (Fig. 36A and AI-5C). This finding was
confirmed by immunestaining of sections of aortic roots of MyD88MC-KO mice and
littermate control mice on both chow diet and HFD (Fig. 39A-D). MyD88 deficiency in
myeloid cells indeed led to a shift from M1-like (F4/80+iNOS+) to M2-like
(F4/80+Arginase1+) macrophages in the aortic lesions of mice on chow diet or HFD (Fig.
39A-D). This result was further corroborated by gene expression profile from sorted
macrophages from aortic tissues of HFD-fed mice. Inflammatory gene expression (iNOS
and IL-6) was substantially reduced in sorted MyD88-deficient M1- (F4/80+CD11c+) and
M2-like (F4/80+CD206+) macrophages compared to their corresponding control
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macrophages, respectively (Fig. 38C). Importantly, M2-associated gene expression (Arg1
and IL-10) was much higher in M2-like than that in M1-like macrophages and significantly
increased in MyD88-deficient M2-like and M1-like macrophages compared to their wildtype control macrophages, respectively (Fig. 38C).
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Figure 39. Deletion of MyD88 in myeloid cells and endothelial cells prevents M1
macrophages polarization in arterial tissue under hypercholesterolemia.
Immunostaining of atherosclerotic lesions from MyD88MC-KO ApoE-/-, MyD88EC-KO ApoE/
- female mice and their respective littermate controls on chow diet (A) or HFD (B) for 3
months. Macrophages were identified as F4/80+ (red) cells. Co-expression of F4/80 and
iNOS (green) or Arg1 (green) was identified by image overlay. Inset: magnification of the
zone delimited in the frame. Arrowheads indicate representative M1-like (F4/80+iNOS+)
or M2-like (F4/80+Arg1+) cells (scale bar=20μm) (n = 4-5 mice per genotype). The results
are representative of three independent experiments. (C) Lesional macrophage content as
determined by percentage of F4/80 positive staining area (mean ±S.E.M). (D) Enumeration
of M1-like or M2-like macrophages by immunofluorescence in aortic root sections as
shown in G. Results are shown as average ±S.E.M of five different sections per mouse and
are representative of 4-5 mice per genotype with similar results. (*P<0.05, **P < 0.01)

Since myeloid-derived MyD88 had a dramatic impact on the ATM phenotype, we
set up an adipocyte-macrophage ex vivo co-culture system to explore the cross-talk
between adipocytes and macrophges. BMDMs and 3T3L1 adipocytes were cultured in the
bottom and inner wells of Boyden chambers, respectively, which permitted passage of
humoral factors between the chamber wells. Pro-inflammatory cytokine/chemokine
mRNAs and proteins in the supernatant were higher in macrophages co-cultured with
adipocytes than those in macrophages cultured alone (Fig. 40A). The effects of coculturing were augmented by the increase of ratios of adipocytes/macrophages (Fig. 40A).
Interestingly, we also found that Arginase-1 and CD206 (M2 markers) expression were
reduced by co-culturing (Fig. 40B). Furthermore, the expression of M1-associated genes
including IL-12a, IL-12b, IRF5 and NOS2 was concomitantly upregulated by the increase
of ratios of adipocytes/macrophages (Fig. 40C). All these effects were reduced in
MyD88KO BMDMs (Fig. 40A-C), demonstrating that MyD88 participates in the crosstalk between adipocytes and macrophages, which might play a critical role in HFD-induced
switching of ATMs from M2-like to M1-like phenotype. The next question is what the
relevant ligands here. ATMs are exposed to high local concentrations of FFAs released
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from enlarged adipocytes and augmented by increased lipolysis in obesity [239-242]. We
indeed detected FFA in the conditioned media of the co-culture experiment of adipocytes
and macrophages by ELISA (Fig. 40D). This finding suggests that FFA from adipocytes
might serve as a TLR ligand to activate macrophages in our co-culture system. In support
of this, we found that palmitate-induced inflammatory gene expression was substantially
reduced in MyD88-deficient macrophages compared to that in control cells, while
completely abolished in TLR4-/- and partially impaired in TLR2-/- macrophages,
suggesting the possible role of saturated fatty acids (SFAs) in promoting TLR-MyD88dependent switching of ATMs from M2-like to M1-like inflammatory macrophages (data
not shown).
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Figure 40. MyD88-dependent cross-talk between adipocytes and macrophages
promotes M1 polarization. Bone marrow-derived macrophages (BMDMs) of WT and
MyD88KO male mice were plated in the bottom wells of Boyden chambers, with or
without (indicated as M) 3T3 adipocytes in the inserts at a ratio of 1:1 or 5:1 (adipocytes:
BMDMs cell numbers). mRNA expression levels of (A) CXCL1, IL-6, TNF-α, IL-1β, (B)
Arginase-1, CD206, (C) IL12a, IL12b, IRF5 and iNOS in the BMDMs were analyzed. The
expression of mRNA normalized to β-actin expression. The data are presented as fold
induction over the levels of mRNAs in WT macrophages cultured alone. (n = 5 wells in
each group) Data represent the mean ± S.E.M. of the results from three independent
experiments. (D) Concentration of FFA in the supernatant was measured by ELISA (n = 5
wells in each group). Data are expressed as mean ± S.E.M of the results from three
independent experiments. (*P<0.05, **P < 0.01).

Endothelial MyD88 mediates GM-CSF production to prime M1-like inflammatory
macrophages
Interestingly, MyD88EC-KO mice also showed moderate reduction in HFD-induced
M1-like macrophages in adipose tissue (Fig. 37C-D and Fig. 38A-B). Consistently,
endothelial-specific MyD88 deficiency rescued insulin signaling substantially in adipose
tissue (Fig. 34E & H). Furthermore, MyD88 deficiency in endothelial cells (MyD88ECKO

ApoE-/-) showed substantial reduction in lesion areas, aortic wall inflammation

(including a shift from M1- to M2-like macrophages) and improved insulin sensitivity of
aortas in both chow and HFD-fed mice (Fig. 35B, 35D, 35E, 36B, 36D, Fig. 38C and
39A-D). Based on these results, we hypothesized that MyD88-signaling in endothelial cells
mediates the cross-talk with macrophages to impact on the initiation of atherosclerosis and
diet-induced exacerbation on atherosclerotic lesions. Interestingly, we noticed that the
expression of GM-CSF was substantially decreased in the arterial tissue and adipose tissue
of MyD88EC-KO mice compared to controls (Fig. 36B & D, 37C and 41A). Immunostaining
showed that GM-CSF was indeed co-localized with CD31+ endothelial cells in the aortic
root lesions of ConEC-KOApoE-/- mice, which was abated in that of the MyD88EC-KOApoE-/-
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mice, demonstrating MyD88-dependent GM-CSF expression in endothelial cells (Fig.
41B). GM-CSF is well-known for its function in promoting monocyte differentiation
towards M1 pro-inflammatory macrophages [131, 243-251]. Based on our results and
previous studies on GM-CSF, we proposed that MyD88-dependent signaling in endothelial
cells induces the production of GM-CSF, which in turn primes the monocytes/macrophages
to become M1-like inflammatory macrophages.
To test this hypothesis, we need to know the relevant ligands for the MyD88dependent signaling in endothelial cells. Ox-LDL (oxidized and related modified forms of
low density lipoproteins) is an endogenous TLR2/4 ligand, which accumulates in the vessel
wall and is an emerging cardiovascular risk factor [238, 252]. Ox-LDL may trigger TLR
signaling in macrophages and as well as directly on endothelial cells. In addition to oxLDL, the endothelium, the interface between vascular structures and blood, can also be
activated by a variety of circulating inflammatory stimuli [222], includ

-6

and IL-1. Therefore, the most relevant ligands for MyD88-dependent signaling in
endothelial cells are ox-LDL and IL-1. Interestingly, we found that both ox-LDL and IL-1
can strongly induce GM-CSF expression in primary endothelial cells, which was
completely abolished in MyD88-deficient endothelial cells (Fig. 41C). We wondered then
whether GM-CSF produced by ox-LDL- and IL-1-treated endothelial cells is able to
influence the macrophage function. We indeed found that the conditioned medium from
ox-LDL-treated wild-type endothelial cells (but not MyD88-deficient endothelial cells)
was able to induce GM-CSF-target gene PPBP (CXCL7,[246, 251]) in CD11b+ monocytes
and enhanced the expression of M1-associated genes including IL-12a, IL-12b and iNOS
(Fig. 41D). Similar results were observed with IL-1-treated endothelial cells (data not
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shown). Neutralization with anti-GM-CSF greatly reduced the expression of PPBP and
M1-associated genes in monocytes in response to the conditioned medium from ox-LDLtreated endothelial cells (Fig. 41D). Moreover, the conditioned medium from ox-LDLtreated wild-type endothelial cells (but not MyD88-deficient endothelial cells) was able to
increase the ratio of CD11c (M1) to CD206 (M2), which was also blocked by anti-GMCSF, supporting the role of GM-CSF in monocyte differentiation towards M1-like
macrophages (Fig. 41D). It is important to note that ox-LDL used in this study was
generated by using MPO/H2O2/Nitrite system (see methods). We found that the ox-LDL
generated by this protocol can consistently activate TLR-induced inflammatory genes and
synergize with GM-CSF for up-regulation of M1-associated genes [253-262].
Since ox-LDL has been shown to directly act on macrophages in vivo [263-266],
we wondered whether it is possible that GM-CSF produced by ox-LDL activated
endothelial cells synergizes with SFAs and ox-LDL to further promote M1-like
proinflammatory macrophages. Palmitate and ox-LDL indeed enhanced the expression of
M1-associated genes in GM-CSF-primed macrophages as compared to that in M-CSFprimed macrophages (Fig. 41E). Interestingly, the expression of M1-associated gene
expression was more robustly enhanced in the adipocyte-macrophage ex vivo co-culture
system when using GM-CSF-primed macrophages as compared to that of M-CSF-primed
macrophages (Fig. 41F). Taken together, these results suggest a potential role of GM-CSF
in priming ATMs to become M1-like macrophages during their cross-talk with adipocytes.
It is important to note that endothelial-specific MyD88 deficiency substantially reduced
HFD-induced GM-CSF expression in adipose tissue (Fig. 37C), which was correlated with
selective rescue of insulin signaling in adipose tissue of HFD fed MyD88EC-KO mice (Fig.
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34E and 34H). These findings implicate the MyD88-dependent involvement of endothelial
cells in the cross-talk between adipocytes and macrophages, which might be important for
the initiation of obesity-associated inflammatory diseases. In support of this, endothelial
MyD88 deficiency improved insulin sensitivity more dramatic at early phase (6 weeks)
compared to that after 3 months of HFD (Fig. 33C-D); and MyD88EC-KOApoE-/- mice
showed greater reduction in atherosclerotic lesions developed under chow diet (70%
reduction) than that in HFD (40% reduction).
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Figure 41. Endothelial MyD88 mediates GM-CSF production to prime M1
inflammatory macrophages. (A) Protein level of GM-CSF in whole aorta lysate taken
from MyD88MC-KO ApoE-/-, MyD88EC-KO ApoE-/- female mice and their respective
littermate controls on chow diet or HFD for 12 weeks beginning at 6 weeks of age were
analyzed by ELISA. Data are expressed as mean ± S.E.M (n=5-6 per genotype) of the
results from three independent experiments. (*P<0.05, **P < 0.01). (B) Immunostaining
of GM-CSF (green) in conjunction with CD31 (red) were performed for frozen sections of
aortic roots from MyD88MC-KO ApoE-/-, MyD88EC-KO ApoE-/- female mice and their
respective littermate controls on chow diet (3 months of age). Then the tissues were
examined by confocal microscopy. Arrowheads indicate representative CD31+ GM-CSF+
cells (scale bar=20μm, L: lumen, A: arterial wall). Shown as are representative of five mice
per genotype with similar results (C) Wild-type (WT) and MyD88-deficient (MyD88KO)
primary aortic endothelial cells (ECs) were treated with ox-LDL (100 μg/ml) or IL-1 (1
ng/ml) for the indicated times (time 0 were treated with native LDL). Protein levels of GMCSF in supernatant from cells treated for 24 hours were analyzed by ELISA. The levels of
GM-CSF mRNA were measured by real-time PCR and presented as fold induction over
the expression of WT cells at time 0. (D) WT and MyD88 KO ECs were treated with oxLDL for 24h, then changed into fresh medium. After 48h, the medium was collected and
used to culture sorted CD11b positive splenic monocytes for 24h with or without anti-GMCSF neutralizing antibody (conditioned medium, conditioned medium + anti-GM-CSF).
Monocytes were cultured in normal medium as negative control (vehicle). Monocytes in
normal medium were treated with 50 ng/ml recombinant GM-CSF alone as positive control
(GM-CSF). Total RNA of monocytes was subjected to real-time PCR to measure the
relative expression of CD11c, CD206, IL-12a, IL12b, iNOS and PPBP. The fold induction
was calculated as compared with vehicle group. (E) Bone marrow derived cells were
cultured in DMEM supplemented with 20% FBS and 20 ng/ml GM-CSF or 50 ng/ml MCSF for 7 days, followed by treatment of ox-LDL and FFA (16:0; Palmitate, 5μM) as
indicated. Total RNA was subjected to real-time PCR to measure the expression of IL-12a,
IL-12b, iNOS and PPBP. The fold induction was calculated as compared with the cells
primed by M-CSF at time 0. (F) BMDMs of WT male mice primed by either M-CSF or
GM-CSF were plated in the bottom wells of Boyden chambers, with or without 3T3
adipocytes in the inserts at a ratio of 5:1 (adipocytes: BMDMs cell numbers). mRNA
expression levels of IL12a, IL12b, IRF5 and iNOS in the BMDMs were analyzed. The fold
induction was calculated as compared with the cells primed by M-CSF and cultured alone.
mRNA expression was normalized to β-actin expression. (C-F) Data represent the mean ±
S.E.M. of triplicate samples from a single experiments, and all results are representative of
three independent experiments. (*P<0.05, **P < 0.01).
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D. Discussion
The study presented here aimed to address how TLR signaling in different cellular
compartments contributes to the initiation and pathogenesis of obesity-associated
inflammatory diseases through the specific deletion of MyD88 in endothelial cells or
myeloid cells. MyD88 deficiency in myeloid cells ameliorated diet-induced systemic
inflammation and global insulin resistance, preserving insulin sensitivity in all the tested
tissues including muscle, liver and adipose tissue. On the other hand, endothelial-specific
deficiency of MyD88 improved diet-induced insulin resistance at early phase with
moderate effect on systemic inflammation, selectively restoring insulin sensitivity in
adipose tissue. While both myeloid- and endothelial-derived MyD88 were equally critical
for the initiation of atherosclerosis in chow fed ApoE-deficient mice, myeloid MyD88
clearly plays a more critical role than endothelial MyD88 in HFD-induced atherosclerosis.
Taken together, these results for the first time demonstrate the non-redundant role of
MyD88-dependent signaling in myeloid and endothelial cells for the development and
progression of atherosclerosis and metabolic inflammatory diseases.
The participation of macrophages and endothelium in atherosclerosis has been
extensively studied. In this study, we found that MyD88 deficiency in endothelial or
myeloid cells inhibited vascular lesion formation in chow fed ApoE-deficient mice, with
similar reduction in atherosclerotic area (60-70%). It is interesting to note that MyD88dependent pathology in chow fed ApoE-deficient mice is restricted to the aorta, since under
chow diet ApoE deficiency does not influence myeloid or endothelial MyD88-dependent
WAT macrophage abundance, polarization or inflammatory cytokine production. These
results clearly indicate the critical role of the MyD88-dependent pathway in the interplay
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between the endothelium and macrophages in the aortic tissue during the initiation of
atherosclerosis. The key initiating event in atherosclerosis is retention and oxidation of
LDL in the vascular wall [267]. Our study suggests that endothelial cell activation by oxLDL through the TLR-MyD88-dependent pathway probably plays an important role in the
initiation of atherosclerosis. While ox-LDL strongly induces the expression of GM-CSF in
a MyD88-dependent manner in endothelial cells, the expression of GM-CSF was greatly
reduced in the arterial tissue of the chow fed MyD88EC-KOApoE-/- mice compared to that in
the control mice. GM-CSF was indeed detected in endothelial cells of atherosclerotic
lesions, which was abolished in the MyD88EC-KOApoE-/- mice. Furthermore, ox-LDLinduced expression of M1-associated genes was more robust in GM-CSF-primed
macrophages than that in M-CSF-primed macrophages. Therefore, MyD88-dependent
GM-CSF production from endothelial cells might serve as an important link between
endothelial cells and macrophages by promoting M1-like inflammatory macrophages. In
support of this, GM-CSF has been shown to be important in plaque development. Using
the hypercholesterolaemic ApoE-/- mouse, it was found that GM-CSF treatment resulted in
increased atherosclerotic lesion extent [268, 269] . LDLR-null mice have been employed
in a study which combined 5-bromo-2’-deoxyuridine pulse labeling with en face
immunoconfocal microscopy to demonstrate that systemic injection of GM-CSF markedly
increased intimal cell proliferation (including dendritic cells), whilst functional GM-CSF
blockade inhibited proliferation[270]. Therefore, in addition to macrophage polarization,
the impact of GM-CSF on dendritic cell proliferation may also contribute to the reduced
lesions in our endothelial cell-MyD88 deficient mice. Future studies using cell-type
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specific GM-CSF receptor knockout mice will be required to clarify the pathogenic role of
GM-CSF in atherosclerosis.
Interestingly, when the mice were fed the HFD, there was a dramatic reduction
(70%) in atherosclerotic area in MyD88MC-KO ApoE-/- mice, but a more moderate reduction
(40%) in MyD88EC-KO ApoE-/- mice. The question is why myeloid MyD88 plays a more
critical role than endothelial MyD88 in HFD-induced atherosclerosis. It is important to
note that myeloid MyD88 deficiency led to greater improvement in HFD-induced systemic
inflammation (circulating TNFα, IL-6 and IL-1) and global insulin resistance than that by
endothelial-specific MyD88 deficiency. Under HFD-induced systemic inflammation, in
addition to ox-LDL, the endothelium can also be activated by a variety of circulating
inflammatory stimuli [222], including TNFα and IL-6. As a result, the activation of
endothelium, the interface between vascular structures and blood, becomes less dependent
on the MyD88-dependent pathway over the course of HFD. Consistently, endothelial
MyD88 deficiency improved global insulin resistance more dramatic at early phase (6
weeks after HFD) than that after 3 months of HFD.
One important question is how systemic inflammation is initiated in a HFD setting.
Previous studies have suggested that metabolic-triggered inflammation in white adipose
tissue plays a key role in the initiation of metabolic syndrome [223, 225-227]. ATMs are
exposed to high local concentrations of FFAs released from adipocytes in obesity, and
these serve as important activating ligands for TLR4 and TLR2 signaling in macrophages
[231, 237, 241, 271-273]. The results from our co-culture model suggest that MyD88
participates in the cross-talk between adipocytes and macrophages and FFA released by
adipocytes might be one of the initial ligands for TLR-MyD88 in this cross-talk. The
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cytokines (e.g. IL-1 and IL-6) may feedback on adipocytes to further promote this crosstalk [274-278]. Consistently, compared to controls, MyD88MC-KO mice showed markedly
reduced infiltration of macrophages and decreased adipose expression of inflammatory
genes. Furthermore, the elimination of MyD88 in myeloid cells increased the number of
M2-like macrophages

(CD11c-CD206+) with decreased M1-like

macrophages

(CD11c+CD206-) in the adipose tissue, confirming the critical role of MyD88-dependent
signaling in HFD-induced ATM switching from M2- to M1-like macrophages. Myeloidspecific MyD88-dependent switch of ATMs from M2-like to M1-like might play a key role
in the initiation of obesity-associated inflammatory diseases. However, it is important to
note that in addition to adipose tissue, myeloid-specific MyD88 deficiency also preserved
insulin sensitivity in liver and muscle, which probably contribute to the improvement of
HFD-induced global insulin resistance and systemic inflammation. Since CD11bCre
mediates deletion of floxed sequences in myeloid cells, we have now crossed MyD88fl/fl
mice with LysMCre mice to delete MyD88 in macrophages. Preliminary data from
LysMCreMyD88fl/fl mice showed similar results with that in MyD88MC-KO mice as
compared to the littermate controls.
Interestingly, MyD88EC-KO mice also showed moderate reduction in macrophage
infiltration, M2-like to M1-like switching and adipose expression of those proinflammatory cytokine and chemokine genes. While FFAs released from adipocytes might
directly act on endothelial cells, IL-1 released from FFA-induced M1-like macrophages
could also activate endothelium through a paracrine manner. While IL-1 strongly induced
the expression of GM-CSF, the GM-CSF levels were substantially reduced in adipose
tissue of HFD fed MyD88EC-KO mice. IL-1-induced GM-CSF in endothelial cells was able
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to promote M1-like inflammatory macrophages. Furthermore, the expression of M1associated gene expression was more robustly enhanced in the adipocyte-macrophage ex
vivo co-culture system when using GM-CSF-primed macrophages as compared to that of
M-CSF-primed macrophages. Thus, endothelial MyD88 might impact on switching of
ATMs from M2-like to M1-like through the production of GM-CSF, which may account
for the selective rescue of insulin sensitivity in adipose tissue of HFD fed MyD88EC-KO
mice. In support of this, endothelial deletion of MyD88 also moderately reduced M1-like
macrophages in the aortas with substantial reduction of GM-CSF expression, which
correlated with improved insulin sensitivity of aortic tissues from HFD-fed MyD88EC-KO
mice. It is important to mention that the GM-CSF levels were not significantly reduced in
liver and muscle of HFD-fed MyD88EC-KO mice (unpublished data, Yu and Li), which
might explain why these two tissues remain insulin insensitive in HFD-fed MyD88EC-KO
mice.
It is important to note that in addition to MyD88, TLR4 also utilizes TRIF to
mediate NFκB activation to upregulate inflammatory gene expression. TRIF deficiency
[279] or TRIFLPS2 lack-of-function mutation were shown to be atheroprotective in
hyperlipidemic LDL receptor knockout (LDLr−/−) mice [280]. Both studies supported a
critical role of TRIF-dependent pathway in the pathogenesis of atherosclerosis. However,
it is important to point out that TLR4 specifically utilizes TRIF to mediate the activation
of transcription factor IRF3 to upregulate Type 1 IFN production which in turn impacts on
IL-10 production [166]. Furthermore, it was reported that TRIF is not required for TLR4
signaling in endothelial cells [281], which was confirmed by our own studies in primary
aortic vascular endothelial cells (Yu and Li, unpublished data). Therefore, mice with cell-
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type specific TRIF deletion will be critical reagents for future studies to compare the
molecular and cellular mechanisms by which MyD88- versus TRIF-dependent pathway
contributes to the development and pathogenesis obesity-associated inflammatory diseases.
In summary, this study has demonstrated that MyD88-dependent signaling in both
myeloid and endothelial cells contributed to the initiation/progression of atherosclerosis
and as well as the development and pathogenesis of HFD-induced inflammatory diseases.
Both myeloid- and endothelial-derived MyD88 are critical for the initiation of
atherosclerosis in chow fed mice. One possible mechanism is that ox-LDL activates
endothelial cells to produce GM-CSF, which in turn primes the monocytes in the arterial
tissues and synergizes with ox-LDL to promote M1 inflammatory macrophages. On the
other hand, MyD88-dependent signaling in myeloid cells makes a greater contribution to
the development of HFD-induced systemic inflammation and consequent exacerbation on
atherosclerosis. FFAs released from adipocytes act on ATMs to promote HFD-induced
switching of ATMs from M2-like to M1-like, resulting in systemic inflammation and
aggravating atherosclerotic lesions. Nevertheless, endothelial-derived MyD88 still has a
noticeable contribution to the diet-induced inflammatory diseases, possibly also through
the production of GM-CSF to feedback on macrophages. Future studies are required to
elucidate how the cell-type specific MyD88-mediated signaling events contribute to the
cross-talks among adipocytes, macrophages, and endothelial cells to establish the dietinduced inflammatory state, leading to inflammatory diseases associated with metabolic
syndrome.
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E. Materials and Methods
Animals. CD11bCre transgenic mice were provided by G. Kollias (Biomedical
Sciences Research Centre ‘‘Alexander Fleming’’) [205]. Tie2eCre transgenic mice were a
gift of X.-Y. Fu (National University of Singapore) [203]. MyD88 flox mice were provided
by A. DeFranco (University of California, San Francisco) [282]. All these transgenic mice
used backcrossed 10 times to C57/ BL 6 background. ApoE-/- mice in the C57/BL6
background were purchased from Jackson laboratory. Mice were housed in a specific
pathogen-free facility (12-h light/dark cycle) and were fed either standard rodent chow or
a high fat, Western style diet (HFD, Harlan Teklad 88137) [283-286]. Animals were fasted
overnight and blood samples were taken for assessment of insulin (Crystal Chem),
FFA(Cayman), cholesterol (Sigma), triglycerides (Sigma) and IL-1β, IL-6, TNF-α,
CXCL1 (R&D systems) levels according to manufacturer’s instructions. All experimental
procedures were carried out with the approval of the Institutional Animal Care and Use
Committee of Cleveland Clinic (Cleveland, OH).
Primary cell isolation. Bone marrow derived macrophages (BMDMs) were
differentiated from bone marrow flushed from the tibia and femur of mice using
Dulbecco’s Modified Eagle’s Media (DMEM). The cells were cultured in DMEM
supplemented with 20% FBS and 30% L929 supernatant for 5 days. Aortic endothelial
cells (MAVECs, ECs) were harvested from mouse aorta under sterile conditions as
previously described [287]. The aorta was excised; all periadventitial fat was removed, and
the aortic pieces were placed onto Matrigel in DMEM plus 15% heat-inactivated FBS
following the methods outlined by Shi et al [288]. After 3 days, the aortic explants were
removed, and the endothelial cells were allowed to grow in DMEM plus 15% heat-
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inactivated FBS supplemented with 180 μg/ml heparin and 20 μg/ml endothelial cell
growth supplement. At confluence, the cells were passaged using dispase and then cultured
for 2 days in DMEM plus 15% heat-inactivated FBS containing d-valine to eliminate
possible fibroblast contamination. After 2 days, the EC were returned to growth medium
without d-valine and allowed to grow to confluence. Mouse endothelial cell cultures were
used in experiments from passages 2–4. Spleens were minced and digested with Liberase
Blendzyme 2 for 15 min in PBS at 21°C, passed through a 40-mm cell strainer, treated with
ACK Buffer (Lonza) to remove red cells, and resuspended in PBE (PBS with 0.5% BSA,
endotoxin free; 1mM EDTA). splenocytes were subsequently sorted on a Dako MoFlo.
Postsort analysis confirmed purity of 96% and viability of 95%.
Biological reagents and cell culture. Human low density lipoprotein (LDL,
1.019<density<1.063) was isolated from plasma of normolipidemic donors by sequential
ultracentrifugation. Native and modified LDL preparations were tested for possible
endotoxin contamination using a Limulus amebocyte lysate kit (Cambrex, Walkersville,
MD). Oxidized LDL (ox-LDL) was prepared by incubating LDL (0.2 mg protein/ml) at
37°C in 50 mM sodium phosphate (pH 7), 100 mM DTPA (diethylene-triamine-pentaacetic
acid) in the presence of 30 nM myeloperoxidase, 100 mg/ml glucose, 20 ng/ml glucose
oxidase (grade II; Boehringer Mannheim Biochemicals, Indianapolis, IN), and 0.5 mM
NaNO2 for 8 hours unless otherwise specified. Preliminary studies demonstrated that under
these conditions, a constant flux of H2O2 (0.18 mM/min) is generated by the glucose
oxidase system. Unless otherwise stated, oxidation reactions were terminated by addition
of 40 mM butylated hydroxytoluene (from a 100 mM ethanolic stock) and 300 nM catalase
to the reaction mixture[289]. FFA solutions were prepared as described previously [290].
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Briefly, 100mM palmitate (Sigma No. P-0500) stocks were prepared in 0.1M NaOH at
70°C and filtered. Five percent (wt/vol) FFA-free BSA (Sigma No. A-6003) solution was
prepared in double-distilled H2O and filtered. A 5mM FFA/5% BSA solution was prepared
by complexing an appropriate amount of FFA to 5% BSA in a 60°C water bath. The above
solution was then cooled to room temperature and diluted 1:5 in RPMI 1640 without FBS
to a final concentration of 1 mM FFA/1% BSA. Antibodies against MyD88, β-actin and
phosphotyrosine (PY20) were purchased from Santa Cruz Biotechnology. Antibodies
against p85-PI3K, GM-CSF, M-CSF and AKT were purchase from Abcam. Anti-Insulin
receptor substrate 1 (IRS1) antibody was purchased from Upstate Biotechnology. AntiPhospho-Akt (Ser473) Antibody, anti-arginase1 and anti-iNOS was purchased from Cell
Signaling. Anti-F4/80 was purchase from Ab serotec. 3T3 L1 pre-adipocytes were cultured
in DMEM, 10% FBS and 1% penicillin/streptomycin, and differentiated using the
Adipogenesis Kit at 37°C and 5% CO2 (Cayman Chemical). Differentiation was initiated
1 day after 100% confluence was reached. Confluent 3T3-L1 cells preadipocytes were
treated with 50ml initiation medium containing 500μM IBMX, 10μM Dexamethasone,
10μg/ml insulin in DMEM/10% FBS for 2 days. Afterwards, medium was changed to 40ml
progression medium consisting of DMEM/10% FBS supplemented with 10μg/ml insulin.
The 3T3-L1 cells were incubated with progression medium for 2 days. Subsequently,
medium was changed at day 6 into 50ml fresh DMEM/10% FBS followed by another 2
day incubation at 37°C. Eight days after the initiation of differentiation, 3T3-L1 cells were
ready for co-culture experiments. Preadipocytes were only differentiated and used prior to
passage 12 greater than 95% of cells displayed the fully differentiated phenotype. For the
co-culture system, differentiated 3T3-L1 adipocytes were co-cultured with differentiated
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BMDMs in DMEM/10% FBS for a maximum of 24 hours using 6-well plates containing
transwell inserts with a 0.4m²porous membrane. 1*104 BMDMs were seeded on the
bottom of the well, while 1*104 or 5*104 3T3-L1 adipocytes were seeded with into the
insert. BMDMs cultured in the well without adipocytes seeded were set as control culture.
After 24 hours of incubation, supernatants were collected, centrifuged for 10 minutes at
10,000g and 4°C; samples were stored at −20°C for cytokines measurement. mRNA was
collected from BMDMs for further gene expression analysis.
Glucose tolerance test (GTT)/Insulin tolerance test (ITT). GTTs were
performed by intraperitoneal injection (IP) of 2g/kg body weight of dextrose (Abbott
Laboratories) after overnight fast. For ITTs, mice were injected with insulin (1mU/g BW,
Sigma) IP after 3 hour fasting. Blood samples were obtained at 0, 15, 30, 60, 90, and 120
minute time points and glucose levels were measured with an ultra-one glucometer.
Insulin signaling analysis. Epididymal fat, liver and quadriceps muscle were
collected from mice in the basal state or 5 minutes after an IP injection of insulin (25
mU/kg), and quickly frozen in liquid nitrogen. Frozen tissues were homogenized on ice in
a Triton-containing lysis buffer (0.5% Triton X-100, 20 mM HEPES (pH 7.4), 150 mM
NaCl, 12.5 mM β-glycerophosphate, 1.5 mM MgCl2, 10 mM NaF, 2 mM dithiothreitol
(DTT), 1 mM sodium orthovanadate, 2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride
and complete protease inhibitor cocktail from Roche), then ground and rocked for 1 hour
in the cold room. Cellular debris was removed by centrifugation at 10,000 x g for 5 minutes.
Immunoprecipitations were performed with the indicated amount of lysates. Supernatants
were incubated with 5 μg of polyclonal antibody overnight and then incubated with protein
A beads for another 1 hour at 4°C. Samples were washed extensively with lysis buffer
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before solubilization in sodium dodecyl sulfate (SDS) sample buffer.Bound proteins and
whole lysates (40 μg) were resolved by 4-12% or 4-20% SDS-polyacrylamide gel
electrophoresis and transferred to nitrocellulose membranes (BioRad). Individual proteins
were detected with the specific antibodies and visualized on film using horseradish
peroxidase-conjugated secondary antibodies (BioRad) and Western Lightning Enhanced
Chemiluminescence (Perkin Elmer Life Sciences). The levels of IRS1, p85-PI3K, activated
AKT (pSer473, pAKT), and total AKT, were determined by immunoblotting of the whole
lysates. Protein extracts were immunoprecipitated with anti-IRS-1, followed by western
analyses with antibodies specific for phosphotyrosine (PY20, pY) or p85-PI3K.
Atherosclerosis lesion measurements. Atherosclerotic lesions were quantified by
2 independent and blinded assessments [291]. Mice were sacrificed by pentobarbital
overdose, perfused with phosphate buffered saline (PBS) and 10% formalin
(Formaldefresh, Fisher), and the entire aortic tree, including the heart, dissected free of fat
and other tissue. Aortae were stained with oil red O, and digitally scanned. En face lesion
area was assessed using Adobe Photoshop software, analyzed by Mann-Whitney U test.
Data are expressed as percent of total aortic area ± S.E.M.
Immunohistochemistry. Freshly isolated adipose tissues were fixed with
phosphate-buffered formalin overnight, then paraffin wax embedded and subsequently
deparaffinized. Sections of 5 μm were incubated overnight with monoclonal anti-F4/80
antibody (AbD Serotec). After washing in PBS, slides were stained and developed using
ABC staining system (Santa Cruz Biotechnology) and counterstained with hematoxylin
(Sigma-Aldrich). The total number of cells and crown-like structure were counted in 10
different high-power fields from each section. Frozen aortic root sections were blocked
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with 2% bovine serum albumin (diluted in PBS) containing 0.1% sodium azide for 1 hour
followed by overnight incubation with the primary antibody (1:50 dilution for anti-GMCSF, and 1:100 for anti-CD31; or 1：50 for anti-F4/80, 1:100 for anti-Arginase1 and 1:100
for anti-iNOS) at 4oC. After washing in PBS, slides were incubated with the fluorochromeconjugated secondary antibody (Alexa fluor-488 labeled donkey-anti-rat IgG and Alexa
fluor-594 labeled mouse-anti-rabbit IgG, or Alexa fluor-488 labeled mouse-anti-rabbit IgG
and Alexa fluor-594 labeled donkey-anti-rat IgG 1:200 diluted in blocking buffer ) for 2 hr
in the dark at room temperature, washed again in PBS and mounted with VECTASHIELD
containing anti-fade reagent (Vector Laboratories, Inc., Burlingame, CA). Fluorescent
images were acquired using a LEICA confocal microscope. No specific immunostaining
was seen in sections incubated with PBS rather than the primary antibody.
Flow cytometry. The visceral adipose tissue (epididymal fat pad) and aorta were
digested as described previously [229, 292]. SVF cells from adipose depots and aortic
single cells were stained with anti-F4/80, CD11b, CD206, and CD11c (eBiosciences) to
identify macrophage subsets. FACS analysis was conducted using FACS Calibur (BD
Pharmingen) and the FACS data was analyzed by post collection compensation using
FlowJo (Treestar Inc) software.
Quantitative real-time PCR. Total RNA was prepared from endothelial cells or
BMDMs of mice with TRIzol reagent (Invitrogen). Tissues were preserved in RNAlater
solution (Ambion), and subsequently homogenized in TRIzol reagent. Three micrograms
of total RNA were then used for the reverse transcription reaction using SuperScript reverse
transcriptase (Invitrogen). Quantitative PCR was performed using an AB 7300 Real-Time
PCR System, and gene expression was examined by SYBR GREEN PCR Master Mix
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(Applied Biosystems). PCR amplification was performed in triplicate, and water was used
to replace cDNA in each run as a negative control. The reaction protocol included
preincubation at 95°C to activate FastStart DNA polymerase for 10 min, 40 cycles of
amplification beginning with 15 seconds of denaturation at 95°C, followed by
annealing/extension for 60 seconds at 60°C. The results were normalized to the
housekeeping gene mouse β-actin. Primer sequences were designed using online tools from
GeneScript. The primer sequences used will be distributed upon request.
Statistical analysis. Data are expressed as mean ± S.E.M. Differences were
analyzed by Student t-test and one-way ANOVA. P ≤ 0.05 was considered significant.
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